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The first chapter in this thesis describes research on the asymmetric [1,2]-sigmatropic 
rearrangement of benzylic ammonium ylids. Our group previousely developed method 
showing that DMSO as solvent, and BTPP as base, in the presence of 5Å molecular sieves, 
dramatically improves the yield of the reaction. Hence, we applied the developed the 
method using 8-(–)-phenylmenthol and (2S)- camphorsultam as chiral auxiliaries. 
 
In the second chapter, a new application of Pd-catalysed allylation is reported. This enabled 
the synthesis of (30) of branched sp3-functionalised sulfonamides, a compound class for 
which few reported methods exist. By reacting benzyl sulfonamides with allylic acetates in 
the presence of Pd0 catalysts and a base, at room temperature, direct allylation was 
efficiently performed, yielding products that are analogues of structural motifs seen in 
biologically active small molecules. The reaction was performed under mild conditions and 
could be applied to nanomolar sigma-receptor binders, thus enabling a late-stage 
functionalisation and efficient expansion of drug-like chemical space. 
 
The third chapter described a synthesis of benzosultam without recourse to transition-metal 
catalysis, or stoichiometric amounts of organometallic building blocks.  Iodomethane 
sulfonylamide adds to benzyne (generated using fluoride sources), and then the formed 
intermediate undergos an intramolecular cyclisation to afford sultam. Using this method 
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List of abbreviation 
Ac                 acetyl 
acac              acetylacetonate 
AIBN             2,2-azo-bis-isobutyonitrile 
app               apparent 
aq.                aqueous 
Ar                 aromatic 
BMIM           1-butyl-3-methylimizadolium 
Bn                 benzyl 
BTPP             P1-t-Bu-tris-(tetramethylene) 
br                  broad 
CS                 camphorsultam 
d                   doublet 
DBU              1,8-diazabicyclo[5.4.0]undec-7-ene 
DMA             dimethylacetamide 
DMAP           N,N-dimethyaminopyridine 
DME             1,2-dimethoxyethane 
DMF             N,N’-dimethylformamide 
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DMSO            dimethylsulfoxide 
de                  diastereoisomeric excess 
dr                   diastereoisomeric ratio 
ee                   enantiomeric excess 
Et                   ethyl 
equiv              equivalents 
HMPA            hexamethylphosphoramide 
LDA                lithium diisopropylamide 
LHMDS           lithium hexamethyldisilazide 
m                    meta 
m                    multiplet 
m-CPBA         meta-chloroperbenzoic acid 
Me                  methyl 
mp                  melting point 
MS                  molecular sieves 
NBS                 N-bromosuccinimide 
NMP               N-methylpyrrolidone 
NMR               nuclear magnetic resonance 
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o                     ortho 
p                     para 
PE                   petroleum ether 
PMB               para-methoxybenzyl 
Rf                   retention factor 
rt                    room temperature 
s                     singlet 
SM                  starting material 
t                      triplet 
TBAT                 tetrabutylammonium difluorotriphenylsilicate 
  TBAF               tetrabutylammonium fluoride 
  TBDMSCl        tert-Butyl dimethylchlorosilane 
  TBDPSCl          tert-Butyl(chloro)diphenylsilane 
  Tf                      trifluoromethanesulfonyl 
TFA                     trifluoroacetic acid 
 THAB                 tetrahexylammonium bromide 
THF                     tetrahydrofuran 
TMEDA              tetramethylethylenediamine  
tmp·ZnCl·LiCl     tmp: 2,2,6,6-tetramethylpiperidine 
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In 1928, Stevens et al. published that benzyl ammonium salts underwent [1,2]-
sigmatropic rearrangement with migration of the benzyl group from the nitrogen to the 
adjacent carbon. Treatment of phenacylbenzyldimethylammonium bromide 1 with 
















This type of reaction, now commonly known as the [1,2]-Stevens rearrangement, has been 
used to produce many different types of nitrogen containing compounds. Since its 
discovery, this rearrangement has been widely studied for its interesting mechanism and for 
its synthetic utility.2 Examples of such a rearrangement have been chosen to illustrate the 
wide use of this reaction for the synthesis of biologically active compounds. 
1.2 Mechanism of the Steven’s rearrangement 
 
There are two accepted mechanisms proposed for the Stevens rearrangement; ion pair 
and radical pair. In his early studies, Stevens revealed the intramolecular character of this 
reaction by mixing phenacyl-m-bromo-benzyl-dimethyl-ammonium and p-
bromophenacylbenzyldimethyl-ammonium-bromide with alkaline solution and the mixture 
yielded only the rearrangement products corresponding to the individual salts. The 
mechanism of reaction proceeded by first formation of a zwitterionic intermediate (3-4) 




























In 1932, Stevens and Thomson studied an alternative mechanism involving a radical 
pathway,4 evidence for this was found later.5,6 The mechanism proceeds via homolytic 
cleavage of the C-N bond to generate a stable radical (using benzyldimethylallylammonium 
bromide). The radical pair, which is held tightly together within the solvent cage, rapidly, 






























In 1983, Ollis studied the rearrangement of -chiral ammonium ylids in cross-over 
experiments that were followed by NMR using chemically induced dynamic nuclear 
polarisation (CIDNP).8 Based on CIDNP spectra, it seemed reasonable that the products were 
formed directly from a radical pair precursor in which the radicals do not drift apart in a 
solvent cage.5,8 The high enantiomeric excess and retention of configuration observed, along 
with the results provided by the CIDNP technique, allowed them to establish that the [1,2]-
sigmatropic rearrangement of ammonium salts involved the formation of radical pair 5. 
When treated with base, the salt is deprotonated to form ylid 4. After homolytic scission of 
the C-N bond, formation of radical 6 occurs which then recombines within the solvent cage 
to yield product 2 (Scheme 3).8 
Ollis and co-workers also reported higher levels of diastereoselectivity when the viscosity 
of the solvent increased. The high viscosity of the solvent seemed to favour the solvent 


























solvent cage 95 %    99% retention
7 8 9 10
Scheme 4 
Nowadays this mechanism, involving the recombination of a radical pair within the solvent 
cage, is widely accepted as being the correct mechanism for the [1,2]-Stevens 
rearrangement for benzyl salts. 
1.3 Competing reactions 
 
The Stevens rearrangement is often beset by competing reactions and other problems. 
Issues with salt synthesis, ylid formation and Hoffman elimination are three of the most 
often observed setbacks.  
1.3.1 [2,3]-sigmatropic rearrangement 
 
Certain substrates allow more than one type of sigmatropic rearrangement to occur. In the 
1960s, during mechanistic studies on the Stevens rearrangement of allylic ammonium salts, 
a competing reaction to the [1,2]-sigmatropic rearrangement was encountered (Scheme 5).6 
The competing reaction followed a [2,3]-sigmatropic pathway and often predominated over 
the [1,2]-reaction. Studying the base-promoted rearrangement of the cinnamyl ammonium 
salt (R=Ph, Scheme 5) Stevens and co-workers obtained a mixture of [1,2]- and [2,3]-
rearranged products, while the crotyl derivative (R=Me, Scheme 5) yielded only the [2,3]-
















11 12 13 14
 
 R= Ph or Me 
Scheme 5 
The [2,3]-sigmatropic rearrangement, generally known as [2,3]-Stevens rearrangement is a 
13 
 
symmetry allowed reaction and believed to proceed via a concerted mechanism with a 
lower activation energy than the [1,2]-reaction,11,12 thus making it possible to obtain the 
[2,3]-rearrangement products by carefully controlling the reaction conditions.12 
 
1.3.2 Hoffmann elimination 
 
In addition to [2,3]- and [1,2]-rearrangements, the other major reaction pathway for 
decomposition of ylides is -elimination. Ammonium salt 15 is prone to give -elimination 










15 15 16  
Scheme 6 
  
1.4 Generation of the ylid species 
 
Traditionally, the ylid precursor to the rearrangement can be formed by treatment of 
corresponding ammonium or sulfonium salts with a base. Using this method, Coutyet al. 
published the generation of pyrrolidines 17 from enantiomerically pure 2-alkenyl 
azetidines 18 via a base-promoted [1,2]-sigmatropic rearrangement.10 Although the 
reaction proceeded with good regioselectivity, low diastereoselectivity at C2 in product 37 










R= H, dr (54:56), 39%






This base-promoted method can be inconvenient since the base can also induce side 
reactions. In 1952 Stevens et al. reported the synthesis of -tertiary amine 22 by heating 













The introduction of a copper catalyst allowed for the generation of metal-carbenes leading 
to a cleaner reaction and better yields. West et al. used copper-bronze catalysis to 
generate ammonium ylids in situ by decomposition of diazocarbonyl compounds 23(a-g).12 


















R1 = OEt, R2 = H, R3 = Me, R4 = CH2Ph                       63 %
R1 = OEt, R2 = H, R3 = Me, R4 = CH2                            35 %
R1 = OEt, R2 = CO2Et, R3 = Me, R4 = CH2Ph                97 %
R1 = OEt, R2 = CO2Et, R3 = CH2CO2Et , R4 = CH2Ph   92 %
R1 = Ph, R2 = H, R3 = Me, R4 = CH2Ph                          70 %
R1 = Ph, R2 = H, R3 = Me, R4 = CH2CO2Et                    26 %
R1 = Ph, R2 = H, R3 = CH2CO2Et, R4 = CH2Ph              70 %





Additionally, the metal-catalysed decomposition of diazo compound 23 (a-g) and trapping of 
the resulting carbenes by tertiary amines 24 (a-g) has successfully been used to rapidly 
access ylids and hence [1,2]-rearrangement products. This method gave better 
regioselectivities and less side reactions, and therefore became a viable alternative to the 
base promoted rearrangement. It is also shown that the use of copper species facilating the 
reaction in good to excellent yields, was superior to the use of rhodium complexes as a 
catalyst, which was unsuccessful whe napplied in the same reaction conditions. This was 
attributed to competitive coordination of the amines 24(a-g) to the empty axial sites on the 
rhodium catalyst.12 The ease and stability of metal-catalysed carbene generation 
reinvigorated research towards the Stevens rearrangement, making the reaction a powerful 
synthetic approach. 
 
1.5 Asymmetric rearrangements 
 
There have been few approaches towards asymmetric synthesis of amino acids via the 
Stevens rearrangement. Most efforts towards amino acids synthesis focus on the 
asymmetric [2,3] sigmatropic rearrangement.2,26,27,28 
A few years later West et al., in another attempt to perform an asymmetric Stevens 
rearrangement, reacted L-proline derivative 26 under basic conditions, to afford -
quaternary amino acid 27 in good yield with moderate diastereoselectivity (Scheme 10).14 
[1,2]-rearrangement 27 was obtained with retention of configuration. However, given the 
modest levels of diastereoselectivity obtained, it was suggested that recombination of the 
radicals from the same face was competing with recombination from the opposite face or 













Similarly, Tayama et al. employed an N-to-C [1,2]-Stevens rearrangement approach 
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towards the synthesis of optically active 3-substituted morpholine-2-ones 29.15 Treating N-
chiral amino acid derivatives quaternary salts 28 with base at low temperature produced 
3-substituted morpholine-2-one derivatives 29 in moderate to good yield and modest 













28 29  
R= H, dr (3.5:1.0), 39%
     Me, dr (2.6:1.0), 76%
     OMe, dr (3.3:1.0), 53%  
Scheme 11 
1.6 Ring expansion methodology 
 
The Stevens rearrangement has also been used as a method towards ring expansion. The 
potential to access many different alkaloid natural product ring systems is an appealing 
aspect of the Stevens rearrangement of ammonium ylids. Efficient access to a variety of 
amine natural product bicyclic ring systems can be achieved through formation of a 
spirocyclic ylid and subsequent Stevens rearrangement to afford the ring expanded 
products.  
West and Naidu16,17 applied this Stevens ring-expansion methodology, in an efficient total 
synthesis of quinolizidine alkaloid 35. As described previously, diazoketone 30 available in 
two-steps from L-proline benzyl ester, was treated with copper catalysts give the 
diastereomeric spirocyclic ylid mixture 31 and 32. A [1,2]-Stevens rearrangement provided 
the desiredquinolizidine ring system 33 and 34, in high yield (84%) and with excellent 
diastereoselectivity (95:5). This level of stereochemical retention suggests that the high 
diastereoselectivity observed derives predominantly from preferential formation of ylid 
diastereomer 31 with stereospecific [1,2]-shift to give 33. Having achieved high levels of 
diastereoselectivity, the authors examined the enantiomeric excess of this major 
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diastereomer. NMR chiral-solvating reagent (BNNPA) showed that quinolizidine 35 was 
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3. N2H4, Na, HOCH2CH2OH, heat
 
Scheme 12 
Saba and co-workers utilised the same tandem metallocarbenoid/ammonium ylid/[1,2]-
Stevens rearrangement in their approach to swansonine analogues which belong to an 
important class of biologically active natural and unnatural chiral polyhydroxylated 
alkaloids.18,19 L-Proline derived substrates 36 with an α-diazoketoester chain, were 
converted into stable isolable [5,5]-spirocyclic ammonium ylide 37 in very good yields (91-
90%, respectively) but with moderate diastereoselectivity, using two transition metal 
catalysts and various reaction conditions. The thermal reaction for ylid 37 afforded 























DCM, reflux 1 h
+
 R = CO2Bn 90%  dr = 70:30
 R = CO2Me 83%  95 % e.e.
 R = CO2MBn 85%  95 % e.e.
toluene, reflux







1.7 Rearrangement of heterocyclic benzylic ammoniumsalts 
 
Ollis et al. were among the first investigate the Stevens rearrangement of heterocyclic 
benzylic ammonium salts. They prepared cyclic ylid 41 by deprotonation of corresponding 
salt 40 using sodium hydroxide.20 However ylid 41 did not spontaneously rearrange but 
instead proved to be rather stable and only underwent [1,2]-sigmatropic rearrangement 


















Wittig and co-workers investigated the rearrangement of similar ammonium ylids, however 
the outcome of the rearrangement proved to be very different.21 When they rearranged 
heterocyclic ammonium salt 43, they obtained the Stevens rearranged products 44 but ring 
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expanded product was not observed, possibly due to the deprotonation of the other 













Later, Brewster and co-workers22 established that spiro quaternary ammonium salt 45 
(Scheme 16) when treated with a base, underwent a [1,2]-Stevens rearrangement to 
provide optically-active tertiary amine 47 with an (S) configuration. Bond-breaking and 
bond-making phases of Stevens rearrangement have happened on the two different rings of 
the spiro system, with a transfer of chirality from the stereogenic centre on the nitrogen to 










45 46  47 
11 %
Scheme 16 
Another example of transfer of chirality has been reported by Padwa and co-workers, who 
synthesized (S) configured product 49 with excellent (ee) by rearrangement of diazepinium 
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1.8 Sommelet-Hauser Rearrangement. 
 
In 1937, Sommelet observed that decomposition of quaternary ammonium salt 50 leads to 
formation of rearranged amine 51 when kept in a desssicator over P2O5. The same result 




50 51  
Scheme 18 
In 1957, Hauser investigated the rearrangement of benzyltrimethylammonium ion 53.25 
Hauser also proposed a possible mechanism for this rearrangement involving the 
deprotonation of quaternary ammonium salt followed by [2,3]-sigmatropic rearrangement 
(Scheme 19).28 
Treatment of the ammonium salt 52 with base initially generates ylid 54, which in turn is in 
equilibrium with yilde 55. Formation of yild 55 allows rearrangement via a concerted, 

























Following their work on the Stevens rearrangement, Tayama and co-workers reported a 
unique example of the Sommelet-Hauser rearrangement that showed no competing [1,2] 
Stevens rearrangement (Scheme 21).26 Treatment of ammonium salt 57 with solid caesium 
hydroxide in DCE at -10 °C leads to formation of rearranged product 58 via a [1,2] Stevens 
rearrangement. Treatment of salt 57 with potassium tert-butoxide at -40 °C in THF leads to 
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tBuOK















99% e.e.  
Scheme 21 
Tayama also reported an asymmetric version of the Sommelet-Hauser rearrangement using 
the above methodology. Various para-substituted N-benzyl ammonium bromide salts 60 
(Scheme 22) were treated with t-BuOK to generate α- tertiary amine 61 in moderate to 
excellent yields with a high level of diastereoselectivity. They also applied these conditions 
to ortho- and meta- substituted N-benzyl ammonium salts, yielding products in good yield 















tBu, -40 °C , 4 h, 95 %, d.r (98:2)
R = CN, -40 °C, 4 h, 84 %, d.r (87:13)
R = CN, -60 °C, 8 h, 82 %, d.r (97:3)
R = CO2Me, -60 °C, 8 h, 85 %, d.r (98:2)
R = COPh, -60 °C, 8 h, 82 %, d.r (98:2)
R = CF3, -60 °C, 15 h, 93 %, d.r (98:2)





The most notable asymmetric [2,3]-sigmatropic rearrangement of acyclic ammonium yilds 
was accomplished recently by Sweeney and co-workers. They elegantly utilized various N-
allyl glycine salts 62 bearing a camphorsultam auxiliary to obtain α-allylic glycines 63 in high 
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R1 = Me, R2 = H,  86 %, dr (96:4)
R1 = Me, R2 = Me,  70 %, dr (97:3)
R1 = MeO2C, R2 = H,  64 %, dr (99:1)  
Scheme 23 
Sweeney and co-workers also developed the first example of a [2,3]-endocyclic 
rearrangement of spirocyclic ammonium ylid 64.29 They reported a facial introduction of the 
quaternary centre of the ring junction of the pyrroloazepine structures, and subsequent 
rearrangement involving the endocyclic alkenes unit furnished the desired bicycle 66 and 67 


















43 % 21 %
Cu(acac)2
toluene, reflux,








2.1 Previous work 
 
Previous work in the group developed new methodology for the [1,2]-rearrangement of N-
benzylic ammonium salts 68 and used LiHMDS in DMF at 0°C.33 Initial investigations 
indicated successful rearrangement in moderate yield, but upon introduction of a 
substituent on the benzyl group, yields decreased (Scheme 25). Significant amounts of 





























64 %, dr (1:3) 33 %
 
Scheme 25 
An initial diastereomeric ratio of 75:25 was promising, but cleavage of the auxiliary needed 
to be addressed. An obvious way to suppress the cleavage was to investigate different 
auxiliaries, using commercially available oxazolidinone, menthol derivatives and camphene. 
The replacement of the sulfonamide linker present in camphorsultam by the carbamoyl 
linker present in oxazolidinones might be expected to reduce the cleavage of the chiral 
auxiliary, as a radical intermediate would be less stabilised, and increase yields of the 
rearrangement. Investigation of rearrangement of salt 71 under a range of conditions 
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71 72Base = tBuOK, NaH, 
            LiHMDS, NaOH
 
Scheme 26 
Many of the reactions carried out led to decomposition of starting material 71. it was 
believed that water present in the reaction would react in situ with the base to generate 
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hydroxide ions, which might cleave the oxazolidinone species.31 When molecular sieves 
were used, 1H NMR analysis of the crude mixture showed some impure rearranged product 
72. However, purification of 72 failed. Using oxazolidinone derivatives was therefore 
abandoned and from these results, it appeared necessary to examine different chiral 
auxiliaries. 
Due to the result obtained when camphorsultam was used as the chiral auxiliary, it seemed 
appropriate to investigate an auxiliary with a similar core structure. A similar structure 
found in nature is camphene (Scheme 27). Salt 73 was rearranged upon treatment with base 

















73 74 (R) 74 (S)
LiHMDS 1.05 equiv
   60 %
dr = 9:1
Scheme 27 
Both products 74(R) and 74(S) were isolated as oils, therefore the stereochemistry of both 
diastereoisomers was proposed by analogy: the radical pair would preferentially recombine 


























A base screen was first performed (Table 1) and the best result was obtained with BTPP 

















73 74 (R) 74 (S)
Base
 
Entry Base (equiv) (2R+2S) % dr (2R:2S) Cleaved (%) 
1 LiHMDS (1.05) 60 9:1 6 
2 BTPP (1.05) 38 19:1 13 
3 BTPP (2.00) 66 8:1 Trace 







However, the reaction was capricious, with three identical reactions giving large differences 
in yield (Entries 3, 4 and 5), diastereomeric ratio and auxiliary cleavage.31 Therefore, 
camphene was disregarded as a suitable auxiliary replacement. 
After abandoning oxazolidinone and camphene options, menthol derivatives31 were chosen 
as auxiliary. Salt 78 was prepared in three steps from menthol. The bromoacetylation step 
was carried out using a weak base (N,N-dimethylaniline), to afford 76  in high yield.31 The 
subsequent steps proceeded smoothly to give the benzyl salt 78 in 44 % overall yield. The 
newly formed salt was rearranged with a base to afforded desired product in good yield 
with a minimal amount of chiral auxiliary returned. The major problem was isolation of the 
product 79 as a 1:1 mixture of diastereoisomers. After purification of crude mixtures by 
extraction and flash column chromatography, an inseparable mixture of the two 





PhNMe2 (1.2 equiv), 
   Et2O, rt-reflux
O
Br
O  HNMe2.HCl (3.0 equiv)


















5 BTPP (2.00) 22 10:1 22 

















79 (S) 79 (R)78
+




In addition, the diastereoselectivity diminished compared to reactions with camphorsultam, 
perhaps indicating the isopropyl group was not bulky enough to shield either face of the 
molecule. This could be remedied by using a morehindered group in this position leading to 
use of auxiliary (-)-8-phenylmenthol. 
Salt 80 was treated with base to afford the desired rearrangement products 81 (S) and 81 
(R) with only a trace amount of cleaved auxiliary. However, the reaction yields for the 
rearrangement were lower than the ones obtained with (-)-menthol. Both products 81 (S) 








  DMF, 3A















However, since the distereoselectivity observed was inferior to that using the sultam 
auxiliary, further investigation of the rearrangement using 8-(-)-phenylmenthol as the chiral 
auxiliary was dismissed. 
As changing auxiliaries gave poor yields and diastereoselectivities, further studies were 
undertaken to understand the mechanism behind the cleavage of camphorsultam auxiliary. 
Attempted rearrangement of camphorsultam n-trimethylammonium salt 82 yielded only 




















This discovery was a strong evidence to support either a hydrolysis mechanism or an anionic 
cleavage (Fig 2). If there were water present in the reaction medium, then the base could 
















Anionic pathway Hydrolysis pathway
 
Fig 2 
Ranges of desiccants were assessed (Table 2), yielding positive results. The best results were 
obtained using molecular sieves, and as the cavity size increased, the yield of the reaction as 
the diastereoselectivity increased as well. Most notably 5Å molecular sieves provided 































Entry Desiccant 2R+2S (%) dr(R:S) Cleaved Aux (%) 
1 None 41 3:1 22 
2 3 Å M.S 50 5:1 8 
3 4 Å M.S 53 4:1 5 
4 5 ÅM.S 65 5.5:1 10 
5 Na2SO4 55 4:1 12 
Table 2 
 With the use of molecular sieves, the reaction proved to be reproducible, giving a minimum 
amount of cleaved camphorsultam and the diastereoselectivity of the reaction increased 
slightly as well. Therefore, a substrate investigation was undertaken to assess the scope of 
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Entry R Substrates 2R+2S (%) dr (R:S) Cleaved Aux (%) 
1 H 69 51 3:1 24 
2 4-NO2 83 65 5.5:1 10 
3 4-CN 84 52 2:1 18 
4 4-CF3 85 54 4:1 11 
5 4-COCF3 86 41 7.2:1 18 
6 2,5-F 87 58 3.6:1 7 
7 2-NO2 88 60 6.5:1 16 
8 4-OMe 89 21 6:1 31 
Table 3 
The substrate of scope the asymmetric [1,2]-Stevens rearrangement was quite broad and 
gave the desired products in good yield and diastereoselectivity. This was the first successful 
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development of the asymmetric [1,2]-Stevens rearrangement of N-benzylic ammonium 
salts. 
 
3.1 Aim of the project 
 
[1,2]-Sigmatropic rearrangements of ammonium salts proceed in good yields and create 
new carbon-carbon bonds with good diastereoselectivities. As the reaction exhibits 
interesting and valuable characteristics, it is peculiar that it has received such little 
attention, especially in total synthesis. One reason might be that the rearrangement product 
is a tertiary amine and is competing to [2,3]-rearrangement unless appropriate conditions 
are employed. The aim of this project was to develop new methodology towards the 
synthesis of - and -amino acid derivatives via [1,2]-sigmatropic rearrangements of 
ammonium ylids. The subsequently formed ammonium salt would then be deprotonated to 
form an ammonium ylide, which is expected to [1,2]-rearrange up on treatment with our 
new conditions. The choice of condition is of special interest, as it most likely influences the 
reactivity of the intermediate ylid towards the [1,2]-rearrangement. First, we selected 
camphorsultam auxiliary for this type of reaction, as previously, it has been reported that 
ammonium salts bearing camphorsultam auxiliaries underwent [1,2]-sigmatropic 
rearrangement in moderate yield, although cleavage of the chiral auxiliary was observed. 
Our attention turned to apply our new conditions towards an asymmetric [1,2]-Stevens 
rearrangement of N-benzylic ammonium salts to gain access to desired products in better 
yield and diastereoselectivity, and minimised cleavage by-product. 
Our second goal is to investigate into alternative auxiliaries such as phenyl menthol. Tayama 
and co-workers successfully applied phenylmenthol as auxiliary towards [2,3]-sigmatropic 
rearrangement. Therefore, this can be investigated to test whether phenylmenthol auxiliary 
suitably provides [1,2]-shift when used in our conditions, the effect of the phenyl menthol 





4.0 Result and Discussion 
 
4.1 Understanding competition between [1,2]-Stevens and [2,3]-Sommelet-Hauser 
rearrangement 
Investigation towards the understanding of the [1,2]-Stevens and [2,3]-Sommelet-Hauser 
rearrangements identified a number of variables. Between the two asymmetric 
methodologies, there are three factors: base, solvent and benzyl substitution. In fact, for the 
reactions developed by Sweeney and Tayama, it is surprising that the temperature is the 
only variable that is discounted as having any controlling factor between the 
rearrangements, particularly when previous reports have expressed temperature as a key 
criterion for rearrangement control. 
Individually, all three factors do not control rearrangement, but utilising a combination of 




Adopting a weak base favours [2,3]-Sommelet-Hauser rearrangement, as shown in (Scheme 
32). A weaker base is key for [2,3]-Sommelet-Hauser rearrangement as it allows for the 
partial deprotonation of the -proton, which promotes the formation of the five-membered 















90 91 92 93
Scheme 32 
In contrast to weak bases which yielded the [2,3]-rearrangement, stronger bases promote 
[1,2]-rearrangement. The deprotonation caused by utilising a strong base, does not allow 
for formation of the five-membered transition state that promotes [2,3]-rearrangement. 
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Instead formation of the yilde is followed by homolysis of the benzyl carbon-nitrogen bond 












90 94 95  
Scheme 33 
4.3 Benzyl substitution 
 
Stevens and co-workers investigated the influence of substitution on the consequence of 
the [1,2]-rearrangement reaction. 3b,3c In fact they postulated that after deprotonation of 
the salt and formation of the corresponding ylid, the velocity of the rearrangement 
depended on the cleavage of the benzylic bond. Therefore, the driving force of the reaction 
lay in the instability of the anionic charge and could be related to the measurement of the 
ylids' dissociation constant. A range of substituted salts were prepared and rearranged, the 
reaction rates were recorded. The authors supposed that the reaction velocity was linked to 
the anionic charge instability; therefore, if the acidity of the ylid diminished, then the 


































Subsequent studies of the effect of substituents on the phenyl ring of the benzyl group have 
demonstrated that an electron donating benzyl substituent undergo [1,2]-shift poorly due to 
inhibits [1,2]-rearrangement by destabilisation of the yild (Figure 3). The conclusion is that 
an electron withdrawing group favoured the reaction (Figure 4) whereas an electron 
donating group disfavoured it. The following order of reactivity was determined: NO2> Hal > 
Me >OMe. The substituent most favourable to the reaction was shown to be the nitro 
group, which particularly accelerates the reaction compared to the other electron 
withdrawing substituents. This can be explained by the radical-stabilising nature of a NO2-
substituted benzyl species. Formation of the radical pair is a key attribute in the [1,2]-




A solvent is a predictable factor that effects both [1,2]- and [2,3]-rearrangement 
competition, as the mechanism requires a suitable solvent to allow an adequate solvent 
cage for radical pair recombination. As previously discussed Ollis and co-workers5 reported 
higher levels of diastereoselectivity when the viscosity of the solvent increased. The high 
viscosity of the solvent seemed to favour the solvent cage effect and to lessen 
intermolecular interactions. This solvent would also account for the high degree of 
intramolecularity and stereoselectivity observed in this rearrangement. Radical escape 
provided achiral free radicals that combined to give racemic by-products, their random 





4.5 Improving the [1,2]-Stevens rearrangement methodology 
 
With further understanding of the behaviour of benzyl ammonium salts during the [1,2]-
Stevens an attempt for improving the yield was iundertaken. Previous investigation had 
explored the base extensively, so in our group Mark Forester was focused towards the 
choice of the reaction solvent. Hence, a solvent screen (Table 4) was undertaken to indicate 
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Entry Solvent 95 (%) 93 (%) 
1 DMF 38 0 
2 THF 0 Trace 
3 DME 15 0 
4 MeCN 22 0 
5 PhMe 0 0 
6 Dioxane Trace 0 
7 DMSO 60 0 
Table 4 
The solvent screening was undertaken and indicated an improvement when using DMSO.  
All solvents gave poor yield, with some solvents achieving no rearrangement with only 
starting material recovered. DMSO was used along with DMF with a variation of counter-ion 




  DMSO, rt,









Entry X DMF 95 (%) DMSO 95 (%) 
1 Br 36 55 
2 Cl 33 57 
3 I 31 54 
4 BPh4 24 43 
Table 5 
As anticipated, DMSO as a solvent improves the [1,2]-rearrangement yield. None of [2,3]-
rearrangement products were observed. To understand this, the electronic distribution 
between DMF and DMSO must be studied.33,34 









DMSO exists with charges on its oxygen and sulfur, whereas DMF exists with partial charges 
on its oxygen and nitrogen. The improved charge upon the oxygen and sulfur atoms of 
DMSO can interact better, which allows the reagents to overcome the energy barrier easier 
and decrease the energy of the transition state. In comparison, the partial charge of DMF 






















Now with a significant improvement of the [1,2]-rearrangement reaction by using BTPP as 









 DMSO,   
   5 Å, rt,  













68 69 (S)  69 (R)
BTPP (1.05 equiv)
10 % 59 %
Scheme 36 
Despite the fact that some variations in diastereomeric ration were observed, using DMSO 
as a reaction solvent successfully improved the [1,2]-rearrangement yield and would be 
utilised for the future asymmetric system. 
 




Focusing on the effect of substituting benzyl group and the auxiliary behaviour, synthesis 
and subsequent rearrangement of salts was planned. Access to salts was achieved through 
reported methods.28 First camphorsultam 70 was reacted with bromoacetylbromide using 
sodium hydride in toluene and formed 97 in good yield, followed by the nucleophilic 
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substitution of the bromide 97 with dimethylamine to furnish the tertiary amine 98 in 
excellent yield. Finally, the amine 98 was heated with (4.0 equiv) of bromide at 50°C in 










0 °C-rt, 72 h







NMe2.HCl Et3N (3.0 equiv), 


























Entry R Substrates Yield (%) 
1 H 68 7a 
2 4-OMe 99 74a 
3 4-COMe 100 89a 
4 2,5-diF 101 93a 
5 4-COPh 102 96a 
6 4-COOMe 103 74a 
7 2,4-diF 104 90a 
8 3,5-diF 105 88a 
9 2,4,6-diF 106 89a 
10 3-F 107 91a 
11 4-Ph 108 86a 
12 2-CN 109 89a 
13 2-CF3 110 46a 
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14 4-CN 111 96 
15 4-CF3 112 95 
16 4-NO2 113 91 
a These salts was prepared by H-Akriem in our group 
Table 6 
Formation of salts (entry 1-16) proceeded in good to excellent yield in general. Salt 110 
which is substituted in the ortho-position, gave a lower yield (Entry 13), presumably due to 
the steric hindrance adjacent to the reacting centre. With the successful synthesis of all 
salts, interest was turned to their behaviour during rearrangement with our new conditions. 
4.7 Steven’s rearrangement of the benzylic ammonium salts 
 
The ammonium salts (68, 99-113) were subjected to the optimised reaction conditions to 
give the desired products in good yields (Table 7). Most of salts delivered [1,2]-







DMSO, 5 Å,   



















Entry R Substrate (2R+2S) dr(R:S) NMR 
1 H 69 65% 80:20 a 
2 4-NO2 83 70% 79:21 
3 4-CN 84 86% 80:20 
4 4-CF3 85 84% 79:21 
5 2,5-diF 87 89% 78:22 a 
6 4-OMe 89 65% 79:21 a 
7 4-COMe 114 68% 77:23 a 
8 2,4-diF 115 61% 80:20 a 











                                      a prepared by H. Akriem. 
                                      b (2S)-[1,2]-product and [2,3]-product as an inseparable mixture. 
Table 7 
The absolute stereochemistry of the major isomer of 69 (S) was assigned from an X-ray 
crystal structure obtained within our group (Figure 6).
                                                                                Fig 6 
The spectroscopic data we obtained for 69 (S) matched the spectroscopic data obtained 
previously within our group. We established a comparison between the 1H NMR spectra of 
10 4-COOMe 117 53% 78:22 a 
11 3,5-diF 118 82% 80:20 a 
12 2,4,6-triF 119 65% 85:15 a 
13 3-F 120 88% 71:29 a 
14 4-Ph 121 73% 80:20 a 
15 2-CN 122 82% 69:18:16[2,3]a,b 
16 2-CF3 123 77% 68:21:11[2,3] a,b 
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the minor (69, 83-89, 111-123) and of the major (69, 83-89, 111-123) diastereoisomers for 
each substituent. A trend was observed: for every major diastereoisomer the splitting 
pattern of the CH2SO2 group resonance is an apparent singlet, whereas for every minor 
diastereoisomer it is two doublets. Therefore, we have a diagnostic signal allowing us to 
assign the diastereoselectivity for each diastereoisomer. When comparing the chemical 
shifts and splitting patterns of respectively CHCH2Ar and CHCH2Ar resonances for both 
diastereoisomers, no significant trend was found. Different regioisomers of the fluorobenzyl 
products 87, 115 and 118 (S) and 87, 115 and 118 (R) were obtained in good yield and 
diastereoselectivity; the position of the fluorine atoms on the ring was of little influence on 
the reaction yield or on the diastereoselectivity (Entries 5, 8 and 11). Perhaps the most 
surprising observation was the absence of competing [2,3]-rearrangement from the reaction 
mixtures, apart from two salts: the 2-cyanobenzyl salt 122, the 2- trifluoromethylbenzyl salt 
123 (Entries 15 and 16), where minor amounts of [2,3]-products were isolated together with 
[1,2]- (2S) product.  
We decided to investigate the stereochemistry of salts (109, 110). Hence the absolute 
stereochemistry of the [2,3]-product 122 and 123 were proposed based on the study of the 








































The [2,3]-sigmatropic rearrangement of 122 and 123 proceeds via a concerted mechanism. 
Approach from the bottom face, with H-to the nitrogen pointing up, is favoured, leading to 
the proposed stereochemistry for (S) products. 
 
4.8 Phenyl menthol as auxiliary 
 
With investigation into benzyl and acyl substituent variation having an impact upon the 
balance between rearrangement pathways, attention was turned to the original asymmetric 
reactions of Sweeney and Tayama. Utilising phenylmenthol auxiliary, investigation was 
undertaken with our new reaction conditions to determine whether phenylmenthol would 
yield [1,2]-rearrangement product as Tayama el al. were only able to isolate [2,3]-shift 
products. 
The synthesis of ylid precursors, using 8-(-)-phenylmenthol as the chiral auxiliary, was 
carried out starting from the commercially available 8-(-)-phenylmenthol 124. All salts were 
obtained in two nucleophilic substitution-benzylation sequences in good overall yield (Table 
8) via the reported method.26, 31 
Ph
OH
Pyridine (1.2 equiv), 

















Entry R Salts Yield (%) 
1 H 80 91 
2 2-CF3 126 64 
3 3-CF3 127 90 
4 3-CN 128 93 
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5 4-CN 129 96 
6 4-NO2 130 94 
7 4-OMe 131 90 
8 2,5-diF 132 94 
9 4-COPh 133 89 
10 4-COOMe 134 90 
11 4-COMe 135 92 
Table 8 
Formation of salts (80, 126-135) proceeded in very good to excellent yield in general. Salt 
(126) which is substituted in the ortho-position, gave a lower yield (Entry 2), presumably due 
to the steric hindrance adjacent to the reacting centre. 
4.9 Stevens’ rearrangement of the benzylic ammonium salts 
 
Using our new optimised conditions, the newly formed salts were converted in to the 
desired rearranged products (Table 9). Only trace amount of cleavage products was 
observed. Despite an increased yield of [1,2]-rearrangement products, the d.r. remained 
modest. The increased yield of products could be attributed to the change in solvent to 
DMSO. Along with [1,2]-rearrangement products, minimal amount of [2,3]-rearrangement 
was also observed from 1H NMR of crude mixture, but no [2,3]-rearrangement products 
were isolated after purification by flash chromatography. Therefore, in all cases [1,2]-
rearrangement were major products. The rearrangement of 140 and 144 identified less than 
10 % of [2,3]-rearrangement products, and suggested that the electron withdrawing 







































Yield S (%) 
 
















































































































































< 10 % 
        a dr determined from NMR of crude mixture. 
     b amount of [2,3]-rearrangement determined from NMR of crude mixture 
Table 9 
Both products (S) and (R) were isolated to determine the reaction diastereoselectivity. A 1H 
NMR analysis of the crude reaction mixture (after aqueous work-up) was obtained and the 
diastereoisomeric ratio was determined by integration of the N,N-dimethyl resonances, 
matching ones after isolation of both diastereoisomers.  
The best results were obtained with benzyl moieties bearing electron withdrawing 
substituents, especially 4-nitrobenzyl product 142 (Entry 8) which afforded the highest yield 
and highest diastereoselectivity. This can be explained by radical stabilising nature of a 4-
nitro-substituted benzyl species, hence the preference of nitro-substituted benzyl species 
towards [1,2]-shift product.  Surprisingly, Tayama and co-workers25 did not investigate 4-
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nitrobenzyl ammonium salts, so it was unknown whether [1,2]- or [2,3]- rearrangement is 
favoured in the Tayama [2,3]-rearrangement conditions. A lower yield was obtained with 
the benzyl groups bearing the electron-donating substituents, 4-methoxy, compound 141 
(entry 7). We have previously mentioned the work from Stevens and co-workers about the 
effect of substitution on the rearrangement velocity,3 indicating a lower reaction rate when 
the salt was substituted by an electron donating group, such as 4-methoxybenzyl salt. 
Although it is not clear why 4-methoxybenzyl products 141 were afforded in low yield (entry 
8), we hypothesise that the 4-methoxybenzyl salt 131 rearranges presumably with 
preventing its full delocalisation/resonance (Figure 3), as shown by Stevens et al.3 
4.10 Determination of the relative stereochemistry of diastereoisomers 
 
Products 81 (S) and 81 (R) were afforded as oils and we were not able to crystallise them. 
The stereochemistry was predicted based on the aforementioned mechanism of the 






















We proposed that the stereochemistry was a result of the recombination of the radical pair 
preferentially from the least hindered face of the molecule. The radical intermediate could 
adopt two conformations A and B (Figure 6). All the substituents are in equatorial positions, 
where interactions are minimised. The 1,1-dimethylbenzyl group being very bulky acts as a 
conformation anchor and leading this particular conformation. From this favoured 
conformation the benzyl radical could recombine from the top or the bottom face (Figure 
6). Approach of the radical from the bottom face is sterically hindered by the large 1,1-
dimethylbenzyl group (B); the benzyl radical would preferentially recombine from the top 
face leading to the major product (A). The level of stereoselectivity observed was in line 
with reported31,32 diastereoselectivity of [1,2]-rearrangement, but there was an increase in 
the reaction diastereoselectivity compared to the reactions with (-)-menthol as auxiliary, 
this shows that a bulky group here is necessary. 
5.0 Conclusion 
 
We have demonstrated that the [1,2]-sigmatropic rearrangement of benzylic ammonium 
ylids can proceed in good yield and diastereoselectivity. By using the phosphazene base 
BTPP and 5Å molecular sieves, we made this reaction more reliable with low return of 
auxiliary. 
We have also demonstrated that there is competition for some examples between the 
Stevens and the Sommelet-Hauser rearrangements, further investigations are needed in 
order to identify and understand the influence of the reaction conditions, such as the choice 
of the chiral auxiliary, of the base or of the solvent. We have also shown that the reaction 
can tolerate substitution at 2-, 3-, and 4-benzyl substituents to participate in this chemistry, 
with electron donating group giving lower yield, due to inhibition of [1,2]-rearrangement by 
destabilisation of the ylid. For the phenyl menthol as auxiliary, the hindered phenyl group 
on menthol led to better diastereoselectivity compared to methyl group on menthol, 
perhaps indicating the isopropyl group was not bulky enough to shield either face of the 










In this report, the best diastereoselectivity was obtained when camphorsultam was used as 
the chiral auxiliary. Due to its ability to form derivatives through its nitrogen atom and the 
structural rigidity of its chirality which allow a reaction to proceed with very specific 
stereoselectivity The advantage of phenyl menthol as chiral auxillary was observed to give a 
minimum amount of cleaved product, since an oxygen radical, higher in energy, is much less 






Unless otherwise stated, all reactions were carried out under an inert atmosphere of dried 
nitrogen, in glassware which had been oven-dried. Reagents were purchased from Sigma-
Aldrich, Acros, Alfa Aesar, Fisher Scientific, TCI UK or Lancaster Research Chemicals and 
were not purified except where stated. Solvents were purchased anhydrous and stored over 
molecular sieves, or distilled under nitrogen from an appropriate drying agent in accordance 
with the procedures of Perrin and Armarego. Toluene and THF were distilled from sodium 
benzophenoneketyl radical while dichloromethane and acetonitrile were distilled from 
calcium hydride. DMSO anhydrous was used as obtained fromSigma-Aldrich.Thin layer 
chromatography (TLC) was carried out using silica gel 60 F254 aluminium sheets. Spots were 
visualised by quenching UV irradiation at 254 nm, and by staining with 2% KMnO4 (w/v) in 
20% K2CO3 (w/v) solution, 15% phosphomolybdic acid (w/v) in EtOH. Flash column 
chromatography was carried out using silica gel 60 A, 70-230 mesh, 63-200 µm obtained 
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from Sigma–Aldrich. The HPLC analysis was conducted on a Chiralpack IB-3 column 
(Dimensions: 4.6mm×250mm; particle size: 3µm). The UV detection was at wavelengths of 
200, 220 and 230. Two solvents were employed; hexane, 2-propanol (1:1) and flow rate of 
1mL/min. Nuclear magnetic resonance (NMR) spectroscopy was performed on a 
BrukerAvance 400 NMR spectrometer (1H NMR at 400 MHz, 13C NMR at 100 MHz) with the 
appropriate deuterated solvent. Chemical shifts in 1H NMR spectra are expressed as ppm 
downfield from TMS and in 13C NMR, are relative to internal standard, and reported as 
singlet (s), doublet (d), triplet (t), quartet (q) and combinations thereof, or multiplet (m). 
Coupling constants (J) are quoted in Hz and are averaged between coupling partners and 
rounded to the nearest 0.2 Hz. Mass spectrometry was performed using a BrukerMicroTOF-
Q instrument with electrospray ionisation in the positive mode. FT-IR data was acquired 
using Thermo Electron Corporation Nicolet 380 FTIR with Smart Orbit diamond window 
instrument with wavenumbers being reported in cm-1.  
General procedure for salt synthesis 
Following previously described method,31 salts were prepared. A round-bottomed flask was 
charged with (1.0 equiv), (–)-8-phenylmenthol (1.0 equiv) andbromoacetylbromide (1.1 
equiv) and pyridine (1.2 equiv) was added at 0 °C, after the addition the reaction was stirred 
at rt overnight. The resulting mixture was washed with saturated aqueous sodium hydrogen 
carbonate and water. The organic layer was dried over sodium sulfate. Evaporation of the 
solvent gave bromoacetic acid (–)-8-phenylmenthol ester in quantative yield. The crude 
product was used in next step without purification. A solution of bromoacetic acid (–)-8-
phenyl menthol ester (1.1 equiv) and amines derivatives (1.0 equiv) in acetonitrile (0.2 M) 
was stirred for 3 days at room temperature. The resulting mixture was concentrated under 
reduced pressure and the residue was purified by chromatography on silica gel 
(dichloromethane/methanol = 10:1 as eluent) to obtain quaternary ammonium salt.26 
 
N-Benzyl-N,N-dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl]ammonium bromide 











1H NMR (400MHz, CDCl3):  7.56-7.54 (m, 3H, ArCH), 7.51-7.42 (m, 2H, ArCH), 7.26-7.24 (m, 
2H, ArCH), 7.14 (t, J 8.0, 2H, ArCH), 6.83 (t, J 7.2, 1H, ArCH), 5.20 (d, J 12.8, 1H, NCH2Ar), 4.97 
(d, J 12.8, 1H,NCH2Ar), 4.92 (td, J 10.8, 4.8, 1H, CH2CHO), 4.20 (d, J 17.2, 1H, COCH2N), 3.42 
(s, 3H, N(CH3)2), 3.26 (s, 3H, N(CH3)2), 2.38 (d, J 17.2, 1H, COCH2N), 2.16 (td, J 10.8, 3.6, 1H, 
CHCPh(CH3)2), 2.03-1.99 (m, 1H, CH2CH2CHCH3), 1.87-1.82 (m, 1H, CHCH2CHO), 1.78- 1.73 
(m, 1H, CH2CH2CHCH3), 1.53-1.43 (m, 1H, CH2CH2CHCH3), 1.28 (s, 3H, CPh(CH3)2), 1.29-1.19 
(m, 1H, CHCH2CHO), 1.15 (s, 3H, CPh(CH3)2), 1.11-0.96 (m, 2H, CH2CH2CHCH3), 0.92 (d, J 6.4, 
3H, CHCH3);  
13C NMR (100 MHz, CDCl3):  163.9 (CO), 152.3 (Ar-C), 133.8 (2 x ArCH), 131.5 (Ar-C), 129.8 
(2 x ArCH), 128.4 (2 x ArCH), 127.1 (ArCH), 125.8 (2 x ArCH), 125.4 (ArCH), 76.9 (CH2CHO), 
68.8 (NCH2Ar), 59.9 (COCH2N), 51.0 (CHCPh(CH3)2), 50.5 (N(CH3)2), 49.7 (N(CH3)2), 41.7 
(CHCH2CHO), 39.7 (CHCPh(CH3)2), 34.5 (CH2CH2CHCH3), 31.7 (CPh(CH3)2), 31.4 (CHCH3), 26.3 
(CPh(CH3)2), 22.1 (CH2CH2CHCH3), 21.9 (CHCH3);  
max (neat, cm-1) (CHCl3): 2942 (CH), 1738 (CO);  
MSm/z (ESI+) calculated for C27H38NO2 [M-Br]+ 408.2902; found 408.2908 
 
N,N-Dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl]-N (2’trifluoromethylbenzyl 










1H NMR (400MHz, CDCl3): 8.11 (d, J 7.2 Hz, 1H, ArCH), 7.82 (d, J 7.2 Hz, 1H, ArCH), 7.72-
7.69 (m, 2H, ArCH), 7.39-7.21 (m, 4H, ArCH), 6.91 (t, J 7.2 Hz, 1H, ArCH), 5.40 (d, J 12.8, 1H, 
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NCH2Ar), 5.18 (d, J 12.8 Hz, 1H,NCH2Ar), 4.92 (td, J 10.8, 4.8, 1H, CH2CHO), 4.45 (d, J 17.2 Hz, 
1H, COCH2N), 3.44 (s, 3H, N(CH3)2), 3.28 (s, 3H, N(CH3)2), 2.48 (d, J 17.2 Hz, 1H, COCH2N), 
2.16-2.14 (m, 1H, CHCPh(CH3)2), 2.03-1.99 (m, 1H, CH2CH2CHCH3), 1.87-1.78 (m, 1H, 
CHCH2CHO), 1.78- 1.72 (m, 1H, CH2CH2CHCH3), 1.53-1.43 (m, 1H, CH2CH2CHCH3), 1.30 (s, 3H, 
CPh(CH3)2), 1.32-1.19 (m, 1H, CHCH2CHO), 1.13 (s, 3H, CPh(CH3)2), 1.11-0.97 (m, 2H, 
CH2CH2CHCH3), 0.88 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 163.4 (CO), 151.6 (Ar-C), 133.5 (ArCH), 131.7 (q, J 29 Hz, Ar-C), 
130.8 (ArCH), 129.5 (q, J 6Hz, ArCH),128.4 (2 x ArCH), 127.1 (ArCH), 125.8 (2 x ArCH), 125.4 
(d, J 1 Hz, ArCH), 123.17 (d, J 273 Hz, CF3), 76.6 (CH2CHO), 68.4 (NCH2Ar), 60.2 (COCH2N), 
50.0 (CHCPh(CH3)2), 46.5 (N(CH3)2), 49.7 (N(CH3)2), 41.7 (CHCH2CHO), 39.7 (CHCPh(CH3)2), 
34.5 (CH2CH2CHCH3), 31.7 (CPh(CH3)2), 31.4 (CHCH3), 25.3 (CPh(CH3)2), 22.4 (CH2CH2CHCH3), 
21.6 (CHCH3); 
max (neat, cm-1) (CHCl3): 2952 (CH), 1742 (CO), 1178 (C-F);  
MSm/z (ESI+) calculated for C28H37F3NO2 [M-Br]+ 476.2776, found 476.2736. 
 
N,N-Dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl]-N-(3,5 difluoromethyl benzyl) 








1H NMR (400MHz, CDCl3): 8.10 (d, J 7.2 Hz, 1H, ArCH), 7.82 (d, J 7.2 Hz, 1H, ArCH), 7.72-
7.69 (m, 2H, ArCH), 7.39-7.21 (m, 2H, ArCH), 6.91 (t, J 7.2 Hz, 1H, ArCH),  6.89-6.86 (m, 1H, 
ArCH) 5.44 (d, J 12.8, 1H, NCH2Ar), 5.24 (d, J 12.8 Hz, 1H,NCH2Ar), 4.96 (td, J 10.8, 4.8, 1H, 
CH2CHO), 4.51 (d, J 17.2 Hz, 1H, COCH2N), 3.48 (s, 3H, N(CH3)2), 3.32 (s, 3H, N(CH3)2), 2.52 (d, 
J 17.2 Hz, 1H, COCH2N), 2.22-2.17 (m, 1H, CHCPh(CH3)2), 2.06-2.01 (m, 1H, CH2CH2CHCH3), 
1.91-1.83 (m, 1H, CHCH2CHO), 1.80- 1.76 (m, 1H, CH2CH2CHCH3), 1.59-1.51 (m, 1H, 
CH2CH2CHCH3), 1.32 (s, 3H, CPh(CH3)2), 1.35-1.26 (m, 1H, CHCH2CHO), 1.15 (s, 3H, 
CPh(CH3)2), 1.12-0.99 (m, 2H, CH2CH2CHCH3), 0.90 (d, J 6.4 Hz, 3H, CHCH3);  
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13C NMR (100 MHz, CDCl3): 165.4 (CO), 162.2 (dd, J 35.5, 23.1 Hz, CF), 160.3 (dd, J 20.0, 
12.6 Hz, CF), 150.8 (Ar-C), 131.7 (Ar-C), 129.5 (ArCH),128.4 (2 x ArCH), 125.8 (2 x ArCH), 
118.1 (2 x ArCH), 112.3 (ArCH), 76.4 (CH2CHO), 68.2 (NCH2Ar), 60.4 (COCH2N), 50.0 
(CHCPh(CH3)2), 46.6 (N(CH3)2), 49.8 (N(CH3)2), 41.6 (CHCH2CHO), 39.9 (CHCPh(CH3)2), 34.3 
(CH2CH2CHCH3), 31.5 (CPh(CH3)2), 31.1 (CHCH3), 25.5 (CPh(CH3)2), 22.4 (CH2CH2CHCH3), 21.3 
(CHCH3);  
max (neat, cm-1) (CHCl3): 2947 (CH), 1736 (CO), 1465 (CC), 1423 (C-F); 
MSm/z (ESI+) calculated for C27H36F2NO2 [M-Br]+ 444.2714; found 444.2741. 
 
N-(3’-Cyanobenzyl)-N,N-dimethyl-N-[(–phenylmenthoyloxycarbonylmethyl]ammonium 








1H NMR (400MHz, CDCl3): 8.14 (d, J 7.2 Hz, 1H, ArCH), 7.84 (d, J 7.2 Hz, 1H, ArCH), 7.72-
7.69 (m, 2H, ArCH), 7.29-7.10 (m, 4H, ArCH), 6.84 (t, J 7.2 Hz, 1H, ArCH), 5.46 (d, J 12.8, 1H, 
NCH2Ar), 5.22 (d, J 12.8 Hz, 1H,NCH2Ar), 4.92 (ddd, J 11.0, 11.0, 4.8, 1H, CH2CHO), 4.45 (d, J 
17.2 Hz, 1H, COCH2N), 3.42 (s, 3H, N(CH3)2), 3.25 (s, 3H, N(CH3)2), 2.42 (d, J 17.2 Hz, 1H, 
COCH2N), 2.15-2.14 (m, 1H, CHCPh(CH3)2), 2.01-1.97 (m, 1H, CH2CH2CHCH3), 1.89-1.80 (m, 
1H, CHCH2CHO), 1.78- 1.74 (m, 1H, CH2CH2CHCH3), 1.55-1.47 (m, 1H, CH2CH2CHCH3), 1.30 (s, 
3H, CPh(CH3)2), 1.34-1.22 (m, 1H, CHCH2CHO), 1.15 (s, 3H, CPh(CH3)2), 1.12-0.97 (m, 2H, 
CH2CH2CHCH3), 0.89 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 164.4 (CO), 152.6 (Ar-C), 138.5 (ArCH), 136.7 (Ar-C), 133.8 
(ArCH), 129.5 (ArCH), 128.8 (2 x ArCH), 127.9 (ArCH), 125.8 (2 x ArCH), 125.4 (ArCH), 117.1 
(Ar-CN), 113.2 (ArCH), 76.8 (CH2CHO), 66.6 (NCH2Ar), 59.4 (COCH2N), 50.4 (CHCPh(CH3)2), 
49.9 (N(CH3)2), 49.7 (N(CH3)2), 41.7 (CHCH2CHO), 39.5 (CHCPh(CH3)2), 34.4 (CH2CH2CHCH3), 
31.4 (CPh(CH3)2), 31.2 (CHCH3), 25.1 (CPh(CH3)2), 22.8 (CH2CH2CHCH3), 21.3 (CHCH3);  
max (neat, cm-1) (CHCl3): 2968 (CN), 1738 (CO), 2219 (C-N);  
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MSm/z (ESI+) calculated for C28H37N2O2 [M-Br]+ 433.2855; found 433.2821. 
 
N,N-Dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl]-N(4’-trifluoromethylbenzyl) 








1H NMR (400MHz, CDCl3): 7.84 (2H, d, J  8.0 Hz, ArCH), 7.72 (2H, d, J  8.0 Hz, ArCH), 7.21 
(2H, d, J  7.6 Hz, ArCH), 7.07 (2H, t, J 7.6 Hz, ArCH), 6.64 (1H, t, J7.6 Hz, ArCH),5.46 (d, J 12.8, 
1H, NCH2Ar), 5.30 (d, J 12.8 Hz, 1H,NCH2Ar), 4.90 (ddd, J 11.0, 11.0, 4.8, 1H, CH2CHO), 4.25 
(d, J 17.0 Hz, 1H, COCH2N), 3.49 (s, 3H, N(CH3)2), 3.42 (s, 3H, N(CH3)2), 2.44 (d, J 17.2 Hz, 1H, 
COCH2N), 2.20-2.16 (m, 1H, CHCPh(CH3)2), 2.05-2.01 (m, 1H, CH2CH2CHCH3), 1.90-1.81 (m, 
1H, CHCH2CHO), 1.79- 1.76 (m, 1H, CH2CH2CHCH3), 1.59-1.52 (m, 1H, CH2CH2CHCH3), 1.32 (s, 
3H, CPh(CH3)2), 1.33-1.24 (m, 1H, CHCH2CHO), 1.15 (s, 3H, CPh(CH3)2), 1.14-0.99 (m, 2H, 
CH2CH2CHCH3), 0.88 (d, J 6.4 Hz, 3H, CHCH3); 
13C NMR (100 MHz, CDCl3): 163.4 (CO), 152.1 (Ar-C), 135.7 (Ar-C), 133.8 (q, J 33 Hz, 
ArCH),130.2 (ArCH), 129.2 (2 x ArCH), 128.4 (2 x ArCH), 127.9(q, J 3 Hz, ArCH), 125.8 (2 x 
ArCH), 125.4 (ArCH), 124.8 (ArCH), 123.8 (q, J 272 Hz, CF3), 76.8 (CH2CHO), 67.4 (NCH2Ar), 
59.4 (COCH2N), 50.1 (CHCPh(CH3)2), 49.9 (N(CH3)2), 49.4 (N(CH3)2), 41.7 (CHCH2CHO), 39.5 
(CHCPh(CH3)2), 34.4 (CH2CH2CHCH3), 31.2 (CPh(CH3)2), 30.9 (CHCH3), 25.2 (CPh(CH3)2), 23.8 
(CH2CH2CHCH3), 21.3 (CHCH3);  
max (neat, cm-1) (CHCl3): 2977 (CN), 1731 (CO), 1170 (C-F);  
MSm/z (ESI+) calculated for C28H37F3NO2 [M-Br]+ 476.2776, found 476.2778. 
 
N-(4’-Cyanobenzyl)-N,N-dimethyl-N-[(–8-phenylmenthoyloxycarbonylmethyl] 










1H NMR (400MHz, CDCl3): 7.88 (2H, d, J  8.4 Hz, ArCH), 7.78 (2H,d, J  8.4 Hz, ArCH), 7.26 
(2H, d, J  7.0 Hz, ArCH), 7.16 (2H, t, J  7.0 Hz, ArCH), 6.83 (1H, t, J  7.0 Hz, ArCH),5.48 (d, J 
12.8, 1H, NCH2Ar), 5.38 (d, J 12.8 Hz, 1H,NCH2Ar), 4.92 (ddd, J 11.0, 11.0, 4.8, 1H, CH2CHO), 
4.25 (d, J 17.0 Hz, 1H, COCH2N), 3.46 (s, 3H, N(CH3)2), 3.29 (s, 3H, N(CH3)2), 2.43 (d, J 17.2 Hz, 
1H, COCH2N), 2.22-2.18 (m, 1H, CHCPh(CH3)2), 2.03-1.98 (m, 1H, CH2CH2CHCH3), 1.89-1.81 
(m, 1H, CHCH2CHO), 1.78- 1.75 (m, 1H, CH2CH2CHCH3), 1.57-1.49 (m, 1H, CH2CH2CHCH3), 
1.30 (s, 3H, CPh(CH3)2), 1.33-1.25 (m, 1H, CHCH2CHO), 1.15 (s, 3H, CPh(CH3)2), 1.09-0.98 (m, 
2H, CH2CH2CHCH3), 0.88 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 163.4 (CO), 162.8 (COMe)152.1 (Ar-C), 135.7 (Ar-C), 133.8 
(ArCH), 131.9 (ArCH), 128.4 (2 x ArCH), 125.6 (2 x ArCH), 121.0 (ArCH), 117.5 (ArCH), 115.3 
(ArCH), 76.8 (CH2CHO), 67.4 (NCH2Ar), 59.4 (COCH2N), 50.1 (CHCPh(CH3)2), 49.9 (N(CH3)2), 
49.4 (N(CH3)2), 41.7 (CHCH2CHO), 39.5 (CHCPh(CH3)2), 34.4 (CH2CH2CHCH3), 31.2 (CPh(CH3)2), 
30.9 (CHCH3), 25.2 (CPh(CH3)2), 23.8 (CH2CH2CHCH3), 21.3 (CHCH3); 
max (neat, cm-1) (CHCl3): 2941 (CH), 1750 (CO), 1474 (CC);  
MSm/z (ESI+) calculated for C29H40NO4 [M-Br]+ 466.2963; found 466.2958. 
 
N,N-Dimethyl-N-(4’-methoxybenzyl)-N-[(–)-8-phenylmenthoyloxycarbonylmethyl] 







1H NMR (400MHz, CDCl3): 7.46 (2H, d, J  8.5 Hz, ArCH), 7.30-7.23 (2H, m, ArCH), 7.15 (2H, 
t, J  7.4 Hz, ArCH), 6.99 (2H, d, J  8.5 Hz, ArCH), 6.81 (1H, t, J  7.4 Hz, ArCH), 5.12 (d, J 12.8, 
53 
 
1H, NHC2Ar), 4.98 (d, J 12.8 Hz, 1H, NCH2Ar), 4.92-4.93 (m, 1H, CH2CHO), 4.19 (d, J 17.0 Hz, 
1H, COCH2N), 3.82 (s, 3H, OCH3), 3.46 (s, 3H, N(CH3)2), 3.29 (s, 3H, N(CH3)2), 2.43 (d, J 17.2 
Hz, 1H, COCH2N), 2.24-2.18 (m, 1H, CHCPh(CH3)2), 2.02-1.96 (m, 1H, CH2CH2CHCH3), 1.86-
1.78 (m, 1H, CHCH2CHO), 1.74- 1.69 (m, 1H, CH2CH2CHCH3), 1.52-1.44 (m, 1H, 
CH2CH2CHCH3), 1.30 (s, 3H, CPh(CH3)2), 1.30-1.19 (m, 1H, CHCH2CHO), 1.12 (s, 3H, 
CPh(CH3)2), 1.1-0.98 (m, 2H, CH2CH2CHCH3), 0.86 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 163.4 (CO), 161.8 (COMe), 153.1 (ArC), 135.7 (ArC), 128.4 (2 x 
ArCH), 125.6 (2 x ArCH), 121.0 (ArCH), 118.4 (ArCH), 114.3 (ArCH), 76.5 (CH2CHO), 67.5 
(NCH2Ar), 59.6 (COCH2N), 50.1 (CHCPh(CH3)2), 49.9 (N(CH3)2), 49.1 (N(CH3)2), 41.4 
(CHCH2CHO), 39.2 (CHCPh(CH3)2), 34.6 (CH2CH2CHCH3), 31.1 (CPh(CH3)2), 30.6 (CHCH3), 26.6 
(Ar-OCH3), 25.3 (CPh(CH3)2), 23.5 (CH2CH2CHCH3), 21.1 (CHCH3);  
max (neat, cm-1) (CHCl3): 2962 (CN), 1766 (CO), 1479 (CC), 1224 (C-O);  
MSm/z (ESI+) calculated for C28H40NO3 [M-Br]+ 438.3008; found 438.3002. 
 
N,N-Dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl]-N(4’-nitromethylbenzyl) 







1H NMR (400MHz, CDCl3): 8.14 (d, J 7.2 Hz, 1H, ArCH), 7.86 (d, J 7.2 Hz, 1H, ArCH), 7.72-
7.69 (m, 2H, ArCH), 7.30-7.12 (m, 4H, ArCH), 6.89 (t, J 7.2 Hz, 1H, ArCH), 5.48 (d, J 12.8, 1H, 
NCH2Ar), 5.32 (d, J 12.8 Hz, 1H,NCH2Ar), 4.90 (ddd, J 11.0, 11.0, 4.8, 1H, CH2CHO), 4.48 (d, J 
17.2 Hz, 1H, COCH2N), 3.44 (s, 3H, N(CH3)2), 3.28 (s, 3H, N(CH3)2), 2.46 (d, J 17.2 Hz, 1H, 
COCH2N), 2.16-2.12 (m, 1H, CHCPh(CH3)2), 2.02-1.99 (m, 1H, CH2CH2CHCH3), 1.89-1.82 (m, 
1H, CHCH2CHO), 1.76- 1.71 (m, 1H, CH2CH2CHCH3), 1.56-1.46 (m, 1H, CH2CH2CHCH3), 1.32 (s, 
3H, CPh(CH3)2), 1.35-1.25 (m, 1H, CHCH2CHO), 1.16 (s, 3H, CPh(CH3)2), 1.11-0.99 (m, 2H, 
CH2CH2CHCH3), 0.89 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 162.4 (CO), 151.6 (Ar-C), 148.5 (Ar-C), 135.8 (ArCH), 129.5 
(ArCH), 128.8 (2 x ArCH), 125.8 (2 x ArCH), 125.4 (ArCH), 122.1 (ArCH), 76.8 (CH2CHO), 66.8 
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(NCH2Ar), 59.1 (COCH2N), 50.2 (CHCPh(CH3)2), 49.9 (N(CH3)2), 49.2 (N(CH3)2), 41.5 
(CHCH2CHO), 39.3 (CHCPh(CH3)2), 34.1 (CH2CH2CHCH3), 31.2 (CPh(CH3)2), 31.4 (CHCH3), 25.1 
(CPh(CH3)2), 22.8 (CH2CH2CHCH3), 21.3 (CHCH3);  
max (neat, cm-1) (CHCl3): 2938 (CN), 1744 (CO), 1535 (NO2);  
MSm/z (ESI+) calculated for C27H37N2O4 [M-Br]+ 453.2753; found 453.2741. 
 
N,N-Dimethyl-N-(4’-metoxycarbonylbenzyl)-N-[(–)-8-phenylmenthoyloxy carbonylmethyl] 







1H NMR (400MHz, CDCl3): 8.10 (2H, d, J  8.2 Hz, ArCH), 7.72 (2H, d, J 8.2 Hz, ArCH), 7.24 
(2H, d, J  7.3 Hz, ArCH), 7.11 (2H, t, J 7.3 Hz, ArCH), 6.79 (1H, t, J  7.3 Hz, ArCH), 5.38 (d, J 
12.8, 1H, NCH2Ar), 5.30 (d, J 12.8 Hz, 1H,NCH2Ar), 4.90 (ddd, J 11.0, 11.0, 4.8, 1H, CH2CHO), 
4.45 (d, J 17.0 Hz, 1H, COCH2N), 3.49 (s, 3H, N(CH3)2), 3.29 (s, 3H, N(CH3)2), 2.42 (d, J 17.2 Hz, 
1H, COCH2N), 2.20-2.18 (m, 1H, CHCPh(CH3)2), 2.04-2.00 (m, 1H, CH2CH2CHCH3), 1.88-1.78 
(m, 1H, CHCH2CHO), 1.76- 1.71 (m, 1H, CH2CH2CHCH3), 1.55-1.51 (m, 1H, CH2CH2CHCH3), 
1.32 (s, 3H, CPh(CH3)2), 1.30-1.24 (m, 1H, CHCH2CHO), 1.15 (s, 3H, CPh(CH3)2), 1.11-0.99 (m, 
2H, CH2CH2CHCH3), 0.88 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 163.4 (CO), 152.1 (Ar-C), 135.7 (Ar-C), 133.8 (2 x ArCH), 129.5 
(ArCH), 128.4 (2 x ArCH), 126.2 (2 x ArCH), 125.6 (2 x ArCH), 115.1 (CN), 110.2 (Ar-C), 76.8 
(CH2CHO), 67.4 (NCH2Ar), 59.4 (COCH2N), 50.1 (CHCPh(CH3)2), 50.0 (N(CH3)2), 49.5 (N(CH3)2), 
41.7 (CHCH2CHO), 39.5 (CHCPh(CH3)2), 34.4 (CH2CH2CHCH3), 31.2 (CPh(CH3)2), 30.9 (CHCH3), 
25.1 (CPh(CH3)2), 22.8 (CH2CH2CHCH3), 21.2 (CHCH3);  
max (neat, cm-1) (CHCl3): 2955 (CH), 2239 (CN), 1766 (CO);  
MSm/z (ESI+) calculated for C28H37N2O2 [M-Br]+ 433.2861; found 433.2858. 
 
N-(4’-Benzoylbenzyl)-N,N-dimethyl-N-[(–)-8-phenylmenthoyloxycarbonylmethyl] 









1H NMR (CDCl3, 400 MHz) δ 7.91-7.73 (6H, m, ArCH), 7.65 (1H, t, J = 7.3 Hz, ArCH), 7.52 (2H, 
t, J = 7.3 Hz, ArCH), 7.30-7.22 (2H, m, ArCH), 7.18 (2H, t, J = 7.3 Hz, ArCH), 6.87 (1H, t, J = 7.3 
Hz, ArCH), 5.42 (d, J 12.8, 1H, NCH2Ar), 5.31 (d, J 12.8 Hz, 1H, NCH2Ar), 4.93 (ddd, J 11.0, 
11.0, 4.8, 1H, CH2CHO), 4.15 (d, J 17.0 Hz, 1H, COCH2N), 3.47 (s, 3H, N(CH3)2), 3.33 (s, 3H, 
N(CH3)2), 2.47 (d, J 17.2 Hz, 1H, COCH2N), 2.24-2.22 (m, 1H, CHCPh(CH3)2), 2.06-2.00 (m, 1H, 
CH2CH2CHCH3), 1.92-1.84 (m, 1H, CHCH2CHO), 1.78- 1.72 (m, 1H, CH2CH2CHCH3), 1.55-1.51 
(m, 1H, CH2CH2CHCH3), 1.34 (s, 3H, CPh(CH3)2), 1.32-1.27 (m, 1H, CHCH2CHO), 1.15 (s, 3H, 
CPh(CH3)2), 1.11-0.97 (m, 2H, CH2CH2CHCH3), 0.86 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3):  195.9 (C=O), 163.4 (CO), 152.1 (Ar-C), 139.2 (Ar-C), 135.7 (Ar-
C), 133.8 (Ar-C), 133.1 (ArCH), 130.7 (2 x ArCH), 130.1 (2 x ArCH), 126.7 (2 x ArCH),  126.2 
(ArCH), 125.6 (2 x ArCH), 125.4 (2 x ArCH), 125.2 (2 x ArCH), 76.8 (CH2CHO), 67.4 (NCH2Ar), 
59.4 (COCH2N), 50.6 (CHCPh(CH3)2), 50.0 (N(CH3)2), 49.2 (N(CH3)2), 41.3 (CHCH2CHO), 39.2 
(CHCPh(CH3)2), 34.0 (CH2CH2CHCH3), 31.2 (CPh(CH3)2), 30.7 (CHCH3), 25.9 (CPh(CH3)2), 22.1 
(CH2CH2CHCH3), 21.3 (CHCH3); 
max (neat, cm-1): 2960 (CH), 1781 (CO), 1669 (CO);  
MSm/z (ESI+) calculated for C34H42NO3 [M-Br]+ 512.3165; found 512.3163. 
 
N-(4’-Cyanobenzyl)-N,N-dimethyl-N-[(–8-phenylmenthoyloxycarbonylmethyl] 










1H NMR (400MHz, CDCl3): 7.82 (2H, d, J  8.4 Hz, ArCH), 7.75 (2H,d, J  8.4 Hz, ArCH), 7.22 
(2H, d, J  7.0 Hz, ArCH), 7.10 (2H, t, J  7.0 Hz, ArCH), 6.80 (1H, t, J  7.0 Hz, ArCH), 5.38 (d, J 
12.8, 1H, NCH2Ar), 5.32 (d, J 12.8 Hz, 1H,NCH2Ar), 4.89 (ddd, J 10.5, 10.5, 4.4, 1H, CH2CHO), 
4.22 (d, J 17.0 Hz, 1H, COCH2N), 3.65 (s, 3H, ArCOCH3), 3.46 (s, 3H, N(CH3)2), 3.26 (s, 3H, 
N(CH3)2), 2.41 (d, J 17.2 Hz, 1H, COCH2N), 2.20-2.116 (m, 1H, CHCPh(CH3)2), 2.01-1.98 (m, 
1H, CH2CH2CHCH3), 1.87-1.78 (m, 1H, CHCH2CHO), 1.76- 1.72 (m, 1H, CH2CH2CHCH3), 1.55-
1.48 (m, 1H, CH2CH2CHCH3), 1.30 (s, 3H, CPh(CH3)2), 1.32-1.26 (m, 1H, CHCH2CHO), 1.15 (s, 
3H, CPh(CH3)2), 1.10-0.99 (m, 2H, CH2CH2CHCH3), 0.88 (d, J 6.4 Hz, 3H, CHCH3);  
13C NMR (100 MHz, CDCl3): 163.4 (CO), 158.8 (COMe), 152.3 (Ar-C), 136.6 (Ar-C), 133.4 
(ArCH), 131.6 (ArCH), 128.2 (2 x ArCH), 125.6 (2 x ArCH), 121.1 (ArCH), 118.1 (ArCH), 115.1 
(ArCH), 76.6 (CH2CHO), 67.2 (NCH2Ar), 59.6 (COCH2N), 50.1 (CHCPh(CH3)2), 49.9 (N(CH3)2), 
49.2 (N(CH3)2), 41.6 (CHCH2CHO), 39.5 (CHCPh(CH3)2), 34.4 (CH2CH2CHCH3), 31.3 (CPh(CH3)2), 
30.8 (CHCH3), 26.8 (ArCOCH3), 25.1 (CPh(CH3)2), 23.9 (CH2CH2CHCH3), 21.5 (CHCH3); 
max (neat, cm-1) (CHCl3): 2958 (CH), 1777 (CO), 1666 (CO);  
MSm/z (ESI+) calculated for C29H40NO3 requires [M-Br]+ 450.3008; found 450.3002. 
 
General procedure for [1,2]-Stevens rearrangement. 
To an oven dried round-bottomed flask, flushed with nitrogen, ammonium bromide salt 
(100 mg, 1 equiv) in DMSO (5 mL) at room temperature with 5Å molecular sieves, was 
added dropwise BTPP (1.05 equiv). The reaction mixture was allowed to stir overnight. The 
crude mixture was filtered through a small pad of Celite and washed with Et2O. The filtrate 
was partitioned with water (10 mL) and extracted with Et2O (3 × 15 mL). The combined 
organic layers were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated 
under reduced pressure to give the crude rearranged product, which was analysed by HPLC 
and then purified by flash chromatography on silica gel. 
(1R,2S,5R)-5-methyl-2-(1-methyl-1-phenylethyl) cyclohexyl 2-(dimethylamino)-3-
)phenyl)propanoate (81). 
The benzylic ammonium bromide salt (100 mg, 0.18 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 























1H NMR (400 MHz, CDCl3): 7.61 (d, J 7.9 Hz, 1H, ArCH), 7.41-7.45 (m, 1H, ArCH), 7.24-7.32 
(m, 6H, ArCH), 7.10-7.15 (m, 1H, ArCH), 4.73 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.12-3.18 (m, 1H, 1-
H), 3.07-3.10 (m, 1H, 1’-H), 2.69 (dd, J 14.3, 7.4 Hz, 1H, 1’-H), 2.37 (s, 6H, N(CH3)2),2.22 (d, J 
5.7 Hz, 1H, 8-H), 1.78-1.89 (m, 1H, 4-H), 1.67-1.77 (m, 1H, 5-H), 1.48-1.57 (m, 1H, 6-H), 1.37-
1.46 (m, 2H, 4-H and 7-H), 1.31 (s, 3H, 9’-H3), 1.20 (s, 3H, 9’’-H3), 0.84-1.03 (m, 2H, 6-H and 
7-H), 0.80 (d, J 6.5 Hz, 3H, 5’-H3), 0.66-0.76 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 171.5 (2-CO), 151.1 (Ar-C), 131.8 (Ar-C), 131.4 (2 x ArCH), 128.0 
(2 x ArCH), 126.4 (ArCH), 126.0 (2 x ArCH), 125.6 (ArCH), 125.1 (2 x ArCH), 75.3 (1-C), 67.0 (3-
C), 50.1 (8-C), 41.5 (N(CH3)2), 41.44 (1’-C), 39.9 (9-C), 34.4 (4-C), 31.2 (5-C), 27.5 (6-C), 26.9 
(7-C), 25.9 (9’-C and 9’’-C), 21.7 (5’-C). 
max (neat, cm-1); 2980 (C-H), 1722 (C=O), 1214 (C-O). 
MSm/z (ESI+) calculated for [M+H]+ C27H38NO2 408.2899; found 408.2897. 


















Isolated impure (20.0 mg, 24 %). Partial characterisation was only possible, as the product 
was not isolated pure. 
 
1H NMR (400 MHz, CDCl3): 7.52-7.21 (m, 10H, ArCH), 4.65 (td, J 10.7, 4.2 Hz, 1H, 3-H), 
3.18-3.12 (m, 1H, 1-H), 3.07-2.98 (m, 1H, 1’-H), 2.59 (dd, J 14.3, 7.4 Hz, 1H, 1’-H), 2..19 (s, 
6H, N(CH3)2), 2.01 (d, J 5.7 Hz, 1H, 8-H), 1.73-1.69 (m, 1H, 4-H), 1.57-1.67 (m, 1H, 5-H), 1.38-
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1.31 (m, 1H, 6-H), 1.27-1.21 (m, 2H, 4-H and 7-H), 1.18-1.12 (m, 2H, 6-H and 7-H), 1.11 (s, 




The benzylic ammonium bromide salt (100 mg, 0.18 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 


















1H NMR (400 MHz, CDCl3): 7.62 (d, J 7.4 Hz, 1H, ArCH), 7.41-7.45 (m, 1H, ArCH), 7.27-7.40 
(m, 5H, ArCH), 7.01-7.20 (m, 2H, ArCH), 4.73 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.06-3.18 (m, 2H, 1-
H and 1’-H), 2.96 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.42 (s, 6H, N(CH3)2), 2.17-2.25 (m, 1H, 8-H), 
1.80-1.89 (m, 1H, 4-H), 1.69-1.76 (m, 1H, 5-H), 1.49-1.56 (m, 1H, 6-H), 1.37-1.46 (m, 2H, 4-H 
and 7-H), 1.31 (s, 3H, 9’-H3), 1.20 (s, 3H, 9’’-H3), 0.9-1.05 (m, 2H, 6-H and 7-H), 0.80 (dd, J 6.5 
Hz, 1H, 5‘-H), 0.68-0.75 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 171.5 (2-CO), 151.1 (Ar-C), 136.9 (Ar-C), 131.8 (ArCH), 131.4 (2 
x ArCH), 128.6 (Ar-C-CF3), 128.0 (ArCH), 126.4 (ArCH), 126.0 (d, ArCH), 125.6 (2 x ArCH), 
125.1 (ArCH), 123.2 (Ar-CF3), 75.2 (1-C), 67.0 (3-C), 50.2 (8-C), 41.5 (N(CH3)2), 41.4 (1'-C), 
39.9 (9-C), 34.4 (4-C), 31.2 (5-C), 27.5 (6-C), 26.9 (7-C), 25.9 (9’-C and 9’’-C), 21.7 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1730 (C=O), 1214 (C-O), 1153 (C-F). 
MSm/z (ESI+) calculated for C28H37F3NO2 [M+H]+ 476.2771; found 476.2770. 



















Isolated as a pale yellow oil (10.0 mg, 12 %) 
1H NMR (400 MHz, CDCl3): 7.63 (d, J 7.4 Hz, 1H, ArCH),7.43-7.22 (m, 7H, ArCH), 4.51 (td, J 
10.7, 4.2 Hz, 1H, 3-H), 3.13-3.01 (m, 2H, 1-H and 1’-H), 2.84 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.22 
(s, 6H, N(CH3)2), 1.99-1.95 (m, 1H, 8-H), 1.88-1.80 (m, 1H, 4-H), 1.75-1.67 (m, 1H, 5-H), 1.58-
1.51 (m, 1H, 6-H), 1.49-1.36 (m, 2H, 4-H and 7-H), 1.10-1.25 (m, 2H, 6-H and 7-H), 1.06 (s, 
3H, 9’-H3), 0.99 (s, 3H, 9’’-H3), 0.80 (dd, J 6.5 Hz, 1H, 5‘-H), 0.68-0.57 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 169.5 (2-CO), 150.1 (Ar-C), 133.9 (Ar-C), 132.3 (Ar-CH), 130.1 (2 
x Ar-CH), 128.2 (Ar-CF3), 127.7 (Ar-CH), 126.1 (Ar-CH), 125.8 (Ar-CH), 125.2 (2 x ArCH), 124.9 
(Ar-CH), 123.0 (Ar-CF3), 76.2 (1-C), 67.3 (3-C), 50.2 (8-C), 42.5 (N(CH3)2), 41.1 (1'-C), 39.7 (9-
C), 34.5 (4-C), 31.3 (5-C), 27.5 (6-C), 26.4 (7-C), 25.5 (9’-Cand 9’’-C), 20.2 (5’-C). 
max (neat, cm-1): 2988 (C-H), 1735 (C=O), 1221 (C-O), 1159 (C-F). 
MSm/z (ESI+) calculated for C28H37F3NO2 [M+H]+ 476.2771; found 476.2766. 




The benzylic ammonium bromide salt (100 mg, 0.19 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 




















1H NMR (400 MHz, CDCl3): 7.02-7.29 (m, 5H, ArCH), 6.73-6.80 (m, 3H, ArCH), 4.73 (td, J 
10.7, 4.2 Hz, 1H, 3-H), 2.98-3.02 (m, 1H, 1-H), 2.85 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.67 (dd, J 
14.0, 7.5 Hz, 1H, 1’-H), 2.39 (s, 6H, N(CH3)2), 1.83-1.95 (m, 1H, 8-H), 1.65-1.74 (m, 1H, 4-H), 
1.37-1.59 (m, 3H, 4-H, 5-Hand 6-H), 1.30 (s, 3H, 9’-H3), 1.14 (s, 3H, 9’’-H3), 0.84-1.04 (m, 2H, 
6-H and 7-H), 0.85 (d, J 6.5 Hz, 3H, 5’-H3), 0.70-0.79 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 171.6 (2-CO), 162.7 (Ar-C-F), 162.2 (Ar-C-F), 151.3 (Ar-C), 132.0 
(Ar-C), 128.0 (2 x ArCH), 125.5 (2 x ArCH), 121.2 (ArCH), 110.9 (2 x ArCH), 103.5 (ArCH), 75.1 
(1-C), 66.6 (3-C), 50.0 (8-C), 41.5 (N(CH3)2), 41.5(1’-C), 39.8 (9-C), 34.5 (4-C), 31.2 (5-C), 28.3 
(6-C), 26.8 (7-C), 26.6 (9’-C and 9’’-C), 21.7 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1722 (C=O), 1152 (C-F).  
MSm/z (ESI+) calculated for C27H36F2NO2 [M+H]+ 444.2709; found 444.2710. 


















Isolated as a pale yellow oil (17.0 mg, 20 %) 
1H NMR (400 MHz, CDCl3): 7.11-6.99 (m, 8H, ArCH),  4.53 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.00-
29.8 (m, 1H, 1-H), 2.67 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.55 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.21 (s, 
6H, N(CH3)2), 1.83-1.69 (m, 1H, 8-H), 1.62-1.54 (m, 1H, 4-H), 1.47-1.38 (m, 3H, 4-H, 5-H and 
6-H), 1.21-1.14 (m, 2H, 6-H and 7-H), 1.13 (s, 3H, 9’-H3), 1.01 (s, 3H, 9’’-H3), 0.85 (d, J 6.5 Hz, 
3H, 5’-H3), 0.70-0.79 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 170.8 (2-CO), 160.1 (Ar-C-F), 159.8 (Ar-C-F), 151.1 (Ar-C), 132.0 
(Ar-C), 128.5 (2 x ArCH), 125.6 (2 x ArCH), 122.2 (Ar-CH), 113.4 (2 x ArCH), 105.5 (ArCH), 75.4 
(1-C), 66.9 (3-C), 50.1 (8-C), 42.3 (N(CH3)2), 41.5(1’-C), 39.8 (9-C), 35.2 (4-C), 32.1 (5-C), 28.8 
(6-C), 27.1 (7-C), 26.5 (9’-C and 9’’-C), 21.9 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1717 (C=O), 1142 (C-F).  
MSm/z (ESI+) calculated for C27H36F2NO2 [M+H]+ 444.2709; found 444.2721. 






The benzylic ammonium bromide salt (100 mg, 0.195 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 


















1H NMR (400 MHz, CDCl3): 7.48-7.50 (m, 1H, ArCH), 7.10-7.41 (m, 8H, ArCH), 4.71 (td, J 
10.7, 4.2 Hz, 1H, 3-H), 2.73-2.80 (m, 2H, 1-H and 1’-H), 2.63 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.36 
(s, 6H, N(CH3)2),1.90-1.97 (m, 1H, 8-H), 1.61-1.70 (m, 3H, 4-H2 and 5-H), 1.40-1.49 (m, 1H, 6-
H), 1.29 (s, 3H, 9’-H3), 1.16 (s, 3H, 9’’-H3), 0.92-1.00 (m, 2H, 6-H and 7-H), 0.86 (d, J 6.5 Hz, 
3H, 5’-H3), 0.75-0.80 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 171.3 (2-CO), 151.8 (Ar-C), 140.0 (Ar-C), 133.7 (ArCH), 132.7 
(ArCH), 130.0 (ArCH), 128.9 (ArCH), 128.0 (2 x ArCH), 125.4 (ArCH), 125.1 (2 x ArCH), 119.0 
(Ar-C-N), 112.2 (Ar-C), 75.1 (1-C), 67.2 (3-C), 49.9 (8-C), 41.6 (N(CH3)2), 41.3 (1’-C), 39.6 (9-C), 
34.5 (4-C), 31.2 (5-C), 28.1 (6-C), 26.6 (7-C), 24.9 (9’-C and 9’’-C), 21.7 (5’-C).
max (neat, cm-1); m/z (ESI+) 2980 (C-H), 2227 (CN), 1722 (C=O), 1214 (C-O).  
MSm/z (ESI+) calculated for C28H36N2O2 [M+NH]+ 433.2855; found 433.2850. 

















Isolated as yellow oil (16 mg, 19 %) 
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1H NMR (400 MHz, CDCl3): 7.52-7.13 (m, 9H, ArCH), 4.69 (td, J 10.7, 4.2 Hz, 1H, 3-H), 2.76-
2.70 (m, 2H, 1-H and 1’-H), 2.56 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.23 (s, 6H, N(CH3)2),1.97-1.92 
(m, 1H, 8-H), 1.66-1.50 (m, 3H, 4-H2 and 5-H), 1.40-1.28 (m, 1H, 6-H), 1.22-1.17 (m, 2H, 6-H 
and 7-H), 1.14 (s, 3H, 9’-H3), 1.06 (s, 3H, 9’’-H3), 0.81 (d, J 6.5 Hz, 3H, 5’-H3), 0.72-0.55 (m, 1H, 
7-H). 
13C NMR (100MHz, CDCl3): 171.1 (2-CO), 151.6 (Ar-C), 139.8 (Ar-C), 133.2 (ArCH), 132.1 
(ArCH), 1295 (ArCH), 128.3 (ArCH), 127.7 (2 x ArCH), 125.6 (ArCH), 125.1 (2 x ArCH), 118.1 
(Ar-C-N), 113.2 (Ar-C), 75.1 (1-C), 66.4 (3-C), 50.1 (8-C), 41.8 (N(CH3)2), 41.2 (1’-C), 39.2 (9-C), 
34.1 (4-C), 31.1 (5-C), 27.4 (6-C), 26.2 (7-C), 24.3 (9’-C and 9’’-C), 21.7 (5’-C).
max (neat, cm-1); m/z (ESI+) 2980 (C-H), 2222 (CN), 1732 (C=O), 1221 (C-O).  
MSm/z (ESI+) calculated for C28H36N2O2 [M+NH]+ 433.2855; found 433.2858. 




The benzylic ammonium bromide salt (100 mg, 0.18 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 


















1H NMR (400 MHz, CDCl3): 7.46 (d, J 8.0 Hz 1H, ArCH), 7.30-7.39 (m, 7H, ArCH), 7.13-7.19 
(m, 1H, ArCH), 4.01 (td, J 10.2, 4.2 Hz, 1H, 3-H), 2.80-2.86 (m, 2H, 1-H and 1’-H), 2.70 (dd, J 
14.0, 7.5 Hz, 1H, 1’-H), 2.38 (s, 6H, N(CH3)2), 1.87-1.94 (m, 1H, 8-H), 1.57-1.67 (m, 3H, 4-H2 
and 5-H), 1.32-1.44 (m, 1H, 6-H), 1.29 (s, 3H, 9’-H3), 1.16 (s, 3H, 9’’-H3), 0.85-1.01 (m, 2H, 6-H 
and 7-H), 0.72-0.84 (d, J 6.5 Hz, 3H, 5’-H3), 0.71-0.76 (m, 1H, 7-H). 
13C NMR (100MHz, CDCl3): 171.5 (2-CO), 151.7 (Ar-C), 139.4 (Ar-C), 132.7 (ArCH), 130.4 (Ar-
C), 128.3 (2 x ArCH), 128.0 (ArCH), 125.9 (Ar-C-CF3), 125.5 (ArCH), 125.1 (2 x ArCH), 123.1 
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(Ar-CF3), 122.9 (Ar-CH), 75.0 (1-C), 67.4 (3-C), 49.9 (8-C), 41.4 (N(CH3)2), 41.3 (1’-C), 39.6 (9-
C), 34.5 (4-C), 31.2 (5-C), 27.8 (6-C), 26.6 (7-C), 25.3 (9’-C and 9’’-C), 21.6 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1724 (C=O), 1214 (C-O), 1129 (C-F). 
MSm/z (ESI+) calculated for C28H36F3NO2 [M+H]+ 476.2776; found 476.2772. 

















Isolated as yellow oil (15 mg, 18 %) 
1H NMR (400 MHz, CDCl3): 7.41-7.15 (m, 9H, ArCH), 3.98 (td, J 10.2, 4.2 Hz, 1H, 3-H), 2.79-
2.71 (m, 2H, 1-H and 1’-H), 2.65 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.21 (s, 6H, N(CH3)2), 1.92-1.84 
(m, 1H, 8-H), 1.67-1.57 (m, 3H, 4-H2 and 5-H), 1.42-1.34 (m, 1H, 6-H), 119-1.14 (m, 2H, 6-H 
and 7-H), 1.09 (s, 3H, 9’-H3), 1.02 (s, 3H, 9’’-H3), 0.86 (d, J 6.5 Hz, 3H, 5’-H3), 0.71-0.66 (m, 1H, 
7-H). 
13C NMR (100 MHz, CDCl3): 170.4 (2-CO), 151.3 (Ar-C), 139.1 (Ar-C), 133.5 (ArCH), 130.4 
(Ar-C), 128.6 (2 x ArCH), 127.6 (ArCH), 125.1 (Ar-C), 124.8 (Ar-C-CF3), 124.1 (2 x ArCH), 123.6 
(Ar-CF3), 122.6 (Ar-CH), 75.0 (1-C), 67.6 (3-C), 50.0 (8-C), 41.7 (N(CH3)2), 41.1 (1’-C), 39.4 (9-
C), 34.3 (4-C), 31.0 (5-C), 27.7 (6-C), 26.2 (7-C), 25.1 (9’-C and 9’’-C), 21.3 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1710 (C=O), 1224 (C-O), 1125 (C-F). 
MSm/z (ESI+) calculated for C28H36F3NO2 [M+H]+ 476.2776; found 476.2752. 




The benzylic ammonium bromide salt (100 mg, 0.183 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 




















1H NMR (400 MHz, CDCl3): 7.93-7.98 (m, 2H, ArCH), 7.21-7.30 (m, 4H, ArCH), 7.13-7.17 (m, 
3H, ArCH), 4.73 (td, J 10.7 Hz, 4.2 Hz, 1H, 3-H), 3.90 (s, 3H, OCH3), 2.92-3.00 (m, 1H, 1-H), 
2.84 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.70 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.37 (s, 6H, N(CH3)2), 
1.87-1.99 (m, 1H, 8-H),1.52-1.67 (m, 3H, 4-H2 and 5-H), 1.35-1.45 (m, 1H, 6-H), 1.29 (s, 3H, 
9’-H3), 1.17 (s, 3H, 9’’-H3), 0.84-1.1 (m, 2H, 6-H and 7-H2), 0.80 (d, J 6.5 Hz, 3H, 5’-H3), 0.71-
0.80 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): 171.6 (2-CO), 167.1 (COOCH3), 151.5 (Ar-C), 144.0 (Ar-C),129.5 
(2 x ArCH), 129.2 (2 x ArCH), 128.1 (2 x ArCH), 125.4 (ArCH), 125.2 (2 x ArCH), 75.0 (1-C), 
67.6 (3-C), 52.0 (COOCH3), 49.9 (8-C), 41.5 (N(CH3)2), 41.5 (1’-C), 39.7 (9-C), 34.5 (4-C), 31.2 
(5-C), 27.2 (6-C), 26.7 (7-C), 25.9 (9’-C and 9’’-C), 21.7 (5’-C).
max (neat, cm-1): 2980 (C-H), 1727 (C=O), 1656 (C=O), 1151 (C-O).  
MSm/z (ESI+) calculated for C29H40NO4 [M+H]+ 466.2957; found 466.2952. 

















Isolated impure. Partial characterisation was only possible, as the product was not isolated 
pure. 
      
1H NMR (400 MHz, CDCl3): 7.82-7.14 (m, 9H, ArCH), 4.69 (td, J 10.7 Hz, 4.2 Hz, 1H, 3-H), 
3.83 (s, 3H, OCH3), 3.03-2.91 (m, 1H, 1-H), 2.79 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.61 (dd, J 14.0, 
7.5 Hz, 1H, 1’-H), 2.23 (s, 6H, N(CH3)2), 1.98-1.91 (m, 1H, 8-H),1.69-1.59 (m, 3H, 4-H2 and 5-
H), 1.41-1.38 (m, 1H, 6-H), 1.22-1.16 (m, 2H, 6-H and 7-H2), 1.10 (s, 3H, 9’-H3), 1.02 (s, 3H, 9’’-





The benzylic ammonium bromide salt (100 mg, 0.193 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted fllowing the general procedure to yield the desired [1,2] 



















1H NMR (400 MHz, CDCl3): 7.25-7.31 (m, 4H, ArCH), 7.13-7.18 (m, 1H, ArCH), 7.01-7.03 (m, 
2H, ArCH), 6.78-6.81 (m, 2H, ArCH), 4.72 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.81 (s, 3H, OCH3), 
2.96-3.00 (m, 1H, 1-H), 2.80 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.72 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 
2.39 (s, 6H, N(CH3)2), 1.85-1.91 (m, 1H, 8-H), 1.62-1.67 (m, 1H, 4-H), 1.44-1.56 (m, 2H, 4-H 
and 5-H), 1.31-1.39 (m, 1H, 6-H), 1.31 (s, 3H, 9’-H3), 1.19 (s, 3H, 9’’-H3), 0.86-1.00 (m, 2H, 6-H 
and 7-H), 0.78 (d, J 6.5 Hz, 3H,5’-H3), 0.68-0.77 (m, 1H, 7-H). 
13C NMR (100 MHz, CDCl3):172.3 (2-CO), 158.1 (COCH3), 151.4 (Ar-C), 130.1 (Ar-C), 128.7 
(2 x  ArCH), 128.0 (2 x  ArCH), 125.5 (ArCH), 125.2 (2 x ArCH), 113.6 (2 x ArCH), 75.0 (1-C), 
68.3 (3-C), 55.2 (COCH3), 50.0 (8-C), 41.7 (N(CH3)2), 41.3 (1’-C), 39.8 (9-C), 34.5 (4-C), 31.2 (5-
C), 26.9 (9’-C and 9’’-C), 26.8 (6-C), 26.4 (7-C), 21.7 (5’-C).  
max (neat, cm-1): 2980 (C-H), 1717 (C=O), 1214 (C-O). 
MSm/z (ESI+) calculated for C28H39NO3 [M+H]+ 438.3003; found 438.3021. 



















Isolated as yellow oil (10 mg, 12 %) 
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1H NMR (400 MHz, CDCl3): 7.19--6.81 (m, 9H, ArCH), 4.65 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.73 
(s, 3H, OCH3), 2.99-2.4 (m, 1H, 1-H), 2.75 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.64 (dd, J 14.0, 7.5 
Hz, 1H, 1’-H), 2.21 (s, 6H, N(CH3)2), 1.91-1.99 (m, 1H, 8-H), 1.61-1.60 (m, 1H, 4-H), 1.46-1.51 
(m, 2H, 4-H and 5-H), 1.29-1.22 (m, 1H, 6-H), 1.17-1.10 (m, 2H, 6-H and 7-H), 1.04 (s, 3H, 9’-
H3), 0.97 (s, 3H, 9’’-H3), 0.75 (d, J 6.5 Hz, 3H, 5’-H3), 0.69-0.57 (m, 1H, 7-H). 
13C NMR (100MHz, CDCl3):170.3 (2-CO), 156.5 (COCH3), 150.4 (Ar-C), 130.2 (Ar-C), 128.6 (2 
x  ArCH), 128.0 (2 x ArCH), 125.6 (ArCH), 125.1 (2 x ArCH), 112.8 (2 x ArCH), 76.2 (1-C), 68.2 
(3-C), 54.4 (COCH3), 50.0 (8-C), 41.7 (N(CH3)2), 41.1 (1’-C), 39.9 (9-C), 34.3 (4-C), 31.6 (5-C), 
27.2 (9’-Cand 9’’-C), 26.2 (6-C), 25.5 (7-C), 21.3 (5’-C).  
max (neat, cm-1): 2980 (C-H), 1727 (C=O), 1219 (C-O). 
MSm/z (ESI+) calculated for C28H39NO3 [M+H]+ 438.3003; found 438.2992. 




The benzylic ammonium bromide salt (100 mg, 0.187 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 


















1H NMR (400 MHz, CDCl3): 7.93 (d, J 8.4 Hz, 1H, ArCH),7.46-7.52 (m, 1H, ArCH), 7.34-7.39 
(m, 2H, ArCH), 7.28-7.29 (m, 1H, ArCH), 7.23-7.25 (m, 4H, ArCH), 7.01-7.13 (m, 1H, ArCH),  
4.73 (td, J 14.0, 7.5 Hz, 1H, 1’-H), 2.85 (dd, J 14.0 Hz, 7.5 Hz, 1H, 1’-H), 2.38 (s, 6H, N(CH3)2), 
1.83-1.89 (m, 1H, 8-H), 1.57-1.67 (m, 3H, 4-H2 and 5-H), 1.37-1.50 (m, 1H, 6-H), 1.32-1.44 
(m, 2H, 6-H and 7-H), 1.29 (s, 3H, 9’-H3), 1.18 (s, 3H, 9’’-H3), 0.78 (d, J 6.5 Hz, 3H, 5’-H3), 0.7-
0.77 (m, 1H, 7-H). 
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13C NMR (100 MHz, CDCl3): 171.1 (2-CO), 151.2 (Ar-C), 149.8 (C-NO2), 133.7 (Ar-C), 132.9 
(2 x ArCH), 128.0 (2 x ArCH), 127.4 (ArCH), 125.3 (2 x ArCH), 124.7 (2 x ArCH), 75.3 (1-C), 
66.9 (3-C), 49.9 (8-C), 41.6 (2 x N(CH3)2), 41.5 (1’-C), 39.8 (9-C), 34.4 (4-C), 31.2 (5-C), 29.7 (6-
C), 26.8 (7-C), 26.5 (9’-C and 9’’-C), 21.7 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1657 (C=O), 1221 (C-O), 1599 and 1381 (NO2). 
MSm/z (ESI+) calculated for C27H36N2O4 [M+H]+ 453.2753; found 453.2748. 

















Isolated as pale yellow (10 mg, 12%) 
1H NMR (400 MHz, CDCl3): 7.90 (d, J 8.4 Hz, 1H, ArCH), 7.50-7.54 (m, 1H, ArCH), 7.34-7.40 
(m, 2H, ArCH), 7.01-7.15 (m, 5H, ArCH),4.62 (td, J 10.7, 4.2 Hz, 1H, 3-H), 3.41-3.39 (m, 1H, 1-
H), 2.86 (dd, J 14.0, 7.5 Hz, 1H, 1’-H), 2.75 (dd, J 14.0 Hz, 7.5 Hz, 1H, 1’-H), 2.13 (s, 6H, 
N(CH3)2), 1.99-1.91 (m, 1H, 8-H), 1.65-1.57 (m, 3H, 4-H2 and 5-H), 1.49-1.39 (m, 1H, 6-H), 
1.32-1.22 (m, 2H, 6-H and 7-H), 1.18 (s, 3H, 9’-H3), 1.05 (s, 3H, 9’’-H3), 0.79 (d, J 6.5 Hz, 3H, 5’-
H3), 0.67-0.57 (m, 1H, 7-H). 
13C NMR (100MHz, CDCl3): 171.1 (2-CO), 151.2 (Ar-C), 149.8 (C-NO2), 133.7 (Ar-C), 132.9 (2 
x ArCH), 128.0 (2 x ArCH), 127.4 (ArCH), 125.3 (2 x ArCH), 124.7 (2 x ArCH), 75.3 (1-C), 66.9 
(3-C), 49.9 (8-C), 41.6 (2 x N(CH3)2), 41.5 (1’-C), 39.8 (9-C), 4.4 (4-C), 31.2 (5-C), 29.7 (6-C), 
26.8 (7-C), 26.5 (9’-C and 9’’-C), 21.7 (5’-C). 
max (neat, cm-1): 2980 (C-H), 1665 (C=O), 1203 (C-O), 1608 and 1389 (NO2). 
MSm/z (ESI+) calculated for C27H36N2O4 [M+H]+ 453.2753; found 453.274860. 






The benzylic ammonium bromide salt (100 mg, 0.169 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 
















1H NMR (400 MHz, CDCl3): 7.78 (d, J 8.8 Hz, 2H, ArCH),7.73 (d, J 8.8 Hz, 2H, ArCH), 7.62-
7.51 (m, 5H, ArCH), 731-7.21 (m, 5H, ArCH), 7.18-7.13 (m, 3H, ArCH), 4.75 (td, J 10.7 Hz, 4.2 
Hz, 1H, 3-H), 3.04-2.99 (m, 1H, 1-H), 2.91-2.82 (dd, J 14.0 Hz, 7.5 Hz, 1H, 1,-H), 2.66 (dd, J 
14.0 Hz, 7.5 Hz, 1H, 1,-H), 2.41 (s, 6H, 2 x N(CH3)2), 201-1.89 (m, 1H, 8-H), 1.74-1.68 (m, 1H, 
4-H), 1.62-1.57 (m, 2H, 4-H and 5-H), 1.44-1.40 (m, 1H, 6-H), 1.26 (s, 3H, 9,-H3), 1.15 (s, 3H, 
9,-H3), 0.93-1.03 (m, 2H, 6 H and 7-H), 0.89-0.74 (d, J 6.5 Hz, 3H, 5,-H3), 0.62-0.55 (dd, 1H, 7-
H). 
13C NMR (100 MHz, CDCl3):  1.96.6 (COPH), 172.3 (2-CO), 151.2 (Ar-C), 143.5 (Ar-C), 136.6 
(Ar-C), 133.5 (ArCH), 129.3 (ArCH), 128.8 (Ar-C), 128.2 (2 x ArCH) 127.7 (2 x ArCH), 125.6 (2 x 
ArCH), 125.3 (2 x ArCH), 125.0 (Ar-C), 75.2 (1-C), 67.3 (3-C), 51.6 (COOCH3), 49.9 (8-C), 41.7 
(2 x N(CH3)2), 39.3 (9-C), 35.4 (4-C), 34.0 (1,-C), 31.1 (5-C), 26.9 (9,-C), 26.1 (6-C), 25.3 (7-C), 
21.7 (5,-C).  
max (neat, cm-1): 2978 (C-H), 1655 (C=O), 1219 (C-O). 
MSm/z (ESI+) calculated for C27H36N2O4 [M+H]+ 512.3165; found 512.3127. 















Isolated as pale yellow (16 mg, 18 %) 
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1H NMR (400 MHz, CDCl3): 7.83 (d, J 8.4 Hz, 2H, ArCH), 7.67 (d, J 8.4 Hz, 2H, ArCH), 7.13-
7.58 (m, 10H, ArCH), 4.71 (td, J 10.7 Hz, 4.2 Hz, 1H, 3-H),  2.92-3.00 (m, 1H, 1-H), 2.81-2.87 
(dd, J 14.0 Hz, 7.5 Hz, 1H, 1,-H), 2.65-2.74 (dd, J 14.0 Hz, 7.5 Hz, 1H, 1,-H), 2.22 (s, 6H, 2 x 
N(CH3)2), 1.87-1.99 (m, 1H, 8-H), 1.64-1.67 (m, 1H, 4-H), 1.52-1.57 (m, 2H, 4-H and 5-H), 
1.35-1.45 (m, 1H, 6-H), 1.29 (s, 3H, 9,-H3), 1.17 (s, 3H, 9,-H3), 0.87-1.03 (m, 2H, 6 and 7-H), 
0.76-0.84 (d, J 6.5 Hz, 3H, 5,-H3), 0.48-0.60 (dd, 1H, 7-H). 
13C NMR (100 MHz, CDCl3): ): 196.4 (COPH), 171.2 (2-CO), 152.2 (Ar-C), 143.1 (Ar-C), 
136.6 (Ar-C), 133.5 (ArCH), 129.0 (ArCH), 128.5(Ar-C), 128.1 (2 x ArCH) 127.6 (2 x ArCH), 
125.6 (2 x ArCH), 125.3 (2 x ArCH), 125.0 (Ar-C), 75.2 (1-C), 67.3 (3-C), 51.6 (COOCH3), 49.9 
(8-C), 41.7 (2 x N(CH3)2), 39.3 (9-C), 35.4 (4-C), 34.0 (1,-C), 31.1 (5-C), 26.9 (9,-C), 26.1 (6-C), 
25.3 (7-C), 21.7 (5,-C).  
max (neat, cm-1): 2978 (C-H), 1665 (C=O), 1222 (C-O). 
MSm/z (ESI+) calculated for C27H36N2O4 [M+H]+ 512.3165; found 512.3170. 




The benzylic ammonium bromide salt (100 mg, 0.195 mmol, 1.0 equiv) and BTTP (0.067 mL, 
1.05 equiv) were reacted following the general procedure to yield the desired [1,2] 








1H NMR (400 MHz, CDCl3):7.46 (d, J 7.4 Hz, 1H, ArCH), 7.31 (d, J 7.4 Hz, 1H, ArCH),7.10-
7.28 (m, 6H, ArCH),  4.61 (td, J 10.7, 4.2 Hz, 1H, 3-H), 2.98-3.02 (m, 2H, 1-H and 1,-H), 2.83 
(dd, J 14.0, 7.5 Hz, 1H, 1,-H), 2.36 (s, 6H, N(CH3)2),1.92-1.99 (m, 1H, 8-H), 1.61-1.69 (m, 3H, 4-
H2 and 5-H), 1.44-1.52 (m, 1H, 6-H), 1.33 (s, 3H, 9’-H3), 1.19 (s, 3H, 9’’-H3), 0.99-1.07 (m, 2H, 
6-H and 7-H), 0.85 (d, J 6.5 Hz, 3H, 5’-H3), 0.75-0.80 (m, 1H, 7-H). 
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13C NMR (100 MHz, CDCl3): 171.3 (2-CO), 151.8 (Ar-C), 142.2 (Ar-C), 133.7 (ArCH), 132.7 
(ArCH), 130.0 (ArCH), 128.6 (2 x ArCH), 125.1 (2 x ArCH), 115.0 (Ar-C-N), 111.2 (Ar-C), 75.4 
(1-C), 67.5 (3-C), 49.9 (8-C), 41.4 (N(CH3)2), 41.3 (1’-C), 39.6 (9-C), 34.3 (4-C), 31.1 (5-C), 28.1 
(6-C), 26.3 (7-C), 24.9 (9’-C and 9’’-C), 21.7 (5’-C).
max (neat, cm-1); 2980 (C-H), 2227 (CN), 1722 (C=O), 1214 (C-O).  
MSm/z (ESI+) calculated for C28H36N2O2 [M+H]+ 433.2855; found 433.2855. 










To a solution of 2-bromo-1-[(1S,5R)-10,10-dimethyl-3,3-dioxido-3-thia-4- 
azatricyclo[5.2.1.01,5] dec-4-yl]ethanone(1.0 g, 3.00 mmol, 1 equiv) and dimethylamine 
hydrochloride salt (734 mg, 9.00 mmol, 3 equiv.) in THF (15 mL) at 0°C under a nitrogen 
atmosphere, was added dropwise Et3N (2.1 mL, 15.00 mmol, 5 equiv). The reaction mixture 
was allowed to warm to r t, stirred for two days, filtered through Celite® and then 
concentrated in vacuo to afford the productas an orange /brown solid (730 mg, 81%).  
m.p. = 124-127°C; 1H NMR (400 MHz, CDCl3):  3.91 (t, J 7.1, 1H, NCH), 3.75 (s, 2H, NCH2CO), 
3.51 (d, J 13.8, 1H, CH2SO2), 3.42 (d, J 13.8, 1H, CH2SO2), 2.37 (s, 6H, 2 x N(CH3)2), 2.17-1.87 
(m, 5H, CH2C(R)HCH2CH2), 1.45-1.26 (m, 2H, C(R)2HCH2CH2), 1.15 (s, 3H, (CH3)2CR2), 0.97 (s, 
3H, (CH3)2CR2);  
13C NMR (62.5MHz, CDCl3): 169.7 (CO), 65.6 (NCH), 61.6 (NCH2CO), 53.3 (CH2SO2), 49.2 
(CCH2SO2), 48.2 (C(CH3)2), 45.9 (2 x N(CH3)2), 45.0 (CH2CH2CHCH2), 38.9 (CR2HCH2C(R)HN), 
33.7 (CR2HCH2CH2CR3), 26.8 (CR2HCH2CH2CR3), 21.2 ((CH3)2CR2), 20.3 ((CH3)2CR2), 
max/cm-1 (CHCl3): 1706 (CO), 1334, 1165 (SO2);  




General procedure for salt synthesis 
A solution of 2-(dimethylamino)-1-[(1S,5R)-10,10-dimethyl-3,3-dioxido-3-thia-4-
azatricyclo[5.2.1.01,5] dec-4-yl]ethanone(200 mg, 0.666 mmol, 1 equiv) and aryl bromide 
(0.142 mL, 1.996 mmol, 4 equiv) in toluene (10 mL) was heated to 50°C under a nitrogen 
atmosphere for 75 hours. The precipitate was collected over a glass sinter and washed with 
pentane (15 mL). Then the solid was dissolved with DCM (20 mL) and concentrated in 
vacuoto afford the product. 
 
2-[(1S,5R)-10,10-Dimethyl-3,3-dioxido-3-thia-4-azatricyclo[5.2.1.01,5]dec-4-yl]-N,N-









Following the method above, the product was isolated as a pale yellow solid (313 mg, 91%,) 
m.p. = 184-192°C; 
1H NMR (400 MHz, CDCl3):  8.29 (d, J8.6, 2H, ArCH), 8.01 (d, J 8.6, 2H, ArCH2), 5.68 (d, J 
12.7, 1H, COCH2N), 5.63 (d, J 12.7, 1H, COCH2N), 5.13-4.90 (br m, 1H, NCH2Ar), 4.67 (d, J 
16.7, 1H, NCH2Ar), 4.15-3.99 (br m, 1H, NCH), 3.69 (s, 3H, N(CH3)2), 3.62 (s, 3H, N(CH3)2), 
3.57 (d, J 14.0, 1H, CH2SO2), 3.54 (d, J 14.0, 1H, CH2SO2), 2.18-1.94 (m, 5H, CH2C(R)HCH2CH2), 
1.54-1.36 (m, 2H, C(R)2HCH2CH2), 0.98 (s, 3H, (CH3)2CR2), 0.94 (s, 3H, (CH3)2CR2); 
13C NMR (100 MHz, CDCl3):  163.0 (CO), 149.2 (Ar-C), 134.9 (Ar-C), 134.0 (ArCH), 133.6 
(ArCH), 124.1 (2 x ArCH), 66.5 (COCH2N), 64.9 (NCH), 61.2 (NCH2Ar), 52.7 (CH2SO2), 51.7 
(N(CH3)2), 51.2 (N(CH3)2), 49.5 (CCH2SO2), 48.1 (C(CH3)2), 44.8 (CH2CH2CHCH2), 
38.2(CR2HCH2C(R)HN), 32.8 (CR2HCH2CH2CR3), 26.2 (CR2HCH2CH2CR), 21.0 ((CH3)2CR2), 19.8 
((CH3)2CR2);  
max/cm-1 (CHCl3): 3020 (CH), 1678 (CO), 1531 (NO2), 1350, 1119 (SO2);  















Following method above, the product was isolated as a beige solid (256 mg,77%). 
m.p. = 165-167°C; 
1H NMR (400 MHz, CDCl3):  7.92 (d, J 7.5, 2H, ArCH), 7.77 (d, J 7.5, 2H, ArCH), 5.63 (d, J 
12.5, 1H, COCH2N), 5.51 (d, J 12.5, 1H, COCH2N), 5.20-4.95 (br m, 1H, NCH2Ar), 4.60 (d, J 
15.0, 1H, NCH2Ar), 4.14-4.01 (br m, 1H, NCH), 3.68 (s, 3H, N(CH3)2), 3.59 (s, 3H, N(CH3)2), 
3.57 (d, J 12.5, 1H, CH2SO2), 3.54 (d, J 12.5, 1H, CH2SO2), 2.18-2.16 and 1.94 (m, 5H, 
CH2C(R)HCH2CH2), 1.50-1.41 (m, 2H, C(R)2HCH2CH2), 1.11 (s, 3H, (CH3)2CR2), 0.99 (s, 3H, 
(CH3)2CR2); 
13C NMR (100 MHz, CDCl3):  163.1 (CO), 134.3 (2 x ArCH), 132.9 (2 x ArCH), 132.6 (Ar-C), 
117.8 (Ar-C-CN), 114.7 (Ar-CN), 66.8 (COCH2N), 64.8 (NCH), 61.1 (NCH2Ar), 52.7 (CH2SO2), 
51.3 (N(CH3)2), 50.9 (N(CH3)2), 49.5 (CCH2SO2), 48.0 (C(CH3)2), 44.8 (CH2CH2CHCH2), 
38.2(CR2HCH2C(R)HN), 32.8 (CR2HCH2CH2CR3), 26.2 (CR2HCH2CH2CR3), 21.0 ((CH3)2CR2),19.8 
((CH3)2CR2); 
max/cm-1 (CHCl3): 2958 (CH), 2234 (CN), 1699 (CO), 1350, 1119 (SO2); 
MSm/z (ESI+) calculated for C22H30N3O3S [M-Br]+ 416.2002; found 416.1985. 
 
2-[(1S,5R)-10,10-Dimethyl-3,3-dioxido-3-thia-4-azatricyclo[5.2.1.01,5]dec-4-yl]-2-oxo-N- 












1H NMR (400 MHz, CDCl3):  7.90 (d, J 7.5, 2H, ArCH), 7.69 (d, J 7.5, 2H, ArCH), 5.53 (d, J 
12.5, 1H, COCH2N), 5.47 (d, J 12.5, 1H, COCH2N), 5.31-5.08 (br m, 1H, NCH2Ar), 4.85 (d, J 
15.0, 1H, NCH2Ar), 4.29-4.07 (br m, 1H, NCH), 3.64-3.56 (m, 8H, 2 x N(CH3)2 and CH2SO2), 
2.21 and 2.00-1.91 (br m, 5H, CH2C(R)HCH2CH2), 1.54-1.35 (m, 2H, C(R)2HCH2CH2), 1.10 (s, 
3H, (CH3)2CR2), 0.97 (s, 3H, (CH3)2CR2); 
13C NMR (100 MHz, CDCl3):  163.4 (CO), 134.0 (2 x ArCH), 132.8 (q, J 32.2 Hz, Ar-CF3), 131.1 
(Ar-C), 126.1 (2 x ArCH), 123.5 (q, J 273 Hz, Ar-C-CF3), 66.9 (NCH2CON), 64.8 (NCH), 61.2 
(NCH2Ar), 52.7 (CH2SO2), 51.2 (N(CH3)2), 50.8 (N(CH3)2), 49.8 (CCH2SO2), 48.1 (C(CH3)2), 44.9 
(CH2CH2CHCH2), 38.2 (CR2HCH2C(R)HN), 32.8 (CR2HCH2CH2CR3), 26.1 (CR2HCH2CH2CR3), 21.0 
((CH3)2CR2), 19.8 ((CH3)2CR2);  
max (neat, cm-1) (CHCl3): 2957 (CH), 1696 (CO), 1324, 1137 (SO2);  






The ammonium bromide salt (100 mg, 0.187 mmol, 1.0 equiv) and BTTP (0.067 mL, 1.05 
equiv) were reacted following the general procedure to yield the desired [1,2] 
rearrangement product as a yellow solid (10 mg, 15 %). Purified by flash chromatography 








1H NMR (400 MHz, CDCl3):  8.13 (d, J 7.5, 2H, ArCH), 7.40 (d, J 7.5, 2H, ArCH), 4.19 (t, J 7.5, 
1H, CHCH2Ar), 3.88 (dd, J 7.5, 5.0, 1H, NCHcamphor), 3.50 (d, J 15.0, 1H, CH2SO2), 3.38 (d, J 
15.0, 1H, CH2SO2), 3.12 (dd, J 12.5, 7.5, 1H, NCHCH2), 2.98 (dd, J 12.5, 7.5, 1H, NCHCH2), 2.39 
(s, 6H, 2 x N(CH3)2), 2.18-1.88 (m, 5H, CH2C(R)HCH2CH2), 1.44-1.25 (m, 2H, C(R)2HCH2CH2), 
1.19 (s, 3H, (CH3)2CR2), 0.98 (s, 3H, (CH3)2CR2); 
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13C NMR (100 MHz, CDCl3): 170.8 (CO), 146.6 (ArC), 146.3 (ArC), 130.3 (2 x ArCH), 123.5 (2 
x ArCH), 66.9 (NCHCH2Ar), 65.4 (NCH camphor), 53.2 (CH2SO2), 48.2 (CCH2SO2), 47.8 
(C(CH3)2), 44.9 (CH2CH2CHCH2), 41.3 (2 x N(CH3)2), 39.1 (CR2HCH2C(R)HN), 33.3 (CH2Ar), 33.0 
(CR2HCH2CH2CR3), 26.4 (CR2HCH2CH2CR3), 21.0 ((CH3)2CR2), 19.9 ((CH3)2CR2);  
max (neat, cm-1) (CHCl3): 1686 (CO), 1521 (NO2), 1346, 1131 (SO2);  







Isolated as white solid (46 mg, 55 %) m.p. = 145-153°C;  
1H NMR (400MHz, CDCl3):  8.11 (d, J 8.0, 2H, ArCH), 7.44 (d, J 8.0, 2H, ArCH), 4.21 (t, J 8.0, 
1H, CHCH2Ar), 3.86 (dd, J 8.0, 4.0, 1H, NCH camphor), 3.41 (s, 2H, CH2SO2), 3.17 (dd, J 12.0, 
8.0, 1H, NCHCH2), 3.06 (dd, J 12.0, 8.0, 1H, NCHCH2), 2.54 (s, 6H, 2 x N(CH3)2), 2.06-2.00 and 
1.88-1.77 (m, 5H, CH2C(R)HCH2CH2), 1.39-1.31 (m, 2H, C(R)2HCH2CH2), 0.89 (s, 3H, 
(CH3)2CR2), 0.67 (s, 3H, (CH3)2CR2);  
13CNMR (100 MHz, CDCl3):  171.9 (CO), 147.2 (Ar-C), 145.9 (Ar-C), 130.8 (2 x ArCH), 123.9 (2 
x ArCH), 67.1 (NCHCH2Ar), 65.5 (NCH camphor), 53.4 (CH2SO2), 48.6 (CCH2SO2), 48.0 
(C(CH3)2), 44.8 (CH2CH2CHCH2), 41.9 (2 x N(CH3)2), 38.6 (CR2HCH2C(R)HN), 34.5 (CH2Ar), 33.2 
(CR2HCH2CH2CR3), 26.7 (CR2HCH2CH2CR3), 20.6 ((CH3)2CR2), 20.1((CH3)2CR2);  
max (neat, cm-1) (CHCl3): 2925 (CH), 1690 (CO), 1522 (NO2), 1348, 1135 (SO2); 
MSm/z (ESI+) calculated for C21H30N3O5S [M+H]+ 436.1901; found 436.1906. 
 
(2S)-2-(Dimethylamino)-1-[(1S,5R)-10,10-dimethyl-3,3-dioxido-3-thia-4-azatricyclo 
[5.2.1.01,5] dec-4-yl]-3-(4-cyanophenyl)propan-1-one and (2R)-2-(dimethylamino)- 1-











The ammonium bromide salt (100 mg, 0.187 mmol, 1.0 equiv) and BTTP (0.067 mL, 1.05 
equiv) were reacted following the general procedure to yield the desired [1,2] 
rearrangement product as a white solid (51 mg, 51 %). Purified by flash chromatography 
Pet.ether:EtOAc (3.0:1.0); m.p. = 147-149°C;  
1H NMR (400 MHz, CDCl3):  7.56 (d, J 8.4, 2H, ArCH), 7.37 (d, J 8.4, 2H, ArCH), 4.18 (t, J 7.5, 
1H, CHCH2Ar), 3.88-3.83 (m, 1H, NCH camphor), 3.41 (s, 2H, CH2SO2), 3.12 (dd, J 13.4, 7.5, 
1H, NCHCH2), 3.01 (dd, J 13.4, 7.5, 1H, NCHCH2), 2.49 (s, 6H, 2 x N(CH3)2), 2.06-1.98 and 
1.89-1.79 (m, 5H, CH2C(R)HCH2CH2), 1.40-1.34 (m, 2H, C(R)2HCH2CH2), 0.87 (s, 3H, 
(CH3)2CR2), 0.68 (s, 3H, (CH3)2CR2);  
13C NMR (100 MHz, CDCl3): 171.8 (CO), 143.7 (Ar-C), 132.5 (2 x ArCH), 130.8 (2 x ArCH), 
119.4 (Ar-C-CN), 110.8 (Ar-CN), 67.1 (NCHCH2Ar), 65.6 (NCH camphor), 53.4 (CH2SO2), 48.6 
(CCH2SO2), 48.0 (C(CH3)2), 44.8 (CH2CH2CHCH2), 41.9 (2 x N(CH3)2), 38.6 (CR2HCH2C(R)HN), 
34.7 (NCHCH2), 33.2 (CR2HCH2CH2CR3), 26.8 (CR2HCH2CH2CR3), 20.7 ((CH3)2CR2), 20.1 
((CH3)2CR2);  
max (neat, cm-1) (CHCl3): 2927 (CH), 2398 (CN), 1698 (CO), 1334, 1134 (SO2);  







The product was not isolated pure. 
 
(2S)-2-(Dimethylamino)-1-[(1S,5R)-10,10-dimethyl-3,3-dioxido-3-thia-4-azatricyclo 











The ammonium bromide salt (100 mg, 0.187 mmol, 1.0 equiv) and BTTP (0.067 mL, 1.05 
equiv) were reacted following the general procedure to yield the desired [1,2] 
rearrangement product as a white solid (51 mg, 51 %). Purified by flash chromatography 
Pet.ether:EtOAc (3.0:1.0); m.p. = 155-157°C;  
1H NMR (400 MHz, CDCl3): 7.50 (d, J 8.1, 2H, ArCH), 7.36 (d, J 8.1, 2H, ArCH), 4.20 (t, J 7.1, 
1H, CHCH2Ar), 3.85-3.80 (br m, 1H, NCH camphor), 3.38 (s, 2H, CH2SO2), 3.10 (dd, J 13.2, 7.1, 
1H, NCHCH2), 3.00 (dd, J 13.2, 7.1, 1H, NCHCH2), 2.50 (s, 6H, 2 x N(CH3)2), 2.04-1.75 (m, 5H, 
CH2C(R)HCH2CH2), 1.35-1.13 (m, 2H, C(R)2HCH2CH2), 0.87 (s, 3H, (CH3)2CR2), 0.59 (s, 3H, 
(CH3)2CR2);  
13C NMR (100 MHz, CDCl3):  171.9 (CO), 141.9 (ArC), 130.3 (2 x ArCH), 129.1 (q, J 32.2 Hz, 
ArCCF3), 128.0 (q, J 290 Hz, ArCCF3), 125.6 (2 x ArCH), 67.2 (NCHCH2Ar), 65.5 (NCH 
camphor), 53.4 (CH2SO2), 48.4 (CCH2SO2), 47.9 (C(CH3)2), 44.9 (CH2CH2CHCH2), 42.0 (2 x 
N(CH3)2), 38.6 (CR2HCH2C(R)HN), 34.3 (NCHCH2Ar), 33.3 (CR2HCH2CH2CR3), 26.8 
(CR2HCH2CH2CR3), 20.5 ((CH3)2CR2), 19.8 ((CH3)2CR2);  
max (neat, cm-1) (CHCl3): 1690 (CO), 1326, 1133 (SO2);  








Isolated as pale yellow solid m.p. = 123-126°C; 
1H NMR (400 MHz, CDCl3): 7.52 (d, J 8.1, 2H, ArCH), 7.37 (d, J 8.1, 2H, ArCH), 4.18 (t, J 8.2, 
1H, CHCH2Ar), 3.90 (dd, J 7.1,5.2, 1H, NCH camphor), 3.49 (d, J 13.7, 1H, CH2SO2), 3.39 (d, J 
13.7, 1H, CH2SO2), 3.03(dd, J 14.3, 8.2, 1H, NCHCH2), 2.97 (dd, J 14.3, 8.2, 1H, NHCHCH2), 
2.39 (s, 6H, 2 x N(CH3)2), 2.11-1.87 (m, 5H, CH2C(R)HCH2CH2), 1.43-1.11 (m, 2H, 
C(R)2HCH2CH2), 0.92 (s, 3H, (CH3)2CR2), 0.85 (s, 3H, (CH3)2CR2);  
13C NMR (100 MHz, CDCl3):  171.6 (CO), 142.9 (ArC), 130.1 (2 x ArCH), 128.6 (q, J 44.6 Hz, 
ArCCF3), 127.8 (d, J 281. Hz, ArCCF3), 125.5 (2 x ArCH), 67.3 (NCHCH2Ar), 65.8 (NCH 
camphor), 53.6 (CH2SO2), 48.6 (CCH2SO2), 48.1(C(CH3)2), 45.3 (CH2CH2CHCH2), 41.6 (2 x 
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N(CH3)2), 39.5 (CR2HCH2C(R)HN), 33.4 (CR2HCH2CH2CR3), 30.1 (NCHCH2Ar), 26.8 
(CR2HCH2CH2CR3), 21.4 ((CH3)2CR2), 20.3 ((CH3)2CR2); 
max (neat, cm-1) (CHCl3): 1690 (CO), 1326, 1133 (SO2);  
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Chapter 2: Catalytic sp3–sp3 Functionalisation of Sulfonamides 
1. Introduction 
1.1 Metal-Catalysed allylic alkylation 
 
The allylic alkylation reaction can be described as a nucleophilic displacement on a cyclic or 
acyclic allylic electrophile, via a metal-allyl complex or a SN2-type allylic substitution. The 
most common leaving groups are halides and acetate.1 
 
R X R Nu+ Nu
Metal catalyst





This reaction has been extensively studied with various classes of substrates (cyclic and 
acyclic), nucleophiles8, metals and ligands2b. It has been applied successfully in both 
medicinal chemistry and in the synthesis of natural products.2 Other advantages of this 
method are its high level of asymmetric induction when used with chiral ligands and 
flexibility in the type of bonds that can be created-besides C-C bonds, this includes C-N, C-P 
and C-S bonds.3 Nowadays several classes of ligands are available for this purpose and many 
different metals catalyse the reaction including palladium4, platinum,1 
gold,5rhodium,6ruthenium.7 At present, chiral palladium complexes have proven to be  the  
most versatile and have the broadest scope.  
Palladium has shown to be a feature in many of different reactions such as the Heck,9 
Stille,10 Suzuki,11 and the Tsuji-Trost12 (allylic alkylation) reaction (Scheme 2, eq 1-4). An 
advantage with palladium catalyzed reactions is that they often proceed under mild 
conditions affording excellent yields with high chemo-, regio-, and diastereoselectivities.12 
Most commonly, these reactions occur at sp2-hybridized carbon atoms (Scheme 2, eq 1-3) 
on the electrophiles. However, in the allylic alkylation reaction the substitution occurs on a 
sp3-hybridized carbon atom (Scheme 2, eq 4) via an (ƞ3-allyl)Pd complex. Another difference 
of Tsuji-Trost reaction is that the nucleophile in the allylic reaction is not necessarily an 
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organometallic compound like in (Stille (Sn) and Suzuk (B)) where organometallic 
compounds participate in the reaction via a transmetallation to palladium (the products are 






  PPh3 0.02 equv
TMED 1.0 equiv









  LiCl 3.0 equiv































1.2 The Tsuji-Trost reaction 
 
The Tsuji-Trost reaction is referred to as the alkylation of allylic substrates by stabilized 
carbanions, such as malonates (Scheme 3). The reaction was first reported by Tsuji et al. in 
1965 using pre-formed (ƞ3-allyl)Pd complexes.13 Thereafter, the reaction was further 
developed by Trost et al. by introduction of phosphine ligands14 leading to improved 
reactivity and numerous asymmetric allylic alkylation strategies.15 
The allylic alkylation can be performed under mild conditions at ambient temperature. The 
most commonly used substrates are allyl acetates, but a wide range of leaving groups can be 
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utilized to form the π allylpalladium complex, for example benzoates, carbonates, 
carbamates and halides.16 A variety of nucleophiles can be applied in the reaction, but the 























The allylic alkylation reaction has been the object of numerous investigations, from the 
scope of  t h e  react ion  to its mechanism.17,18 The catalytic cycle of the allylic alkylation 
reaction starts by co-ordination of the palladium (0) species to the alkene forming a ƞ2- 
complex (Scheme 4). The next step is oxidative addition, forming a (ƞ3-allyl)Pd complex with 
the leaving group as a counter ion. The resulting (ƞ3-allyl)Pd complex reacts with the 
nucleophile, yielding a ƞ2-complex between Pd0 and the product. At the completion of the 































The mechanism of the reaction determines that the ionisation step occurs with inversion of 
configuration in the case of soft nucleophiles, the attack of nucleophile leads to second 
inversion which ultimately leads to forming the final product with an overall retention 
(Scheme 4). Hard unstabilized carbon nucleophiles react with the ƞ3-allyl complex by 
another mechanism: at the beginning a trans-metalation to Pd occurs and then transfer to 
anallylic carbon atom by reductive elimination, thus forming the final product with an 
overall inversion (Scheme 5). One valuable difference between these two classes of 
nucleophiles is the distinct mechanistic pathways through which each undergoes transition 
metal-catalyzed allylic substitution reactions: “soft” nucleophiles leads to outer-sphere 
nucleophile attack to directly afford the product, while “hard” nucleophiles internally attack 

























1.3 Factors effecting mechanism  
 
The first step in the catalytic cycle after co-ordination involves an oxidative addition of Pd0 
in to the C-leaving group leading to the formation of the PdII-intermediate. The -allyl-
palladiumII complexes can react with another incoming zero valent palladium through an 
SN2-type pathway, leading to stereo-inversion of the intermediate (Scheme 6). As the 
equilibration rate (Kc) between 19 and 21 is faster than the nucleophilic attack, a mixture of 
the diastereomeric products 20 and 22 will be achived. The role of the concentration of the 
catalyst in the reaction was also significant. If the amount of catalyst increases, often results 
















21 22  
Scheme 6 
Kočovský and Farthing showed the steric course of the first step of Pd0-catalyzed allylic 
substitution with stabilized C-nucleophiles can be completely reversed by a suitably 
positioned co-ordinating Ph2P group, resulting in inversion of stereochemistry, as opposed 
to the normally observed retention.22 Therefore, in the presence of a PPh2 group on the 
amine, the reaction was completely reversed resulting in trans-product 25. They also 
observed the formation of the same syn-η3-intermediate regardless of the stereochemistry 
of the starting allylic acetate when treating 23 with a stoichiometric amount of Pd(PPh3)4 in 
the absence of the nucleophile. Hence, these results strongly support the participation of 
η3-chelate 24 in the formation of the trans-product 25 (Scheme 7). This work showed how 







   NaH 1.25 equiv, THF, rt,















The Kurosawa group investigated the effect of solvent on the stereochemistry of oxidative 
addition to allylic chlorides. They showed solvent polarity had significant impact on the 
intermediate stereochemistry (Scheme 8). As they predicted, the formation of 27-trans in 
the reaction was obtained in less polar solvents (benzene, DCM, THF), whereas 27-cis- was 





Bäckvall et al. investigated the effect of an acetate anion on the stereochemical outcome of 
the reaction. The reaction of complex 28 in the presences of benzoquinone at room 
temperature gave a cis attack by a concerted mechanism to yield only trans-product (>98%) 
(Scheme 9). When they performed the same reaction in the same condition with complex 
31 in the presence lithium acetate and lithium chloride pure cis-33 was obtained (>95%) 
(Scheme 10). The reason behind this is chlorine atom obstructs the lower face of the 
molecule. (Scheme 9) shows cis migration seems to occur via σ-allyl palladium complex 29 in 









benzen        100                     0
DCM            94                      6
THF             95                      5
acetone       75                     25
DMF            29                     71
MeCN           5                     95
























  HOAc, rt, 
LiOAc, LiCl
OMe










Due to the importance of this reaction in organic chemistry, it has been extensively studied 
with various classes of nucleophiles, electrophiles, and ligands. Walsh et al. applied Pd-
catalysed allylic substitution with diarylmethane and heterocyclic derivatives. 8 The synthetic 
significance of this method was that the scope of soft nucleophiles would be expanded to 
some pronucleophiles that have much higher pKa than (25). Some of the nucleophiles have 
reported pKa ranging all the way to (32). These reactions were undertaken by employing 






Pd(COD)Cl2 5 mol %
 Xantphos 7.5 mol %
NaN(SiMe3)2 3 equiv,
    DME, rt, 12 h
Ph
R
R = pyridine,    99 %
R = thiophene, 93 %
R = furun,        80 %





Diallylation of diarylmethanes was optimised under similar reaction conditions. Products 37 





Pd(COD)Cl2 5 mol %
 Xantphos 7.5 mol %
KN(SiMe3)2 5 equiv,
    DME, rt, 12 h
Ph
R
R = pyridine,    84 %
R = thiophene, 70 %





Carretero et al. reported the allylic substitution of 1,3-diphenyl-2-propenyl acetate 38 with 








1.0 equiv 3.0 equiv
 [PdCl(C3H5)]2 2 mol %
(1-Phosphino-2-sulfenylferrocenes) 6 mol %











In 2001, Tamaru et al published the first example of direct -allylic alkylation of aldehydes 
with allyl alcohols in the presence of palladium (10 mol %) and stoichiometric amounts of 
Et3B, Et3N, and LiCl at room temperature. They observed that the reaction did not take place 
in the absence of triethylamine, due to formation of PdCl2 and its subsequent de-
coordination being difficult, and remain intact. They hypothesised that in the presence of 








     PPh3 20 mol%
Et3B 2.4 equiv,
Et3N 1.2 equiv, LiCl 1.0 equiv







41 42   43
 92 %
44
4 %  
Scheme 14 
Asymmetric allylation of an alcohol as the nucleophile was first reported by Trost and Toste 
in 1998. They showed that oxygen nucleophiles could be allylated using palladium catalyst 
(0) witha phosphoamidite ligand. The allylation of phenol 45 proceeded under mild 




     Pd2(dba)3 1.0 mol%
    DACH-Phenyl 3 mol%
DCM, rt, 4 h
O
OMe




In 2003, Gais and co-workers reported the asymmetric allylation of sulfonates. Using 
Pd2(dba)3, acetate 48 was reacted with sulfinate salt 49 to yield sulfone 50 in excellent yields 





     [Pd2(dba)3].CHCl3 1.5 mol%





    DCM, H2O, 
THAB (Hex4NB)

















Sulfonamides have been a leading constituent in new drugs since their first appearance in a 
drug the 1930s.30 The impact of the development of sulfur therapeutics is instrumental to 
the evolution of the pharmaceutical industry.31,32 Sulfonamide drugs were the first 
antibiotics33 to be used systemically, and paved the way for the new antibiotic revolution in 
medicine. However, antibiotics are not the only use of of sulfonamides, they are widely used 
in numerous applications example as an anticancer agent,34 as an antiviral HIV protease 
inhibitor 35 and in central nervous system disease such as (Stroke and trauma).36 
 
1.5 Direct -functionalisation of sulfonamides 
 
Within the traditional chemical space of drug-like molecules, the sulfonamide motif is a 
frequently seen subunit of synthetic biologically active molecules. The motif is a robust, 
pharmacologically reliable unit that appears in both drug substances and drug-like 
molecules. 37-Substitution with alkyl groups can improve the binding properties; 38 
however, despite the wide interest in the exploitation of sulfonamides, many of the 
compounds reported bear sparse substitution patterns adjacent to the sulfonyl moiety.  In 
the context of the drive for late-stage molecular functionalisation, there has been a recent 




Enders and co-workers developed an efficient chiral auxiliary that would allow, for the first 
time, asymmetric -alkylation of sulfonamides. They lithiated sulfonamides 51a-c with 
lithium diisopropylamide (LDA) and allowed reaction with benzyl bromide at -78 °C to afford 
the sustituted sulfonamides 52a-c with good yield but poor diastereoselectivity. They 
determined that unsatisfactory diastereoselectivities (de) were due to the lower steric 






1. LDA 1.0 equiv,
    TMEDA 3.0 equiv
      0 C, THF
2. BnBr 1.01 equiv,






 R = MeOCH2OCH2   85 %,  4% d.e
 R = MeOCH2             94 %, 11 % d.e
 R = MeOC(Me)2        78 %,  27% d.e
51 a-c 52 a-c
 
Scheme 17 
Considerable efforts have been directed towards the discovery of selective RORc (retinoic 
acid receptor-related orphan receptor) inverse agonists as potential treatments of 
inflammatory diseases by Fauber and co-workers.38 They prepared sultam 54 by reacting 
compound 53 with phenylmethanesulfonyl chloride and triethylamine to yield the 
secondary sulfonamide, followed by treatment with two equivalents of base to facilitate 
cyclization to sultam 54.38 
 
 1. BnSO2Cl, Et3N, THF, 0-23 °CH2N
Br
.HBr
2. n-BuLi, (i-Pr)2NH, phenanthroline,






            54




As shown above, traditional methods (Scheme 17-18) for direct alkylation of sulfonamides 
require strong bases, reactive electrophiles, low temperatures and the use of stoichiometric 
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amounts of polar additives such as tetramethylethylenediamine (TMEDA),40 
hexamethylphosphoramide (HMPA),41 and phenanthroline.38 With a demand for functional 
group tolerance milder condition were needed, therefore, several recent reports have 
described metal-catalysed -arylation of alkyl sulfonamides.43 
Northrup et al. described the reaction of -methanesulfonamide 56 with aryl bromide 55(a-
d) using palladium catalysis and a bulky electron rich trialkylphosphine ligand in the 
precence of sodium-tert-butoxide at high temperature. Authors believed that the bulky 
trialkylphosphine ligand led to increased conversions by reducing homocoupling and 









  Pd(OAc)2 5 mol%
t-BuPH.BF3 15 %mol
NaOt-Bu 3.0 equiv,







R = 4-Cl           72 %
R = 4-CN         85 %
R = 4-CO2
tBu   77 %
R = 4-CF3        74 %




In 2016, Knauber and Tucker developed a palladium catalyzed Negishi-type α-arylation of 
sulfones and sulfonamides with a broad range of aryl bromides. In situ sulfonamide 
selectively reacts with tmp·ZnCl·LiCl base (tmp: 2,2,6,6-tetramethylpiperidine) and 
undergoes transmetalation with arylpallaium species. They also successfully coupled a 
board range of electron-deficient, electron-rich, and heterocyclic aryl bromides with 
sensitive functional groups well tolerated. Aryl bromides were converted within 2 h at 130 
°C in a microwave reactor. The desired monoarylated α-branched benzyl sulfones and 








      tmp·ZnCl·LiCl-solution 
(0.25 M in THF, 5 mL, 2.5 equiv,
THF, 130 °C, 2 h
     W
Pd(dba)2 10 mol%,
  Xphos 10 mol%
R = Me        79 %
R = CF3        83 %
R = NO2       91 %















      tmp·ZnCl·LiCl-solution 
(0.25 M in THF, 5 mL, 2.5 equiv,
THF, 130 °C, 2 h
     W
Pd(dba)2 10 mol%,














      tmp·ZnCl·LiCl-solution 
(0.25 M in THF, 5 mL, 2.5 equiv,
THF, 130 °C, 2 h
     W
Pd(dba)2 10 mol%,
















Yajima and co-workers published Palladium(0)-catalyzed conditions for the -arylation of 
sultams with iodobenzene (Scheme 21).43c Product 66–a was isolated in very good yield 85% 
and good diastereoselectivity (2.5:1). The slightly more sterically demanding iso-butyl-
containing sultam 65-b also proved to be a suitable coupling partner and gave rise to 
arylated product 66–b in 75% yield, with a slight improved 3:1 dr in favour of the cis 
product. Furthermore, the bulkier phenyl substituted 65–a yielded product 66–c in 89% 
isolated yield and 9:1 dr. Overall, it appears that the steric demand of the C3 substituent 
significantly contributes to the diastereomeric outcome of the reaction, with the bulkier 




      TMP·ZnCl·LiCl- 2.5 equiv,
THF, 60 °C, 4 h
   PhI 1.1 equiv
Pd(dba)2 10 mol%,









R = Me   85 %, dr 2.5:1
R = 
iBu   75 %, dr 3:1






65 a-c 66 a-c 67 a-c
 
Scheme 21 
Zhou et al reported a single example of branched sulfonamide synthesis. When they reacted 
bromobenzene 69 with sulfonamide 68 in the presence of a palladium (0) catalyst and 










    LiHMDS 1.0 equiv,
ZnCl2 1.2 equiv, 70 °C,










2. Aim of the project 
 
A palladium catalyzed α-allylation of benzyl sulfonamides with a broad range of ally acetates 
has been presented. At the beginning, we hypothesized that anions derived from benzyl 
sulfonamides would be amenable to Pd-catalysed allylation (Figure 2); however, there are 
relatively few reports of the use of nucleophiles other than carbonyl-stabilised carbanions in 
such reactions,49 and fewer examples still of the use of non-carbonyl abranched anions.8 
Hence, sulfonamides were deprotonated with NaH base in situ and cross-coupled in the 
presence of a Pd catalyst and ligand at room temperature. Several allyl acetate derivatives 
have been successfully cross-coupled, and sigma-receptor binders were tolerated. The 
desired monoallylated α-branched sulfonamides were obtained in good yields. This method 
would be suitable for late stage functionalization in medicinal chemistry.  
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In addition, the pka of sulfonamide-derived anions are not definitively established; direct 
deprotonation even of benzyl sulfonamides often requires strong base,50 suggesting that the 
anions thus obtained might be considered to be (hard) and therefore likely to lead to 
products of inversion upon reaction with-allylpalladium species. Nevertheless, 
mechanistic studies of Pd-catalysed allylation indicated direct attack at the carbon rather 
than Pd, this confirms that the anions derived from benzylsulfonamides can be considered 

















3. Result and Discussion 
 
The difficulties in accessing non-planar “hard-to-make” chemical matter for incorporation 
into drug molecules have been well-enumerated,44 and in some therapeutic areas these 
difficulties have significant consequences. There has been a drive to deliver new small 
molecules with enhanced biological relevance, and a concomitant call for late-stage 
functionalisation45 to enable improvements in pharmacological properties. Since the 
discovery of the antibacterial activity of streptozone and sulfachrysoidine by Domagk,46 
sulfonamides have found widespread application in the development of new antibiotics. 
Numerous examples of - substituted sulfonamides of the general type 71 displayed potent 
pharmacological activity. The racemic -substituted sulfonylmethanesulfonamide 
derivatives 72 and 73 are reported to be inhibitors of carbonic anhydrase (CA).47 In 
particular, fluorosulfonamide 72 was determined as the most potent inhibitor among the 
compounds of this type examined. The small improvements in binding affinity observed 
upon introducing a methyl group have been attributed to desolvation effects.48 Increased 
methylation reduces the free energy of desolvation required to strip a ligand of solvated 































Given these important applications, we set out to introduce diarylmethane derived 
nucleophiles for the Pd-catalyzed allylic substitution. Sulfonamide 76 was readily prepared 
in multi-gram scale in 86% yield from phenylsulfonyl chloride 74 and stoichiometric amount 















We commenced our study with an examination of the reaction of dimethylsulfonamide 73 
with allyl acetate 74 under Pd-catalysed allylation conditions. Given that the transformation 
was previously unreported, we were gratified to observe that the reaction afforded the 








[Pd(allyl)Cl]2 2.5 mol %
dppb 11 mol %
NaOtBu (1.2 equiv),





73 74   75




A screening of several organic solvents was initiated and all reactions were monitored by 
TLC analysis of crude mixtures. A solvent screen was undertaken with the Pd-allylation 
reaction using same conditions as mentioned above. When CHCl3 was applied as a solvent 
only starting material was recovered. It was found that DME solvent gave the best results. 
The reaction also readily went to work in DMF, THF, NMP, DCM and Benzene with low yields 
to DME. For reactions performed in MeCN and Dioxane were observed a significant amount 
of starting material in the NMRs, therefore the yields quoted are with impurities. 
As shown in (Scheme 24), this study was initially evaluated in the reaction of sulfonamide 
with allyl acetate in the presence of allyl palladium catalyst and dppb ligand. Gratifyingly, 
under influence of 1.2 equiv sodium tert-butoxide base at a room temperature, the reaction 
produced allyl sulfonamide 75 in 74 % yields in DME. Having recognised the significant 










2.5 mol % [Pd(allyl)Cl]2
11 mol % dppb





Entry R1 R2 Base (equiv) Yield (%) 
1 Ph H (1.2, 3.0, 5.0) - 
2 CH3 H 5.0 24 % 
3 CH3 CH3 (1.2, 3.0, 5.0) - 
4 CH2- CH2- CH3 H 1.2 63 % 
Table 1 
Unfortunately, most of the hindered allyl acetate derivatives (prenyl acetate and cinnamyl 
acetate) provide to be fruitless under the same reaction condition. It was thought that to 
increase the conversion of starting material, more bases would necessary. Unfortunately, no 
reaction was observed when 3.0 equiv of sodium tert-butoxide was used. But when 5.0 
equiv of the base was used the desired product was obtained in 24% yield (Table 1, entry 2). 
Potassium tert- butoxide (Pka of conjugate acid around 17 similar to sodium-tert-butoxide) 
(1.2, 3.0, 5.0 equiv) failed to give any observable product and only starting materials were 
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recovered. We, therefore, believe that reaction conditions play a critical role in this 
transformation. We hypothesized that generation of deprotonated sulfonamide was 











2.5 mol % [Pd(allyl)Cl]2
11 mol % dppb





Entry Base Amount (equiv) Yield (%) 
1 LiHMDS 1.5 0 
2 LiHMDS 3 0 
3 LiHMDS 4 8 
4 LiHMDS 5 11 
5 KHMDS 5 0 
6 NaHMDS 5 0 
7 BTPP 5 0 
8 NaH 1.0 0 
9 NaH 3.0 Trace 
10 NaH 6.0 94 % 
Table 2 
Based on the assumption that NaOtBu was a weak base to deprotonate the -C adjacent to 
sulfonamide group, a stronger base was needed. Walsh and co-workers8 actually obtained 
good yield of the desired allylated product with strong anionic bases. Hence, 73 and 76 were 
treated with NaHMDS, LiHMDS and KHMDS under the same reaction conditions. Several 
approaches were tried and some selected results are presented in (Table 2). Unfortunately, 
low or no yield of the rearranged product 77 was obtained and starting material 73 was 
recovered in various amounts. To test if a base with lower Pka value could increase the 
conversion of the allylated product, NaH was probed. Treating a mixture of 73 and 76 with 
NaH (1.0 equiv) at room temperature yielded no product, but at elevated base (3.0 equiv) 
some conversion could be observed by 1H NMR. Finally, using NaH (6.0 equiv) 76 was 
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converted to product 77 in 94% yield. Hence, sodium hydride was chosen and compared to 
the allylation promoted by NaOtBu, this base gave a best result. 
We believed that one of the main aspects of the reaction that required significant 
optimisation was the source of palladium. A catalyst screen was performed to investigate 
the effect of the catalyst on the reaction. In addition, hexenyl acetate was chosen as it gave 
the highest yield with the optimised condition (Table 4, entry 5). (Table 3, entry 1, 2, 3 and 
4) summarizes the result. As shown, PdCl2(MeCN)2 gave the good results. Pd(OAc)2, 
Pd2(dba)3 and Pd(PPh3)4did give a moderate conversion to the desired product 79 but with 










2.5 mol % catalyst
11 mol % dppb
DME, 25 °C, 20 h73 78 79
NaH (6.0 equiv)
 
Entry Catalyst Yield (%) 
1 Pd(OAc)2 21 
2 Pd2(dba)3 30 
3 Pd(PPh3)4 43 
4 PdCl2(MeCN)2 90 
5 Pd(allyl)Cl2 96 
Table 3 
Armed with these initial data, we proceeded next to probe the scope of the reaction with 
regard to the allyl component (Table 4), using a range of commercial or easily prepared 
substrates. It quickly transpired that the catalytic allylation reaction proceeded in generally 
good yield under mild conditions with a diverse range of allyl donors to afford -substituted 
sulfonamides. Both acyclic and cyclic acetates delivered the corresponding C-allylated 
sulfonamides efficiently, and, if present, alkene stereochemistry was generally retained (75, 
77, 79-86).  For compound 77 a mixture of E/Z product was observed. It appeared to us that 
a rigid bidentate ligand should interfere more sterically with a syn substituent, leading to a 
preference for the anti configuration. Provided isomerisation is sufficiently fast, this offers 
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the possibility of obtaining Z-products in palladium-promoted reactions of allylic substrates, 





(anti) R = H, R = Me










[Pd(C3H5)Cl]2  2.5 mol%
        dppb 11 mol%
DME, 25 °C, 48 h





























































































































           [a] yields are quoted for isolated compounds. 
           [b] 1,2-bis(diphenylphosphino)ethane (dppe) used as ligand. 
           [c] 1,1’-bis(diphenylphosphino)ferrocene (dppf) used as ligand.  
           [d] d.r. refers to the relative configuration at the exocyclic stereogenic centre. 
            [f] Prepared by S. Walton 
Table 4 
In all cases in which isomerism was possible, linear products were exclusively favoured over 




       dppb 11 mol%










R R = Me   62 %
R = Ph    57 %




The regioisomeric ratio of products is influenced by several factors, including the nature of 
the R-group, the ability of the intermediate to syn-anti isomerize, and the ligands used. 52 
When applying a monosubstituted allylic substrate, terminal attack of the nucleophile at -
allyl specie swas the preferred result. The allylic carbon atoms in the syn- and anti-isomers 
of the η3-allyl-palladium complex possess different reactivity. In monosubstituted allylic 
substrates the resulting anti-isomer has a moderate preference for internal nucleophilic 
substitution whereas the syn isomer has a strong preference for terminal nucleophilic 
attack.52b The syn-isomer is usually more stable than the anti-isomer and, as a result, the 
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major product in palladium catalyzed allylic alkylation reactions is the product of attack on 
the least substituted carbon linear product (Scheme 25). 
 
[Pd(C3H5)Cl]2 2.5 mol%
       dppb 11 mol%
















The allylated products still have an acidic -proton, the possibility exists for a second 
functionalisation. Thus, when reacted with excess allyl acetate, sulfonamide 73 was directly 
converted to diallylated product 90 (96% yield), which could be converted by ring-closing 






[Pd(C3H5)Cl]2  2.5 mol%
        dppb 11 mol%













Grubbs G2 5 mol%














[Pd(C3H5)Cl]2  2.5 mol%
        dppb 11 mol%












Entry R R1 Compound Yield (%) 
1 Boc-piperazinyl Allyl 92 71 
2 Boc-piperazinyl Hexenyl 93 52 
3 Boc-piperazinyl Nerayl 94 52 
4 Boc-piperazinyl Crotyl 95 59 
5 Boc-piperazinyl Prenyl 96 52 
6 Morpholinyl Allyl 97 52a 
7 Morpholinyl Hexenyl 98 79 a 
8 Morpholinyl Nerayl 99 45 a 
9 Piperidinyl Allyl 100 77 
10 Pyrrolidinyl Allyl 101 61 
11 Tetrahydropyridinyl Allyl 102 82 a 
         [a] prepared by S. Walton 
Table 5 
After we had conclusively demonstrated the feasibility of the sulfonamide allylation 
reaction, our attention turned to an examination of the scope in the nitrogen sub-unit: again 
we observed generally efficient reaction of sulfonamides under the catalytic allylation 
conditions, leading to new sulfonamides 92-102 (Table 5). In contrast, the Boc-piperizene 
derivatives 92-9658 resulted in modest 52-59% yields (Entry 1-5). The lower yield is likely due 
to attack of nucleophile on the tert-butyl ester carbonyl. When crotyl acetate (entry 4) 
reacted with the anion of nucleophile, only E-product 95 could be detected, confirming a 
higher relative reactivity at the anti substituted carbon.51 
OAcR +
[Pd(C3H5)Cl]2 2.5 mol%
       dppb 11 mol%

































Entry R R1 R2 Compound Yield (%) Linear:Branched 
1 H H H 103 76 10:0 a 
2 H F H 104 67 10:0 
3 H Me H 105 53 10:0 
4 CH3CH2CH2 H H 106 58 10:0 
5 CH3 H Br 107 63 10:0 a 
6 H H OMe 108 37 10:0 a 
7 Ph Cl H 109 62 3:2 
[a] Prepared by S. Walton 
Table 6 
To probe the suitability of the reaction as a late-stage functionalisation tool, we next 
examined nanomolar receptor ligands as substrates. Thus, sigma-receptor binding 
sulfonamides57 reacted smoothly under the reaction conditions to afford new -
functionalised products 103-107 and 109 in good yield (Table 6). Compounds containing 
halogens substituted are important because of their bioactivities and uses in material 
science.54 Therefore, the reaction was interesting with 3-fluoro sigma receptor binding 
sulfonamide (Entry 2) as nucleophile afforded the desired product 104 in 67% yield (Entry 
2). We then applied our reaction conditions to 4-bromo and 3-chloro sigma receptor binding 
sulfonamides (Entry 5 and 7). A potential problem with these substrates lies in the 
competing oxidative addition of C−X (X = Cl, Br) bonds to the active Pd(0) species. We were 
pleased to find that Pd-catalyzed allylic substitution afforded the allylated products 107 and 
109 in 63 and 62% yield, respectively. These results suggest that generation of the π-allyl 
palladium intermediate is significantly faster than the oxidative addition of C−X bonds to the 
Pd(0) species under our reaction conditions. As might be anticipated, nucleophiles with 
electron donating groups are less acidic and, therefore, more difficult to deprotonate. We 
found that 3-methyl sigma receptor binding sulfonamide (Entry 3) underwent substitution 
to give 105 in 53% yield. Surprisingly, 4-methoxy sigma receptor binding sulfonamide (Entry 
6) reacted to provide 108 in 37% yield under our reaction conditions as Walsh et al failed to 
gain a desired product with 4-methoxy substitutent.8 
Notably, reaction with cinnamyl acetate afforded both linear and branched products (109, 
respectively, 3:2 ratio), whereas reactions with hexenyl and crotyl acetates afforded only 
linear products 106, 107 and 108. The reduced regioselectivity in this case, relative to cases 
with less basic nucleophiles, is likely a manifestation of the high reactivity of the 3-
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chlorobenzylpyparizen phenyl sulfonamide nucleophile. The additional substituent (Ph) on 
the η3-allyl in the phenyl causes this group to adopt a conformation positioning it anti to the 
bulky (legend)Pd center (Figure 6). The substituent partially blocks the nucleophilic attack at 
the more substituted terminus, resulting in a modification of the regioselectivity toward the 
less substituted carbon of the allyl.8 The mildness of the method is emphasised by the fact 









L = linear, B = branched
 
Fig 6 
In our group, the structure of the product was confirmed by X-ray crystallography. The 
mechanism of Pd-catalysed allylation is well-predicated to occur by one of two pathways, 
depending on the polarisation of the nucleophile component.55 If the allylation reaction was 
performed with cis-cyclohexenyl acetate 110,56 cis products 111 were obtained exclusively 
(as confirmed by X-ray (Fig 7) analysis of a single crystal of a p-bromobenzoyl derivative, 
111, of the major product, Scheme 29). The cis-configured product indicates direct attack at 
the carbon rather than Pd, this confirms that the anions derived from benzylsulfonamides 
































In summary, we have developed a new application of Pd catalysed allylation for direct sp3-
sp3 coupling of sulfonamides and demonstrated that the reaction is applicable to bioactive 
small molecules. The transformation occurs at ambient temperature, is tolerant to sensitive 
functional groups and provides ready access to new compounds in good yields. Mechanistic 
studies have shown that benzyl sulfonamide derivatives behave as (soft) or stabilized 
nucleophiles. The nucleophile derived from benzyl sulfonamide undergoes external attack 
on π-allyl palladium species under our reaction conditions. The use of asymmetric protocols 
in this process has proved non-productive, delivering allylated products in variable yields 









General methods  
Unless otherwise stated, all reactions were carried out under an inert atmosphere of dried 
nitrogen, in glassware which had been oven-dried. Reagents were purchased from Sigma-
Aldrich, Acros, Alfa Aesar, Fisher Scientific, TCI UK or Lancaster Research Chemicals and 
were not purified except where stated. Solvents were purchased anhydrous and stored over 
molecular sieves, or distilled under nitrogen from an appropriate drying agent in accordance 
with the procedures of Perrin and Armarego. Dimethoxyethane and THF were distilled from 
sodium benzophenone ketyl radical while DCM was distilled from calcium hydride. Thin 
layer chromatography was performed on aluminium sheets coated with Merck silica gel 60 
F254 with visualisation using potassium permanganate solution, phosphomolybdic acid 
and/or scrutinised under 254 nm UV light. Column chromatography was performed using 
Silica 60 (35-70 microns) supplied by Fisher unless otherwise stated. Nuclear magnetic 
resonance (NMR) spectroscopy was performed on a Bruker Avance 400 NMR spectrometer 
(1H NMR at 400 MHz, 13C NMR at 100 MHz) with the appropriate deuterated solvent. 
Chemical shifts in 1H NMR spectra are expressed as ppm downfield from TMS and in 13C 
NMR, are relative to internal standard, and reported as singlet (s), doublet (d), triplet (t), 
quartet (q) and combinations thereof, or multiplet (m). Coupling constants (J) are quoted in 
Hz and are averaged between coupling partners and rounded to the nearest 0.2 Hz. Mass 
spectrometry was performed using a Bruker MicroTOF-Q instrument with electrospray 
ionisation in the positive mode. FT-IR data was acquired using Thermo Electron Corporation 
Nicolet 380 FTIR with Smart Orbit diamond window instrument with wavenumbers being 
reported in cm-1.  
General Procedure for the Palladium-catalysed sulfonamide allylation 
To an oven dried round-bottomed flask, flushed with nitrogen, sodium hydride 60 % in 
mineral oil (120 mg, 3.0 mmol) was added, and was immediately washed with petrol. To 
this, palladium chloride dimer (4.7 mg, 0.0125 mmol), 1,4-bis(diphenylphosphino)butane 
(dppb, 23 mg, 0.055 mmol) in DME (1 mL) was added and stirred for one hour at 25 °C. To 
this mixture, sulfonamide (0.50 mmol) and allylic acetate (0.55 mmol) in DME (1 mL) was 
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added and stirred for 48 hours at 25 °C. After this time the reaction was quenched with 









HbHa 4  
N,N-Diphenylmethanesulfonamide (100 mg, 0.50 mmol) and allyl acetate (0.06 mL, 0.55 
mmol) were reacted following the general procedure to yield N,N-dimethyl-1-phenylbut-3-
en-1-sulfonamide (98 mg, 82 %) as a colourless solid; Rf= 0.5 (95:5 toluene: EtOAc); mp: 91–
92 °C; 1H NMR (CDCl3 400 MHz) 7.34-7.42 (5H, m, Ar-H); 5.57 (1H, ddt,J 7.0 Hz 10.1 Hz 17.1 
Hz, 3-H); 5.06 (1H, dd, J 1.4 Hz 17.0 Hz,4-Hb); 4.99 (1H, dd, J 0.8 Hz 10.1 Hz, 4-Ha); 4.15 (1H, 
dd, J 4.2 Hz11.3 Hz 1-H); 3.00-3.10 (2H, m, 2-H2); 13C NMR (100 MHz) C133.3 (3-CH); 129.6 
(Ar-CH); 128.9 (Ar-CH); 128.7 (Ar-CH); 118.2 (4-CH2); 37.6 (N-(CH3)2); 34.3 (2-CH2); max 
(solid, cm-1) 1137 & 1310 (sulfonamide S-N); 969 (CH=CH); m/z(ESI+) calculated for 










N,N-Dimethyl-1-phenylmethanesulfonamide (92mg, 0.5 mmol) and E-2-butenyl acetate (95 
% E) (0.07 ml, 0.55 mmol) was reacted following the general method, to yield (E)-N,N-
dimethyl-1-phenylpent-3-ene-1-sulfonamide (E:Z 67:33) (103 mg, 82% or 119 mg, 94 % with 
dppe) as a colourless solid; Rf= 0.52 (95:5 toluene:EtOAc); mp: 92 – 94 °C; Data for trans 
isomer 1H NMR (CDCl3 400 MHz)  7.34-7.42 (m, 5H, Ar-H); 5.44-5.54 (1H, m, 3-H); 5.11-5.19 
(1H, m, 4-H); 4.11 (1H, dd, J 4.1 Hz 11.2 Hz, 1-H); 2.8-3.0 (2H, m, 2-H2); 2.50 (6H, s, N-(CH3)2); 
1.5 (3H, dd, J 0.8 Hz 6.5 Hz, 5-H3); 13C NMR (100 MHz) C 133.4 (Ar-C); 129.6 (Ar-CH); 128.9 
(Ar-CH); 128.8 (3-CH); 125.6 (4-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 33.2 (2-CH2); 17.8 (5-CH3); 
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max (solid, cm-1) 1137 & 1319 (sulfonamide S-N); m/z (ESI+) calculated for C13H19NO2S 









44'' 4'  
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol) and prenyl acetate (0.075 
mL, 0.55 mmol) was reacted following the general method to yield N,N-4-trimethyl-1-
phenylpent-3-ene-1-sulfonamide (115 mg, 86 % or 0.99 mg, 74 % with dppe) as a colourless 
solid; Rf= 0.58 (95:5 toluene:EtOAc); mp 90–92°C; 1H NMR (CDCl3 400 MHz)  7.34-7.42 (5H, 
m, Ar-H); 4.87 (1H, ddt, J 1.4 Hz 3.0 Hz 7.3 Hz, 3-H); 4.07 (1H, dd, J 4.0 Hz 11.3 Hz, 1-H); 3.05-
2.84 (2H, m, 2-H2); 2.50 (6H, s, N-(CH3)2); 1.56 (6H, s, 4’’-CH3, 4’-CH3; 13C NMR (100 MHz) 
134.9 (Ar-C); 133.6 (4-C); 129.6 (Ar-CH); 128.7 (Ar-CH); 128.6 (Ar-CH); 118.9 (3-CH); 67.4 (1-
CH); 37.6 (N-(CH3)2); 28.8 (2-CH2); 25.6 (4’’-CH3); 17.9 (4’-CH3); max (solid, cm-1) 1133 & 1304 









N,N-Dimethyl-1-phenylmethanesulfonamide (97 mg, 0.49 mmol) and 2-methylallyl acetate 
(72 mg, mmol) was reacted following the general method to yield N,N-3-trimethyl-1-
phenylbut-3-ene-1-sulfonamide (102 mg, 82 %) as a colourless solid; Rf= 0.50 (95:5 
toluene:EtOAc); m.p: 127 – 128 °C; 1H NMR (CDCl3 400 MHz) 7.35-7.42 (5H, m, Ar-H); 4.67 
(1H, bs, 3’-H); 4.61 (1H, bs, 3’-H); 4.30 (1H, dd, J 3.7 Hz 11.6 Hz, 1-H); 2.88-3.06 (2H, m, 2-H); 
2.54 (6H, s, N-(CH3)2); 1.61 (3H, 4-H3); 13C NMR (100 MHz) 140.3 (3-C); 133.3 (Ar-C); 129.6 
(Ar-CH); 128.9 (Ar-CH); 114.1 (3’-CH2); 66.0 (N-(CH3)2); 37.7 (N-(CH3)2); 22.3 (4-CH3); max 
(solid, cm-1) 1132 & 1323 (sulfonamide S-N); 895 (geminal alkene); m/z (ESI+) calculated for 














N,N-Dimethyl-1-phenylmethanesulfonamide (0.099 g, 0.5 mmol) and E-2-hexenyl acetate 
(0.09 mL, 0.55 mmol) was reacted following the general method to yield (E)-N,N-dimethyl-1-
phenylhept-3-ene-1-sulfonamide (137 mg, 96%) as a colourless solid; Rf= 0.60 (95:5 
toluene:EtOAc); mp: 65 – 67 °C; 1H NMR (CDCl3 400 MHz)  7.34-7.41 (5H, m, Ar-H); 5.38-
5.47 (1H, m, 4-H); 5.08-5.17 (1H, m, 3-H); 4.10 (1H, dd J 4.2 Hz 11.1 Hz, 1-H); 2.81-3.04 (2H, 
m, 2-H2); 2.54 (6H, s, N-(CH3)2); 1.76-1.88 (2H, m, 5-H2); 1.19-1.26 (2H, m, 6-H2); 0.72 (3H, t, J 
7.1 Hz, 7-H); 13C NMR (100 MHz) 134.5 (4-CH); 133.4 (Ar-C); 129.7 (Ar-CH); 128.8 (Ar-CH); 
128.6 (Ar-CH); 124.5 (3-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 34.4 (2-CH2); 33.2 (5-CH2); 22.3 (6-
CH2); 13.4 (7-CH3); max (solid, cm-1) 1137 & 1320 (sulfonamide S-N); 964 (E-alkene);m/z 











N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, mmol) and cinnamyl acetate (0.097 g, 
mmol) was reacted following the general method, replacing dppb with1,1’-
bis(diphenylphosphino)ferrocene as the ligand, to yield (E)-N,N-dimethyl-1,4-diphenylbut-3-
ene-1-sulfonamide (125 mg, 79 %) as a colourless solid; Rf= 0.5 (95:5 toluene:EtOAc); mp: 
88–90 °C; 1H NMR (CDCl3 400 MHz) 7.36-7.46 (5H, m, Ar-H); 7.17 (5H, m, Ar-H); 6.43 (1H, d, 
J 15.6, 4-H); 5.93 (1H, dt, J 7.2, 15.7, 3-H); 4.22 (1H, dd, J 4.2, 10.8, 1-H); 3.25 (1H, dddd, J 1.0 
Hz 4.2 Hz 7.6 Hz 14.2 Hz, 2-H); 3.08 (1H, dddd, J 1.1 Hz 6.8 Hz 10.9 Hz 14.2 Hz, 2-H); 2.55 (6H, 
s, N-(CH3)2); 13C NMR (100 MHz) C 136.9 (Ar-C); 133.2 (Ar-C); 133.1 (4-CH); 129.6 (Ar-CH); 
129.0 (Ar-CH); 128.8 (Ar-CH); 128.5 (Ar-CH); 127.4 (Ar-CH); 126.2 (Ar-CH); 124.8 (3-CH); 67.3 
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(1-CH); 37.6 ((N-CH3)2); 33.7 (2-CH2); max (solid, cm-1) 1135.6 & 1317 (sulfonamide S-N); 















N,N-Dimethyl-1-phenylmethanesulfonamide (98 mg, 0.5 mmol) and cyclohex-2-en—yl 
acetate (77 mg, mmol) was reacted following the general method to yield 1-(cyclohex-2-en-
1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (dr (59:41 determined by 1H NMR) (105 
mg, 74 %) as a colourless solid; Rf= 0.42 (95:5 toluene:EtOAc); m.p:119–121 °C; data for 
diastereomer A: 1H NMR (CDCl3 400 MHz) 7.36-7.43 (5H, m, Ar-H); 5.69-5.72(1H, m, 3’-H); 
5.46 (1H, bd, J 10.2 Hz, 2’-H); 3.99 (1H, d J 8.5 Hz, 1-H); 3.19-3.22 (1H, m, 1’-H); 2.44 (6H, s, 
(N-CH3)2); 2.13 (1H, dt J 6.3 Hz 11.0 Hz, 6’-H); 1.88-1.97 (2H, m, 4’H); 1.58-1.63 (2H, m, 1-H, 
6’-H); 13C NMR (100 MHz) 133.4 (Ar-C); 130.1 (Ar-CH); 129.7 (3’-CH); 128.8 (Ar-CH); 128.6 
(Ar-CH); 127.0 (2’-CH); 71.8 (1-CH); 37.5 (N-CH3)2); 37.4 (1’-CH); 28.0 (6’-CH); 24.9 (4’-CH); 
21.2 (5’-CH); data for diastereomer B: 1H NMR(CDCl3 400 MHz) 7.36-7.43 (5H, m, Ar-H); 
6.22 (1H, dd J 2.3 Hz 10.5 Hz, 2’-H); 5.78-5.83 (1H, m, 3’-H); 4.07 (1H, d J 9.9 Hz, 1-H); 3.12-
3.17 (1H, m, 1’-H); 2.42 (6H, s, N-(CH2)2); 1.92-1.97 (2H, m, 4’-H2); 1.52-1.63 (3H, 5’-H2, 6’-H); 
1.09-1.16 (1H, m, 6’-H); 13C NMR (100 MHz) 133.6 (Ar-C); 130.0 (Ar-CH); 128.7 (3’-CH2, 4 x 
Ar-CH); 128.6 (2’-CH); 72.6(1-CH); 36.5 (N-(CH3)2); 30.9 (1’-CH); 26.7 (6’-CH2); 25.0 (4’-CH2); 
20.6 (5’-CH2); max (solid, cm-1) 1319 & 1136 (sulfonamide S-N); m/z (ESI+) calculated for 














N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol) and cyclopent-2-en-1-yl 
acetate (70 mg, 0.55 mmol) was reacted following the general method to yield 1-(cyclopent-
2-en-1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (d.r 50:50) (114 mg, 79 %) as a 
colourless solid; Rf=0.45 (95:5 toluene:EtOAc); m.p 88–91 °C; data for diastereomer A: 1H 
NMR (400 MHz CDCl3)7.35-7.37 (5H, m, Ar-H); 5.77 (1H, dd J 2.3 Hz 5.6 Hz, 2’-H); 5.42 (1H, 
dd J 1.7 Hz 5.5 Hz, 3’-H); 3.98 (2H, d J 8.8 Hz, 1-H); 3.72-3.79 (1H, m, 1’-H); 2.47 (6H, s, N-
(CH3)2); 2.31-2.36 (1H, m, 5’-H); 2.27-2.29 (2H, m, 4’-H2); 1.88-1.93 (1H, m, 5’-H); 13C NMR 
(100 MHz)C 134.2 (Ar-C); 133.3 (2’-CH); 131.1 (3’-CH); 128.7 (Ar-CH); 128.6 (Ar-CH); 128.5 
(Ar-CH); 71.6 (1-CH); 46.7 (1’-CH); 37.5 (N-CH3)2); 32.3 (5’-CH); 29.2 (4’-CH); data for 
diastereomer B: 1H NMR (400 MHz CDCl3)H7.38-7.43 (5H, m, Ar-H); 6.27 (1H, dd J 2.2 Hz 
5.7 Hz, 2’-H); 5.86 (1H, dd J 2.4 Hz 5.6 Hz, 3’-H); 3.98 (1H, d J 10.4 Hz, 1-H); 3.66-3.70 (1H, m 
1’-H); 2.45 (6H, s, N-(CH3)2); 2.19-2.26 (2H, 4’-H2);1.83-1.86 (1H, m, 5’-H); 1.22-1.32 (1H, m, 
5’-H); 13C NMR (100 MHz) C133.7 (Ar-C); 132.9 (2’-CH); 132.2 (3’-CH); 130.0 (Ar-CH); 129.7 
(Ar-CH); 128.7 (Ar-CH); 72.4 (1-CH); 46.9 (1’-CH); 37.4 (N-(CH3)2); 30.9 (4’-CH2); 29.0 (5’-
CH);max (solid, cm-1) 1316 & 1131 (sulfonamide S-N);m/z (ESI+) calculated for C14H19NO2S 















N,N-Dimethyl-1-phenylmethanesulfonamide (108 mg, 0.5 mmol) and neryl acetate (119 mg, 
0.55 mmol) was reacted following the general method to yield (Z)-N,N,4,8-tetramethyl-1-
phenylnona-3,7-diene-1-sulfonamide(140 mg, 83 % or 114 mg, 68 % with dppe) as a yellow 
oil; Rf= 0.62 (95:5 toluene:EtOAc); 1H NMR (CDCl3 400 MHz) H 7.35-7.42 (5H, m, Ar-H); 5.07-
5.09 (1H, m, 3-H); 4.83-4.87 (1H, t, J 7.2, 7-H); 4.05 (1H, dd, J3.9 Hz 11.2 Hz, 1-H); 3.02-3.09 
(1H, m, 2-H); 2.79-2.88 (1H, m, 2-H); 2.54 (6H, s, (CH3)2); 2.00-2.03 (2H, m, 5-CH2); 1.70 (2H, 
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bs, 6-CH2); 1.60 (3H, s, 8-CH3); 1.57 (3H, s, 8-CH3); 1.53 (3H, s, 4-CH3). 13C NMR (100 MHz) 
138.6 (4-C); 133.6 (Ar-C); 131.8 (8-C); 129.6 (Ar-CH); 128.8 (Ar-CH); 128.6 (Ar-CH); 123.9 (7-
CH); 119.5 (3-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 32.0(5-CH2); 28.4 (2-CH2); 26.3 (6-CH2); 25.8 
(8-CH3); 23.8 (8-CH3) 17.6 (4-CH3); 16.2 (4-CH3);max (solid, cm-1) 1136 & 1329 (sulfonamide 
















N,N-Dimethyl-1-phenylmethanesulfonamide (101 mg, mmol) and geranyl acetate (108 mg, 
mmol) was reacted following the general method, using dppf ligand (30 mg, 0.055 mmol) to 
yield (E)-N,N,4,8-tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (140 mg, 84 %) as a 
colourless solid; Rf= 0.6 (95:5 toluene:EtOAc); m.p: 52 – 53 °C ; 1H NMR (400 MHz) 7.34-
7.42 (5H, m, Ar-CH); 4.87-4.9 (1H, m, 7-H); 4.83-4.85 (1H, m, 3-H); 4.07 (1H, dd J 3.8 Hz 11.3 
Hz, 1-H); 3.00-3.07 (1H, m, 2-H); 2.82-2.89 (1H, m, 2-H); 2.54 (6H, s, N-CH3)2); 1.90-1.94 (2H, 
m, 6-H2); 1.83-1.89 (2H, m, 5-H2); 1.61 (3H, s, 8-CH3); 1.56 (3H, s, 4-CH3); 1.51 (3H, s, 9-CH3); 
13C NMR (100 MHz) C138.5 (4-C); 133.6 (Ar-C); 131.4 (8-C); 129.6 (Ar-CH); 128.7 (Ar-CH); 
123.9 (7-CH); 118.9 (3-CH); 67.4 (1-CH); 39.5 (5-CH2); 37.7 (N-CH3)2); 28.7 (2-CH2); 26.4 (6-
CH2); 25.6 (8-CH3); 17.6 (9-CH3); 16.2 (4-CH3);max (solid, cm-1) 1323 & 1135 (sulfonamide S-














N,N-Dimethyl-1-phenylmethanesulfonamide (99 mg, 0.5 mmol) and (±)-trans-diphenylallyl 
acetate (138 mg, 0.55 mmol) was reacted following the general method to yield (E)-N,N-
dimethyl-1,2,4-triphenylbut-3-ene-1-sulfonamide (dr 80:20 determined by 1H NMR) (172 
mg, 87 %) as a colourless solid; Rf= 0.6 (95:5 toluene:EtOAc); m.p: 131 – 133 °C; data for 
diastereomer A: 1H NMR (CDCl3 400 MHz)  7.17-7.47 (15H, m, Ar-CH); 6.32-6.39 (2H, m, 3-
H, 4-H); 4.61 (1H, t J 7.1 Hz, 2-H), 4.51 (1H, d J7.1 Hz, 1-H); 2.44 (6H, s, N-(CH3)3); 13C NMR 
(100 MHz)  141.4 (Ar-C); 137.2 (Ar-CH); 132.6 (3/4-CH); 132.4 (Ar-CH); 130.7 (2 x Ar-CH); 
128.9 (1 x Ar-CH); 128.8 (3/4-CH); 128.6 (2 x Ar-CH); 128.5 (2 x Ar-CH); 128.4 (2 x Ar-CH); 
128.3 (2 x Ar-CH); 127.4 (1 x Ar-CH); 127.1 (1 x Ar-CH); 126.3 (2 x Ar-CH); 71.8 (1-CH); 50.2 
(2-CH); 37.4 (N-(CH3)2); max (solid, cm-1) 1133 & 1459 (sulfonamide S-N); m/z (ESI+) 


















To an oven dried round-bottomed flask flushed with nitrogen, sodium hydride 60 % in 
mineral oil (160 mg, 4 mmol) was added and immediately washed with petrol. To this, 
Pd2Cl2(allyl)2 (4.8 mg, 0.0125 mmol) and dppb (22 mg, 0.055 mmol) was added in DME (1 
mL), stirred for one hour at 25 °C. To this mixture, N,N-dimethyl-1-
phenylmethanesulfonamide (100 mg, 0.5 mmol) and allyl acetate (250 mg, 2.5 mmol) was 
added in DME (1 mL) stirring at 25 °C for 48 hours. The reaction was quenched with water 
(0.2 mL) and purified using column chromatography to yield N,N-dimethyl-4-phenylhetpa-
1,6-diene-4-sulfonamide (131 mg, 96 %) as a colourless solid; Rf = 0.52 (95:5 toluene:EtOAc); 
m.p:80 – 83 °C; 1H NMR (400 MHz) 7.59-7.61 (2H, m, Ar-CH); 7.35-7.42 (3H, m, Ar-CH); 5.86 
(2H, ddt J 7.0 Hz 10.2 Hz 14.0 Hz, 2-CH, 6-CH); 5.19 ( 2H, dd J 1.2 Hz 17.0 Hz, 1-CHa, 7-CHa); 
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5.12 (2H, d J 10.3 Hz, 1-CHb, 7-CHb); 3.27 (2H, dd J 6.7 Hz 15.1 Hz, 3-CH, 5-CH); 3.01 (2H, dd J 
7.1 Hz 15.1 Hz, 3-CH, 5-CH); 2.46 (6H, s, N-(CH3)2); 13C NMR (100 mHz) 135.9 (Ar-C); 132.4 
(1-CH, 6-CH), 129.3 (Ar-CH); 128.4 (Ar-CH); 128.2 (Ar-CH); 119.3 (1-CH2, 7-CH2); 71.7 (4-C); 
38.7 (N-(CH3)2); 36.7 (2-CH2, 7-CH2); max (solid, cm-1) 1312 & 1131 (sulfonamide S-N); 919 












N,N-Dimethyl-4-phenylhetpa-1,6-diene-4-sulfonamide (100 mg, 0.36 mmol) and Grubbs 2nd 
generation catalyst (15.2 mg, 0.018 mmol) was dissolved in DCM (6 mL) and the reaction 
mixture was stirred at 25 °Cfor overnight. The reaction mixture was passed through a silica 
plug and the solvent evaporated to dryness to yield N,N-dimethyl-1-phenylcyclopent-3-ene-
1-sulfonamide (84 mg, 93 %) as a grey solid; m.p: 111 – 114 °C; 1H NMR (400 MHz) 7.50-
7.52 (2H, m, Ar-CH); 7.31-7.39 (3H, m, Ar-CH); 5.83 (2H, s, 3-CH, 4-CH); 3.55 (2H, d J 15.7, 
2/5-CH2); 3.15 (2H, d J 16.6, 2/5-CH2); 2.64 (6H, s, (N-(CH3)2); 13C NMR (100 MHz) 139.1 (Ar-
C); 129.6 (Ar-CH); 128.3 (3-CH, 4-CH); 128.2 (Ar-CH); 128.1 (Ar-CH); 41.9 (2-CH2, 5-CH2); 38.9 
(N-(CH3)2), max (solid, cm-1) 1312 & 1131 (sulfonamide S-N); 705 (cis-alkene); m/z (ESI+) 
calculated for C13H17NO2S [M+Na]+; 274.0872, found 274.0873. 











Tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate (170 mg, 0.5 mmol) and allyl acetate 
(57 mg, 0.55 mmol) was reacted following the general procedure to yield tert-butyl 4-[(1-
phenylbut-3-en-1-yl)sulfonyl]piperazine-1-carboxylate (135 mg, 71 %) as a colourless solid; 
Rf= 0.31; (95:5 toluene:EtOAc); m.p: 88 – 91 °C; 1H NMR (400 MHz) H 7.38 (5H, s, Ar-CH); 
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5.52 (1H, ddt J 7.0 Hz 10.0 Hz 14.0 Hz, 3-H); 5.05 (1H, dd J 1.3 Hz 17.0 Hz, 4-Ha); 4.97 (1H, dd 
J 1.2 Hz 10.1 Hz, 4-Hb); 4.07 (1H, dd J 4.1 Hz 11.2 Hz, 1-H); 3.28 (2H, bs, N-(CH2)2); 3.17-3.23 
(2H, m, N-(CH2)2); 3.06-3.12 (1H, m, 2-H); 2.96-3.02 (2H, m, N-(CH2)2); 2.85-2.98 (1H, m, 2-
CH); 2.72-2.77 (2H, m, N-(CH2)2); 1.42 (9H, s, (CH3)3); 13C NMR (100 MHz) C 154.3 (C=O); 
133.1 (3-CH); 132.7 (Ar-C); 129.7 (Ar-CH); 129.2 (Ar-CH); 128.9 (Ar-CH); 118.4 (4-CH2); 80.3 
((CH3)3); 68.2 (1-CH); 45.9 (N-(CH2)2); 34.4 (2-CH2); 21.5 (N-(CH2)2); max (solid, cm-1) 1692 
(C=O); 1131 & 1321 (sulfonamide S-N); m/z (ESI+) calculated for C19H28N2O4S [M+Na]+; 
403.1662, found 403.1671. 












Tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate (174 mg, 0.5 mmol) and E-2-hexenyl 
acetate (78mg, 0.55 mmol) was reacted following the general procedure to yield tert-butyl 
(E)-4-[(1-phenylhept-3-en-1-yl)sulfonyl]piperazine-1-carboxylate (110 mg, 52 %) as a yellow 
oil; Rf= 0.29; (95:5 toluene:EtOAc); 1H NMR (400 MHz) H 7.35 (5H, s, Ar-H); 5.41 (1H, dt J 6.9 
Hz 15.2 Hz, 4-H); 5.07 (1H, dt J 7.0 Hz 15.0 Hz, 3-H); 4.07 (1H, dd J 4.1 Hz 11.2 Hz, 1-H); 3.18-
3.22 (2H, m, N-(CH2)2); 3.15-3.21 (2H, m, N-(CH2)2); 2.95-3.04 (3H, m, 2-CH, N-CH2); 2.66-
3.04 (3H, m, 2-CH, N-CH2); 1.77-1.84 (2H, m, 5-CH2); 1.39 (9H, s, (C-CH3)3); 1.13-1.24 (2H, m, 
6-H2); 0.69 (3H, t J 7.5, 7-H3); 13C NMR (100 MHz) C 154.4 (C=O); 134.6 (4-CH); 132.9 (Ar-C); 
129.7 (Ar-CH); 129.0 (Ar-CH); 128.7 (Ar-CH); 124.3 (3-CH); 80.3 (C-(CH3)3); 68.6 (1-CH); 45.8 
(N-(CH2)4); 34.4 (5-CH2); 33.3 (2-CH2); 28.3 ((CH3)3); 22.3 (6-CH2); 13.4 (7-CH3); max (solid, 
cm-1) 1693 (C=O); 1145 & 1338 (S=O); m/z (ESI+) calculated for C22H34N2O2S [M+Na]+; 




















Tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate (175 mg, 0.5 mmol) and neryl acetate 
(109 mg, 0.55 mmol) was reacted following the general procedure to yield Tert-butyl (Z)-4-
([4,8-dimethyl-1-phenylnona-3,7-dien-1-yl]sulfonyl)piperazine-1-carboxylate (127 mg, 52 %) 
as a yellow oil; Rf = 0.23; (95:5 toluene:EtOAc); 1H NMR (400 MHz); 7.37 (s, 5H, Ar-H); 5.04-
5.12 (1H, m 7-H); 4.80-4.87 (1H, t J 6.76 Hz 11.24 Hz, 3-H); 3.97 (1H, dd J 4.0 Hz 11.4 Hz, 1-
H); 3.14-3.42 (4H, m, N-(CH2)2); 2.60-3.10 (6H, m, 2-H2, N-(CH2)2); 1.81-2.10 (4H, m, 5-H2, 6-
H2); 1.70 (3H, s, C-H3); 1.60 (3H, s, C-H3); 1.57 (3H, s, C-H3); 1.42 (9H, s, ((CH3)3); 13C NMR 
(100 MHz) 154.3 (C=O); 138.8 (4-C); 133.2 (Ar-C); 131.9 (8-C); 126.7 (Ar-CH); 129.0 (Ar-CH); 
128.7 (Ar-CH); 123.9 (7-CH); 119.3 (3-CH); 80.3 (C(-CH3)3); 68.7 (1-CH); 45.8 (N-(CH2)2); 32.0 
(5-CH); 28.3 ((CH3)3); 26.3 (6-CH); 25.8 (4-CH3); 23.3 (2-CH2); 17.7 (8-CH3); 16.2 (8-CH)3); max 
(oil, cm-1) 1694 (C=O); 1281 & 1134 (sulfonamide S-N); 702 (cis-alkene); m/z (ESI+) calculated 
for C26H40N2O2S [M+Na]+; 499.2601, found 499.2587. 










Tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate (174mg, 0.5 mmol) and crotyl acetate 
(62mg, 0.55 mmol) was reacted following the general procedure to yieldtert-butyl (E)-4-([1-
phenylpent-3-en-1-yl]sulfonyl)piperazine-1-carboxylate (116 mg, 59 %) as a colourless solid; 
Rf = 0.28; m.p: 84 – 85 °C; 1H NMR (400 MHz) 7.42-7.46 (2H, m, Ar-H); 7.34-7.39 (3H, m, Ar-
H); 5.34-5.52 (1H, m, 4-H); 5.05-5.18 (1H, m, 3-H); 4.01 (1H, dd J 4.0 Hz 11.1 Hz, 1-H); 3.05-
3.20 (4H, m, N-(CH2)2); 2.69-3.04 (6H, m, 2-H2, N-(CH2)2); 1.51 (3H, d J 6.4 Hz, 5-H3); 1.40 (9H, 
s, C-(CH3)3); 13C NMR (100 MHz) 154.4 (C=O); 133.0 (Ar-C); 130.2 (Ar-CH); 129.7 (4-CH); 
129.1 (Ar-CH); 128.8 (Ar-CH); 125.4 (3-CH); 80.3 (C(CH3)3); 68.6 (1-CH); 45.8 (N-CH2); 33.2 (2-
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CH2); 28.4 (C-(CH3)3);17.9 (5-CH3); max (solid, cm-1) 1684 (C=O); 1337 & 1148 (sulfonamide S-
N); m/z (ESI+) calculated for C20H30N2O4S [M+Na]+; 417.1818, found 417.1821. 









44'' 4'  
Tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate (174 mg, 0.5 mmol) and prenyl acetate 
(70 mg, 0.55 mmol) was reacted following the general procedure to yieldtert-butyl-4-([4-
methyl-1-phenylpent-3-en-1-yl]sulfonyl)piperazine-1-carboxylate (104 mg, 52 %) as 
acolourless solid; Rf = 0.3; m.p: 93 – 96 °C; 1H NMR (400 MHz) 7.44-7.48 (2H, m, Ar-H); 
7.36-7.41 (3H, m, Ar-H); 4.84-4.90 (1H, m, 3-H); 3.98 (1H, dd J 4.0 Hz 11.2 Hz, 1-H); 3.1-3.34 
(4H, m, N-(CH2)2); 2.65-3.01 (6H, m, 2-H2, N-(CH2)2); 1.55 (3H, s, 4’’-H3); 1.53 (3H, s, 4’-H3); 
1.38 (9H, s, C-(CH3)3); 13C NMR (100 MHz) 154.4 (C=O); 133.5 (Ar-C); 133.2 (4-C); 129.7 (Ar-
CH); 129.0 (Ar-CH); 128.7 (Ar-CH); 118.0 (3-CH); 80.3 (C(-CH3)3); 68.2 (1-CH2); 45.8 (N-(CH2)2); 
28.9 (4’’-CH3); 28.3 (C-(CH3)3); 25.7 (2-CH2); 17.9 (4’-CH3); max (solid, cm-1) 1687 (C=O); 1337 












4-(Benzylsulfonyl)morpholine (120 mg, 0.5 mmol) and allyl acetate (60 mg, mmol) was 
reacted following the general method, to yield 4-[(1-phenylbut-3-en-1-
yl)sulfonyl]morpholine (274 mg, 98 %) as a colourless solid; Rf = 0.25 (95:5 
Toluene:EtOAc);m.p: 84 – 87 °C; 1H NMR (400 MHz) 7.36-7.40 (5H, m, Ar-CH); 5.52 (1H, ddt 
J 7.0 Hz 10.0 Hz 17.0 Hz, 3-H); 5.04 (1H, dd J 1.2 Hz 17.0 Hz, 4-H); 4.96 (1H, d J 10.1 Hz, 4-H); 
4.09 (2H, dd J 4.1 Hz 11.2 Hz, 1-H); 3.53 (2H, ddd J 3.0 Hz 6.3 Hz 11.5 Hz, O-CH2); 3.44 (2H, 
ddd J 3.0 Hz 6.2 Hz 11.2 Hz, O-CH2); 3.08-3.13 (1H, m, 2-H); 2.89 (1H, ddd J 6.8 Hz 11.2 Hz 
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14.0 Hz, 2-H); 3.02-3.07 (2H, m, N-CH2); 2.76 (2H, bs, N-CH2); 13C NMR (100 MHz)  133.0 (3-
CH); 132.8 (Ar-C); 129.7 (Ar-CH); 129.2 (Ar-CH); 128.9 (Ar-CH); 118.4 (4-CH2); 67.9 (1-CH); 
66.8 (N-(CH2)2); 46.1 (O-(CH2)2); 34.4 (2-CH2); max (solid, cm-1) 1335 & 1125 (sulfonamide S-
N); 1110 (mono-substituted alkene); m/z (ESI+) calculated for C14H19NO3S [M+Na]+; 
304.0978, found 304.0978. 










4-(Benzylsulfonyl)morpholine (124 mg, 0.5 mmol) and trans-2-hexenyl acetate (82 mg, 0.55 
mmol) was reacted following the general method, to yield (E)- 4-([1-phenylhept-3-en-1-
yl]sulfonyl)morpholine (102 mg, 79 %) as a colourless solid; Rf = 0.25 (95:5 Toluene:EtOAc); 
m.p: 69 – 71 °C; 1H NMR (400 MHz) 7.36-7.38 (5H, m, Ar-CH); 5.43 (1H, dt J 6.9 Hz 14.3 Hz, 
4-H); 5.09 (1H, dt J 6.9 Hz 14.5 Hz, 3-H); 4.04 (1H, dd J 4.0 Hz 11.2 Hz, 1-H); 3.54 (2H, ddd J 
2.8 Hz 6.3 Hz 11.2 Hz, O-CH2); 3.45 (2H, ddd J 2.9 Hz 6.3 Hz 9.2 Hz, O-CH2); 2.99-3.07 (3H, m, 
N-CH2, 2-H); 2.78 (3H, m, N-CH2, 2-H); 1.77-1.87 (2H, m, 5-H2); 1.16-.25 (2H, m, 6-H2); 0.71 
(3H, t J 7.4, 7-H3); 13C NMR (100 MHz) 134.6 (4-CH); 132.9 (Ar-C); 129.8 (Ar-CH); 128.9 (Ar-
CH); 128.7 (Ar-CH); 124.3 (3-CH); 68.4 (1-CH); 66.8 (N-(CH2)2); 46.1 (O-(CH2)2); 34.4 (5-CH2); 
33.4 (2-CH2); 22.3 (6-CH2); 13.4 (7-CH3); max (solid, cm-1) 1106& 1322 (sulfonamide S-N); 952 
















4-(Benzylsulfonyl)morpholine (120 mg, 0.5 mmol) and neryl acetate (118 mg, 0.55 mmol) 
was reacted following the general method, to yield (Z)-4-((4,8-dimethyl-1-phenylnona-3,7-
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dien-1-yl)sulfonyl)morpholine (83 mg, 45 %) as a yellow oil; Rf= 0.30 (95:5 Toluene:EtOAc); 
1H NMR (400 MHz) 7.36-7.41 (5H, m, Ar-H); 5.06-5.07 (1H, m, 7-H); 4.84 (1H, t J 7.1, 3-H); 
3.98 (1H, dd J 3.8 Hz 11.2 Hz, 1-H); 3.54 (3H, ddd J 2.9 Hz 6.4 Hz 11.5 Hz, O-CH2)2); 3.45 (2H, 
ddd J 2.9 Hz 6.3 Hz 9.1 Hz, O-(CH2)2); 3.01-3.10 (3H, m, 2-H, N-(CH2)2); 2.77-2.85 (2H, m, 2-H, 
N-(CH2)2); 1.98-2.14 (4H, m, 6-H2, 5-H2); 1.69 (3H, s); 1.59 (3H, s); 1.57 (3H, s, 4-CH3); 13C 
NMR (100 MHz)  138.8 (4-C); 133.2 (Ar-C); 131.9 (8-C); 129.7 (Ar-CH); 129.0 (Ar-CH); 128.8 
(Ar-CH); 123.9 (7-CH); 119.2 (3-CH); 68.4 (1-CH); 66.8 (N-(CH2)2); 46.1 (O-(CH2)2); 32.0 (5-
CH2); 28.6 (2-CH2); 26.3 (6-CH2); 25.7 (-CH3); 23.3 (-CH3); 17.7 (4-CH3); max (oil, cm-1) 1339 & 
1112 (sulfonamide S-N); 702 (cis alkene); m/z (ESI+) calculated for C21H31NO3S [M+Na]+; 









4 HaHb  
1-(Benzylsulfonyl)piperidine (119 mg, 0.5 mmol) and allyl acetate (57 mg, 0.55 mmol) was 
reacted following the general method, to yield 1-([1-phenylbut-3-en-1-yl]sulfonyl)piperidine 
(107 mg, 77 %);Rf=0.42(95:5 Toluene:EtOAc); m.p: 78–80 °C; 1H NMR (400 MHz) 7.34-7.41 
(5H, m, Ar-H); 5.53 (1H, ddt,  J 6.9 Hz 10.0 Hz 13.9 Hz, 3-H); 5.0 (1H, dd J 1.4 Hz17.0 Hz, 4-
Ha); 4.95 (1H, d J 10.0 Hz, 4-Hb); 4.05 (1H, dd J 3.9 Hz 11.2 Hz, 1-H); 3.06-3.12 (1H, m, 2-H); 
2.97-3.03 (2H, m, N-CH2); 2.85-2.93 (1H, m, 2-H); 2.76 (2H, bs, N-CH2); 1.39-1.44 (6H, m, (-
CH2)3); 13C NMR (100 MHz)133.4 (3-CH); 133.3 (Ar-C); 129.7 (Ar-CH); 128.8 (Ar-CH); 128.6 
(Ar-CH); 118.1 (4-CH2); 67.7 (1-CH); 46.9 (N-(CH2)2); 34.5 (2-CH2); 25.9 (C-(CH2)2); 23.7 (C-
CH2);max (solid, cm-1) 1132 & 1276 (sulfonamide S-N); 937 (mono-substituted alkene); m/z 











4 HaHb  
1-(Benzylsulfonyl)pyrrolidine (112 mg, 0.5 mmol) and acetate (57 mg, mmol) was reacted 
following the general method, to yield 1-([1-phenylbut-3-en-1-yl]sulfonyl)pyrrolidine (109 
mg, 83 %) as a colourless solid; Rf= 0.48 (95:5 Toluene:EtOAc);m.p: 84 – 86 °C; 1H NMR (400 
MHz)  7.35-7.41 (5H, Ar-H); 5.56 (1H, ddt J 7.0 Hz 10.0 Hz 14.0 Hz, 3-H); 5.06 (1H, dd J 1.3 
Hz 17.0 Hz, 4-Ha); 4.97 (1H, dd J 9.9 Hz, 4-Hb); 4.18 (1H, dd J 4.0 Hz 11.2 Hz, 1-H); 3.14-3.23 
(2H, m, N-CH2); 3.10 (1H, ddd J 4.2 Hz 5.5 Hz 7.0 Hz, 2-H ); 2.94 (1H, ddd J 6.9 Hz 11.2 Hz 14.3 
Hz 2-H); 2.79-2.84 (2H, m, N-CH2); 1.62-1.73 (4H, m,N-(CH2)2); 13C NMR (100 MHz)  133.5 
(3-CH); 133.4 (Ar-C); 129.7 (Ar-CH); 128.8 (Ar-CH); 128.6 (Ar-CH); 118.1 (4-CH2); 67.1 (1-CH); 
48.1 (N-(CH2)2); 34.0 (2-CH2); 25.8 (N-(CH2)2; max (solid, cm-1) 1107 & 1334 (sulfonamide S-

















1-(Benzylsulfonyl)-1,2,5,6-tetrahydropyridine (116 mg, 0.5 mmol) and allyl acetate (63 mg, 
0.55 mmol) was reacted following the general method, to yield 1-([1-phenylbut-3-en-1-
yl]sulfonyl)-1,2,3,6-tetrahydropyridine (113 mg, 82 %) as an orange oil; Rf= 0.50 (95:5 
Toluene:EtOAc); 1H NMR (400 MHz) 7.34-7.41 (5H, Ar-H); 5.68-5.71 (1H, m, 4-H); 5.52-5.58 
(1H, m, 3’-H); 5.47-5.51 (1H, m, 5-H); 5.04 (1H, dd J 1.1 Hz 17.0 Hz, 4’-Ha); 4.95 (1H, d J 10.0 
Hz, 4’-Hb); 4.11 (1H, dd J 4.1 Hz 11.0 Hz, 1’-H); 3.61 (1H, dt J 2.5 Hz 5.1 Hz, 6-H);3.35-3.36 
(1H, m, 6-H); 3.06-3.14 (2H, m, 2’-H, 3-H); 2.87-2.95 (2H, m, 2’-H, 3-H); 2.04-2.00 (1H, m, 2-
H); 1.84-1.88 (1H, m, 2-H); 13C NMR (100 MHz)  133.3 (3’-CH); 133.1 (Ar-C); 129.7 (Ar-CH); 
128.8 (Ar-CH); 128.7 (Ar-CH); 125.2 (5-CH); 123.3 (4-CH); 118.2 (4’-CH2);67.8 (1’-CH); 44.7 (6-
CH2); 42.7 (3-CH2); 34.3 (2’-CH2); 25.6 (2-CH2); max (oil, cm-1) 1144 & 1309 (sulfonamide S-
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1-Benzyl-4-(benzylsulfonyl)piperazine (165 mg, 0.5 mmol) and allyl acetate (57 mg, 0.55 
mmol) was reacted following the general method, to yield 1-benzyl-4-((1-phenylbut-3-en-1-
yl)sulfonyl)piperazine (141 mg, 76 %) as a colourless solid; Rf=; m.p: 74 – 78 °C; 1H NMR (400 
MHz) 7.36-7.39 (5H, m, Ar-H); 7.23-7.31 (5H, m, Ar-H); 5.53 (1H, ddt J 7.0 Hz 10.0 Hz 14.0 
Hz, 3’-H); 5.02 (1H, d J 10.2 Hz, 4’-Ha); 4.96 (1H, d J 10.2 Hz, 4’-Hb); 4.07 (1H, dd J 4.0 Hz 11.2 
Hz, 1’-H); 3.44 (2H, bs, 1-H2); 3.05-3.13 (3H, m, 2’-H,3-H2); 2.85-2.94 (3H, m, 2’-H,3-H2); 2.22-
2.36 (4H, m, 2-H2); 13C NMR (100 MHz) 137.4 (Ar-C); 133.2 (3’-CH); 132.9 (Ar-C); 129.8 (Ar-
CH); 129.1 (Ar-CH); 128.9 (Ar-CH); 128.7 (Ar-CH); 128.3 (Ar-CH); 127.3 (Ar-CH); 118.2 (4’-
CH2); 68.0 (1’-CH); 62.7 (1-CH2); 52.9 (2-CH2); 46.0 (3-CH2); 34.5 (2’-CH2); max (solid, cm-1) 
1147 & 1340 (sulfonamide S-N); 959 (mono-substituted alkene); m/z (ESI+) calculated for 














1-(Benzylsulfonyl)-4-(3-fluorobenzyl)piperazine (174 mg, 0.5 mmol) and allyl acetate (60 mg, 
0.55 mmol) was reacted following the general method to yield 1-(3-fluorobenzyl)-4-([1-
phenylbut-3-en-1-yl]sulfonyl)piperazine (130mg, 67 %) as an orange oil; Rf= 0.20 (95:5 
toluene:EtOAc); 1H NMR (400 MHz) 7.38-7.39m (5H, m, Ph-H); 7.17-7.27 (1H, m, Ar-H); 
6.91-7.00 (3H, m, Ar-H); 5.54 (1H, ddt J 7.0 Hz 9.9 Hz 17.0 Hz 3’-H); 5.0 (1H, d J 17 Hz, 4’-Ha); 
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4.96 (1H, d J 10.0 Hz, 4’-Hb); 4.08 (1H, dd J 3.9 Hz 11.0 Hz, 1’-H2); 3.47 (2H, s, 1-H2); 3.06-3.16 
(3H, m, 2’-H, N-CH2); 2.86-2.94 (2H, m, 2’-CH, N-CH2); 2.22-2.40 (4H, m, N-(CH2)2); 13C NMR 
(100 MHz) C164.1 (Ar-C); 161.7 (Ph-C); 140.3 (Ar-CF, d JCF 6.7); 133.2 (Ph-CH); 130.8 (Ph-
CH); 129.7 (Ar-CH); 128.7 (Ph-CH); 124.5 (Ar-CH); 118.3 (4’-CH2); 115.7 (Ar-CH, d JCF 21.2); 
114.3 (Ar-CH, d JCF 21.2); 68.1 (1’-CH); 62.1 (1-CH); 52.9 (N-(CH2)2); 45.9 (N-(CH2)2); 34.2 (2’-
CH2) ); max (oil, cm-1) 1486 (C-F); 1340 & 1140 (sulfonamide S-N); m/z (ESI+) calculated for 














1-(Benzylsulfonyl)-4-(3-methylbenzyl)piperazine (174 mg, 0.5 mmol) and allyl acetate (60 
mg, 0.55 mmol) was reacted following the general method to yield 1-(3-methylbenzyl)4-([1-
phenylbut-3-en-1-yl]sulfonyl)piperazine (100 mg, 53 %) as an orange oil; Rf = 0.35 
(CH2Cl2:EtOAc 95:5); 1H NMR (400 MHz) 7.36-7.39 (5H, m, Ar-H); 5.54 (1H, ddt J 7.0 Hz 10.0 
Hz 13.9 Hz, 3’-H); 5.05 (1H, dd J 1.2 Hz 17.0 Hz, 4’-Ha); 4.96 (1H, bd J 10.5 Hz, 4’-Hb); 4.07 
(1H, dd J 3.9 Hz 11.2 Hz, 1’-H); 3.40 (2H, s, 1-H2); 3.05-3.12 (3H, m, 2’-H, N-H2); 2.85-2.93 
(3H, m, 2-H, N-H2); 2.32-2.35 (5H, s, Ar-CH3, N-H2); 2.23-2.28 (2H, m, N-H2); 13C NMR (100 
MHz)  137.9 (Ar-C); 137.2 (Ar-C); 133.2 (3-CH); 129.9 (Ar-CH); 129.7 (Ph-CH); 128.9 (Ph-CH); 
128.7 (Ph-CH); 128.1 (Ar-CH); 128.0 (Ar-CH); 126.3 (Ar-CH); 118.2 (4-CH2); 68.1 (1-CH); 62.7 
(Ar-CH2); 52.9 (N-(CH2)2); 45.9 (N-(CH2)2); 34.4 (2-CH2); 21.4 (Ar-CH3); max (oil, cm-1) 1341 & 



















1-Benzyl-4-(benzylsulfonyl)piperazine (165 mg, 0.5 mmol) and E-2-hexenyl acetate acetate 
(60 mg, 0.55 mmol) was reacted following the general method, to yield  (E)-1-Benzyl-4-([1-
phenylhept-3-en-1-yl]sulfonyl)piperazine (120 mg, 58 %) as a colourless solid; Rf = 0.22 
(toluene:EtOAC); 1H NMR (400 MHz)7.34 (5H, m, Ar-H); 7.22-7.31 (5H, m, Ar-H); 5.38 -5.45 
(1H, m, 4’-H); 5.05-5.13 (1H, m, 3’-H); 4.00 (1H, dd J 3.9 Hz 11.2 Hz, 1’-H); 3.42 (2H, s, 1-H2); 
2.99-3.08 (3H, m, 2’-H, N-CH2); 2.79-2.85 (3H,m, 2’H, N-CH2); 2.22-2.32 (N-(CH2)2); 1.20 (2H, 
ddd J 2.4 Hz 7.4 Hz 9.8 Hz, 6’-H2); 0.74 (3H, t J 7’-H3); 13C NMR (100 MHz) 137.5 (Ar-C); 
134.5 (4’-CH); 133.2 (Ar-CH); 129.8 (Ar-CH); 129.1 (Ar-CH); 128.8 (Ar-CH); 128.6 (Ar-CH); 
128.3 (Ar-CH); 127.2 (Ar-CH); 124.5 (3’-CH); 68.5 (1’-CH); 62.7 (1-CH2); 52.9 (N-(CH2)2); 46.0 
(N-(CH2)2); 34.4 (5’-CH2); 33.4 (2’-CH2); 22.3 (6’-CH2); 13.4 (7’-CH2); max (solid, cm-1) 1147& 

















1-(Benzylsulfonyl)-4-(3-bromobenzyl) piperazine (100 mg, 0.244 mmol) and allyl acetate 
(36.4 mg, 0.0.29 mmol) was reacted following the general method to yield(0.71 g, 63 %) as 
an orange oil Rf = 0.27 (95:5 toluene:EtOAc); 1-(4-bromobenzyl)-4-([1,4diphenylpent-3-en-1-
yl]sulfonyl)piperazine. Rf = 0.27 (toluene:EtOAc 95:5); m.p: 88 – 90 °C;1H NMR (400 
MHz)7.3-7.42 (7H, m, Ar-H); 7.14-7.29 (2H, m, Ph-H);5.43-5.54 (1H, m, 3’-H); 5.06-5.16 
(1H, m, 4’-H); 4.00 (1H, dd J 3.9 Hz 11.1 Hz, 1’-H); 3.36 (2H, s, 1-H2); 2.98-3.07 (3H, m, 2’-H, 
N-(CH2); 2.76-2.84 (3H, m, N-CH2); 2.20-2.30 (4H, m,N-(CH2)2); 1.52 (3H, d J 6.3 Hz, 5’-H3); 13C 
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NMR (100 MHz) C 136.6 (Ph-C); 133.1 (Ar-C); 134.4 (Ar-CH); 130.7 (Ph-CH); 129.8 (3’-CH); 
128.9, 128.8, 128.7, 128.6, 128.4 (Ar-CH, Ph-CH); 125.5 (4’-CH); 121.1 (C-Br); 68.5 (1’-CH); 
61.9 (1-CH2); 52.8 (N-(CH2)2); 45.9 (N-(CH2)2); 33.4 (2’-CH2); 17.9 (5’-CH3);max (solid, cm-1) 
1148 & 1340 (sulfonamide S-N); 960 (mono-substituted alkene); 704-730 (C-Br); m/z (ESI+) 















1-(Benzylsulfonyl)-4-(4-methoxybenzyl) piperazine (180 mg, 0.5 mmol) and allyl acetate (58 
mg, 0.55 mmol) was reacted following the general method to yield 1-(4-Methoxybenzyl)-4-
([1-phenylbut-3-en-1yl]sulfonyl)piperazine (71 mg, 37 %) as an orange oil; Rf = 0.25 
(DCM:MeOH 98:2); 1H NMR (400 MHz) 7.34-7.43 (5H, m, Ph-H); 7.13 (2H, d J8.6 Hz, Ar-H); 
6.83 (2H, dd J 1.9 Hz 6.7 Hz, Ar-H); 5.52 (1H, ddt J 7.1Hz 10.0 Hz 13.9 Hz, 3’-H); 5.02 (1H, dd J 
1.7 Hz 17.1 Hz, 4-Ha); 4.96 (1H, dd J 1.2 Hz 10.4 Hz, 4-Hb); 3.78 (3H, s, -OCH3); 3.36 (2H, s, 1-
H2); 3.03-3.14 (2H, m, 2’-H, 3-H); 2.84-2.92 (2H, m, 2’-H, 3-H); 2.19-2.32 (4H, m,  2-(H2)2); 13C 
NMR (100 MHz) 158.8 (C-OMe); 133.2 (3’-CH); 132.9 (Ph-C); 130.3 (Ar-CH); 129.7 (Ph-CH); 
129.4 (Ar-C); 128.9 (Ph-CH); 128.7 (Ph-CH); 118.2 (4’-CH2); 113.5 (Ar-CH); 68.0 (1’-CH); 62.1 
(1-CH2); 55.3 (-OCH3); 52.7 (2-(CH2)2); 46.0 (2-(CH2)2); 34.5 (2’-CH2); max (oil, cm-1) 













1-(Benzylsulfonyl)-4-(3-chlorobenzyl) piperazine (100 mg, 0.27 mmol) and allyl acetate (50 
mg, 0.30 mmol) was reacted following the general method to yield 1-(4-chlorobenzyl)-4-
((1,4diphenylbut-3-en-1-yl)sulfonyl)piperazine as a mixture of linear:branched compound 
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(49 mg, 37 % linear, 33 mg, 25 %, branched) as an orange oil; Data for linear isomer: Rf = 
0.26 (95:5 toluene:EtOAc); m.p: 102 – 104 °C; 1H NMR (400 MHz) 7.37-7.45 (5H, m, Ph-H); 
7.15-7.26 (9H, m, Ph-H, Ar-H); 7.09-7.11 (1H, m, Ar-H); 6.42 (1H, d J 6.42 Hz, 4’-H); 5.91 (1H, 
dt J 7.5, 14.8, 3’-H); 4.12 (1H, dd J 3.9 Hz 11.0 Hz, 1’H); 3.40 (2H, s, 1-H2); 3.00-3.11 (3H, m, 
2’-H, N-CH2); 2.86 (2H, bs, 2’-H, N-CH2); 2.31-2.36 (2H, m, N-CH2); 2.22-2.27 (N-CH2); 13C 
NMR (100 MHz) 136.9 (Ar-C); 134.2 (Ph-C-Cl); 133.3 (4’-CH); 132.9 (Ph-C); 129.7 (Ar-CH); 
129.8 (Ph-CH); 129.1 (Ar-CH); 129.0 (Ar-CH); 128.9 (Ar-CH); 128.8 (Ar-CH); 128.5 (Ar-CH); 
127.5 (Ar-CH); 127.4 (Ph-CH); 127.1 (Ar-CH); 126.2 (Ph-CH); 124.8 (3’-CH); 68.3 (1’-CH); 62.1 
(1-CH2); 52.9 (N-(CH2)2); 45.9 (N-CH2)2); 33.9 (2’-CH2); max (solid, cm-1) 1149 & 1341 
(sulfonamide S-N); 960 (mono-substituted alkene); 567-690 (C-Cl); m/z (ESI+) calculated for 













Ha Hb  
Data for branched isomer: (dr 1:0.8 A:B) Rf = 0.21 (95:5 toluene:EtOAc); m.p: 96 – 98 °C;data 
for diastereomer A; 1H NMR (400 MHz CDCl3) 6.98-7.38 (14 H, m, Ar-H, Ph-H); 6.34 (1H, 
ddd J 8.9, 10.0, 17.0, 3’-H); 5.22 (1H, d J 16.8 Hz,4’-Hb); 5.17 (1H, d J 10.0 Hz, 4’-Ha); 4.26-
4.33 (2H, m, 1’-H,2’-H);3.35 (2H, s, 1-H2); 2.92-3.02 (2H, m, N-(CH2)2); 2.69 (2H, bs, N-(CH2)2); 
2.12-2.24 (4H, m, N-(CH2)2); 13C NMR (100 MHz) 141.1, 140.5, 139.8 (Ar-C); 138.9 (3’-CH); 
134.2 (Ar-C); 130.7, 129.9, 129.5, 128.9, 128.5, 128.4, 128.3, 128.2, 127.4, 127.0, 126.5 (Ar-
CH); 116.3 (4’-CH2); 72.9 (1’-CH); 62.0 (1-CH2); 52.8 (2’-CH); 52.7 (N-CH2)2); 45.7 (N-CH2); 
data for diastereomerB:1H NMR (400 MHz) 6.98-7.38 (14H, m Ar-H, Ph-H); 5.95 (1H, ddd J 
8.4 Hz 10.2 Hz 16.9 Hz, 3’-H); 5.01 (1H, d J 10.0 Hz, 4’Ha); 4.99 (1H, d J 17.0 Hz, 4-Hb); 4.38-
4.45 (2H, m, 1’-H, 2’-H); 3.33 (2H, s, 1-H2); 2.92-3.02 (2H, m, N-(CH2)2); 2.69 (2H, bs, N-
(CH2)2); 2.12-2.24 (4H, m, N-(CH2)2);13C NMR (100 MHz) 137.0 (3’-CH); 133.1 (Ar-C); 132.4 
(Ar-C);130.7, 129.9, 129.5, 128.9, 128.5, 128.4, 128.3, 128.2, 127.4, 127.0, 126.5 (Ar-CH); 
117.7 (4’-CH2); 73.5 (1’-CH); 51.2 (2’-CH); 45.7 (N-(CH2)2); 29.7 (N-(CH2)2); max (solid, cm-1) 
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1152 & 1335 (sulfonamide S-N); 960 (mono-substituted alkene); 597-695 (C-Cl); m/z (ESI+) 
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Chapter 3: Transition-Metal-Free Coupling/Intramolecular Annulation of 
Arynes in the synthesis of sultams 
1. Introduction 
 
1.1 Benzene generation 
Benzyne 1 is a highly reactive species formed by removal of two ortho-hydrogen 
substituents from the system.1 Arynes are usually described as having a strained triple bond; 
however, they possess some biradical2 or zwitteric ion3 character as well. The discovery of 
benzyne led to rapid developments in synthetic methodologies to make this highly reactive 
intermediate useful for organic synthesis. Varieties of natural products have been prepared 
using arynes as intermediates. The exploitation of these reactive species have been 
extensively studied over the past seven decades. 
1  
Fig 1 
Stoermer and Kahlert published the first indication of aryne in 1902.4 The reaction was 
undertaken by treating 3-bromobenzofuran (2) (Scheme 1) with bases in absolute ethanol 
and generated 2-ethoxybenzofuran (4). This product was unexpected as the desired 









2 3 4  
Scheme 1 
Over the year’s numerous new methods were developed to generate benzyne. Some of the 
more popular methods for generating arynes are detailed below. 
In 1955, Wittig and Pohmer5,6 generated benzyne by treating 2-bromofluorobenzene with 
organometallic bases. Treatment of 2-bromofluorobenzene 5 with a metal (either lithium or 
magnesium) generated a metallated intermediate 6 or 7, (Scheme 2) which then underwent 
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elimination to form benzyne 1. This procedure has a remarkable advantage over the mono-


















The formation of aryne from aminobenzotriazole 8 was first reported by Rees and co-
workers in 1969.7 The procedure includes an oxidation of triazole 8 producing nitrene 














Despite the formation of benzyne in excellent yield in a short time, the use of stoichiometric 
amounts of toxic metals such as lead has strictly limited the use of this method in synthesis. 
The application of oxidative conditions would probably also prove problematic with some 
sensitive substrates. This process has also been shown to occur with N-iodosuccinimide 















In 1963, Friedman et al. reported the generation of arynes by treating anthranilic acid 10 
with sodium nitrite. Formation of the zwitterionic intermediate 13 was first observed, then 
132 
 
intermediate 13 decomposes on heating to produce benzyne, CO2 and nitrogen (Scheme 5).9 
Although, this strategy is a clean and efficient procedure for the formation of aryne, the 













All of the methods described above have major drawbacks, which have restricted the 
development of aryne chemistry. The requirement of strong bases,5,6 oxidants,7 metallic 
reagents,5,6 high temperatures4 or explosive intermediates9 (extreme caution during 
preparation) limited the compatibility of aryne chemistry in use. 
 
In 1983, Kobayashi reported a novel method showing that 2- (trimethylsilyl)phenyl 
trifluoromethanesulfonate 14 would successfully desilylate and eliminate triflate to 
generate benzyne 1 in high yield under extremely mild conditions when treated with a 
suitable fluoride source.13 Advantages are that this methodology tolerates several motifs 
which may be incompatible with previously described conditions, as reactions could be 
performed at room temperature, without need for harsh reagents. Moreover, the reaction 
carried out smoothly with a range of fluoride sources (cesium fluoride, TBAF, TBAT, and 













1.2 Arynes reactivity 
 
1.2.1 Nucleophile addition 
 
Benzyne is an excellent electrophile that will react with many nucleophiles. Reaction of 
benzyne with nucleophile results in the formation of a mono-substituted arene 17. When an 
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electrophile introduced in the reaction (three-component coupling) ortho-disubstituted 
arenes 18 are formed. Alternatively, both nucleophile and electrophile parts can be on the 



















The simple addition of nucleophilic species to benzyne has been extensively studied over 
the last century and numerous examples of each of these processes have been reported. 
In 2006, Liu and Larock employed many classes of nucleophiles with 2-(trimethylsilyl) phenyl 















MeCN, rt, 12 h
CsF (4.0 equiv)
MeCN, rt, 24 h
CsF (3.0 equiv)























Double arylation occurred with some species; using primary sulfonamides and an excess of 
silylaryltriflate, one obtains the corresponding diarylation product in high yield in a fairly 







MeCN, rt, 72 h
98 %
CsF (4.0 equiv)





In 2016, Stoltz et al. reported the insertion of arynes into acetylacetamide 26 (Scheme 10), 
using arynes which generated insitu from 14 under mild reaction conditions. The reaction 
proceeds by deprotonation of the acetylacetamide in the presence of a fluoride, resulting 27 





























1.2.2 Peri-cyclic reactions 
A common way to verify wether arynes are formed efficiently is to subject them to 
cycloaddition (Diels-Alder) condition using furan. This reaction was initially reported by 
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Wittig and Pohmer in 1955 (Scheme 11).5 They used 2-bromofluorobenzene 5 as the 











In the past, several examples of [4 + 2] cycloadditions with benzynes have been published in 
the literature. The diene substrate sphere is widely enlarging, and currently includes several 
dienes containing sulfur, nitrogen and oxygen,7,17,39 as well as some aromatic structures.18 In 
addition, aryne cyclisations have proved to be an exceptional method for gaining metal-free 
access to heterocyclic molecules.19 In 2008 Stoltz and co-workers reported the synthesis of 
isoquinoline 33 via aryne annulations. 33 arises from a Diels-Alder reaction between the N-
acyl enamine 32 and aryne 14 followed by dehydrative aromatization. Under optimized 
conditions (TBAT, THF, 23 °C, 6 h), reaction of benzyne and N-acetyl dehydroalanine ester 


















In the same report, Stoltz et al. predicted the formation of indolines via [2+3] cycloaddition 
from N-carbamoyl dehydroalanine esters (Scheme 13). These substrates, when reacted with 
silyl aryl triflate 14 in the presence of TBAT, in THF, under mild condition, produced an 
indoline adduct arising from a formal [3+2] cycloaddition (eq 1-3). Moreover, 
dehydrophenylalanine derivative afforded the corresponding 1,2,3-trisubstituted indoline as 
a single isolated diastereoisomer (eq 4). Interestingly, an unexpected cis stereochemical 
relationship is observed, they believed the reason behind this is that protonation occurs 

































































In the same year, Yamamoto and Jin reported a [3+2] cycloaddition between substituted 
derivatives of diazomethane 43 and affording 1H-indazoles in good to excellent yields and 












R = TMS           90 %            
R = Ph              50 %








Arynes are also undergoing [2+2] processes including dimerisation to biphenylene in the 
absence of nucleophile species in situ,22 and there are many reactions of benzyne with 
olefins.23 For example, Kunai and co-workers obtained 9-arylxanthene derivative product 51 
upon treatment of aryl aldehyde 47 with benzyne (Scheme 15). The mechanism was thought 
to proceed via a zwitterionic intermediate. First, a nucleophilic attack of a carbonyl oxygen 
atom on benzyne gives zwitterion 48, which then undergoes intramolecular cyclization to 
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afford benzoxete 49. Subsequent isomerization to o-quinonemethide 50, followed by [4 + 2] 





















Hsung and co-workers developed an enamide-benzyne [2 + 2] cycloaddition using benzyne 
precursor 14 and enamide 52 in the presence of CsF in 1,4 dioxane at 110 °C. Aza-tricycle 55 
as a single diastereomer was achieved by using enamide 52 tethered with an olefin. The 
formation of 55 involves four-bond formation through benzocyclobutane [2 + 2] 
cycloaddition in tandem with the ring opening to o-quinonedimethide 54 which undergoes 
























1.2.3 Transition Metal-Catalyzed Aryne Annulation 
 
Catalytic transformation of arynes have been of major interest over the last three decades, 
since Guitián and co-workers reported the first palladium-catalysed reaction of arynes to 














This methodology has since been extended to include co-cyclisation reactions, particularly 
with other electron-deficient species, as well as intramolecular [2+2+2] reactions for the 
preparation of fused polycycles. For examples, Mori and co-workers obtained tetracycle 58 
(an intermediate for the synthesis of taiwanins C and E) from the palladium-catalysed co-
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Pd2(dba)3 5 mol%







Greaney and co-workers have also developed a three-component coupling (TCC) of benzyl 
bromides, benzyne, and tert-butyl acrylate using 5 mol % of Pd(OAc)2/dppe as a catalyst. 
This methodology presents alternatives to simple allylchlorides as the initial 
carbopalladation electrophile, introduces the Heck reaction to benzyne TCC, and provides 
139 
 
rapid and efficient access to diverse 1,2-functionalized arenes. The use of benzyl bromides 












Pd(OAc)/dppe  5.0 mol%
DME, 50 °C, 40 h Ot-Bu
O
R
R1 = H     14
R1 = Me   59
R2
R2 = OMe  60
R2 = NO2    61 R1 = H,   R2 = OMe    63  76 %
R1 = H,   R2 = NO2      64  69 %





Benzosultams are important targets for drug discovery because of their potent biological 
activities. These motifs are present in the substructures of many pharmaceutical agents. The 
potent bioactivities include phosphotyrosine phosphatase 1B (PTP1B) inhibitors for 
treatment of type I and II diabetes, progesterone receptor antagonist and opioid receptor-







ORL 1 antagonist  
Recently, there has been a sharp increase in the number of publications concerning the 
synthesis and use of sultams as cyclic analogs of sulfonamides. This is related to the absence 
of general methods for their synthesis, despite numerous skinds of sultams being already 
well established in clinical practice as anticonvulsant, 31 1-adrenoblocking 32 and diuretic 33 
agents. One of the important example of this family is 1,2-benzisothiazoline 2,2-dioxide, 
which has got numerous potential applications. The total synthesis of saccharine-based 
cyclic sulfonamide derivatives,51 the core structure of spiropyrrolidinyl-benzoisothiazoline 
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derivatives29,30 and a novel potent inhibitors of proline-rich tyrosine kinase 2 (PYK 2) are 





























Proline-rich tyrosine kinase 2 (PYK 2)
inhibitor
      
 
Other benzosultams have also shown their importance in pharmaceutical and medicinal 
chemistry because they are widely used as benzothiazine diuretics, such as 
trichloromethiazide, chlorthalidone, indapamide, and furosemide.36 They also significantly 
inhibit carbonic anhydrases (CAs) and the X-ray crystal structures of their CA adducts exhibit 
a different behavior as compared to classical inhibitors, e.g., acetazolamide, methazolamide, 
and ethoxyzolamide. The newly found binding modes of these diuretics may be exploited for 
designing better CA II inhibitors as well as compounds with selectivity/affinity for various 
isoforms with medicinal applications. Because of the important biological activities of 














In 2000, Dauban and Dodd described a new methodology for the preparation of 
benzosultams based on copper- or bromine catalyzed aziridination.38 Olefinic primary 
sulfonamide 66 was treated with iodobenzene diacetate and potassium hydroxide in 
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methanol to give intermediate iminoiodinane 67, which was immediately treated with a 
catalytic amount of copper triflate to yield the aziridine 68. Aziridine 68 was ring opened 























66 67 68 69
Scheme 20 
In 2000, Takeuchi and co-workres reported the synthesis of 3,3-disubstituted benzosultams 
74-76 by o-lithiation of N-tertbutylbenzenesulfonamide 70 and subsequent reaction with 

















R = Me               71 85 %
R = Ph                72 86 %









R = Me               74 95 %
R = Ph                75 99 %
R = 1-Naphthyl   76 98 %
 
Scheme 21 
Hanson and co-workers reported a new approach for the preparation of benzosultam using 
a domino process where a classical Heck reaction was coupled to an aza-Michael reaction, 
ultimately resulting in a one-pot protocol for a three-component reaction of α-
bromobenzenesulfonylhalide, amines, and Michael acceptors (Scheme 22).41 Several 
examples of benzosultams were prepared using this one-pot protocol (Scheme 22). First, α-
bromobenzenesulfonyl chlorides 77 were coupled with a range of aromatic, cyclic, 
andalkylamines to yield the intermediate sulfonamides. After 2 h, Et3N, Bu4NCl, Pd2(dba)3, 
CHCl3, and the appropriate Michael acceptor were added to the reaction, which was 





























 R1 = C5H9












In 1986, Chiarino and Contri obtained 1,2-benzisothiazoline 2,2-dioxide 83 and derivatives 
by heating a mixture of 82, potassium carbonate and copper-bronze powder in 2,3-




















In the same report, they worked with an alternative route for the formation of sultam 83. 
For this purpose, 2-aminobenzylsulfonic acid sodium salt 84 was refluxed with phosphorus 
oxychloride (Scheme 24). After cooled down the mixture treated with sodium hydroxide in 












1. POCl3 reflux at 170 °C
2. 20% sodium hydroxide
     70 °C
 
Scheme 24 
In 1974, Skorcz et al. reported an aryne-mediated intramolecular substitution in 2- chloro-N-





















85 86  
Scheme 25 
Pyridosultams 93-94 were synthesized from 3-amino-2-chloropyridine 88.44 Aminopyridine 
was reacted to yield monosulfonylated products 89-90 in high yields. The products were 
subsequently N-alkylated with a methyl iodide in the presence of K2CO3 in 
dimethylformamide. Cyclization of the N-alkylsulfonamides 91-92 by SNAr with solid NaOH 














R = H      89   68 %










R = H      91   84 %








R = H      93   63 %
R = Me    94   70 %
 
Scheme 26 
The same group reported the application of vicarious nucleophilic substitution (VNS) for the 
synthesis of pyrido- and quinolinosultams.45 However, attempted cyclization of 97 by 
intramolecular VNS under standard conditions (powdered NaOH in DMSO or t-BuOK in 
DMF) for thesynthesis of sultams failed. This is probably due to the lack of reactivity toward 
nucleophilic substitution of the pyridine ring. The electrophilicity of the pyridine ring was 
enhanced by either N-oxidation (using 30% hydrogen peroxide in acetic acid) or by 
quaternization of the nitrogen atom (using MeI) to give more reactive 98 and 99 
respectively. N-oxide 99 in the presence of NaOH in DMSO and salt 98 in the presence of 
10% aqueous NaOH underwent fast intramolecular VNS reactions to afford the 








2. 20 % NaOH














MeI, K2CO3 DMF, rt
H2O2, AcOH


















































90 %  
Scheme 27 
 
In 1996, Buchwald and co-workers developed reaction conditions for intramolecular amide 
cyclizations, as well as cyclizations of sulfonamides. Reactions proceeded optimally for five-







Pd2(dba)3   4 mol%
P (o-tolyl)3 8 mol %
K2CO3, toluene




104 n = 1, 5 h, 88%




Recently, Blagg and co-workersobtained sultam 93 from 2-chlorobenzylsulfonyl chloride in 
three steps.34 Treatment of 2-chlorobenzylsulfonyl chloride 106 with ammonium hydroxide 
solution in acetone at rt, gave (2-chlorophenyl) methanesulfonamide 107 in excellent yield. 
Intramolecular-coupling of (2-chlorophenyl) methanesulfonamide followed by reaction with 
















Pd2(dba)3  5 mol %
tBu-xphos   20 mol %
    K2CO3, THF, 
80 °C, seald tube


















2. Aim of the project 
 
Our research group focused on the synthesis of sultam. Traditional methods for preparation 
of sultams required strong bases, costly reagents and high temperatures. 
Initial investigation began with studying methods to employ benzyne precursors in the 
preparation of sultams. Over ten decades, arynes have gained a powerful role in a chemistry 
methodology and been shown to serve as electrophiles towards nucleophiles such as 
nitrogen.16,21,22,26 Therefore, we visualised a novel pathway for the synthesis of sultam 93 
from arynes and sulfonyl amide species 108 (Scheme 30). Specifically, we expected benzyne 
to undergo nucleophilic addition of sulfonamide 108 to form phenyl anion 109, which would 
then add to -carbon next to sulfonyl group with an elimination of chloride to form the five-
membered ring, giving sultam 93. Up to this point, we were positive that the addition of the 
nitrogen to benzyne would be competent, but there was no lead for the interamolecular 
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cyclisation step. We therefore tried to undestand whether this may be a feasible approach 
for the synthesis of sultams. The successful development of a one-pot reaction method for 
sultam synthesis from simply preparable materials would unlock a new direction toward 
bioactive products and hence, become an improvement in the organic chemistry and 

























3. Result and discussion 
The initial design focused on substrates derived from 2-chloromethane sulfonyl chloride, 
particularly 2-chloromethane sulfonyl amide which was prepared by treating 2-
chloromethane sulfonyl chloride with methylamine solution in chloroform at 0 °C for 4 h,61 
yielding the desired product in high yield. Treating this reagent 108 with Kobayashi’s 
benzyne precuorse 14, we undertook a reaction by applying conditions formerly used to 
boost aryne acyl-alkylation using acetonitrile as a solvent and TBAF as a fluoride source.47 
Unfortunately, this initial attempt failed to give the desired product and instead produced 
uncyclised product 110 in good yield (Scheme 31). In an attempt to gain cyclised 






































Table 1, Scheme 32 
Initial screening did not show any trace of desired cyclysed products. Although in all cases 
benzyne precursors were undergoing N-arylation reactions (Table 1, Scheme 32), which 
showed that the nitrogen atom of sulfonylamide was nucleophilic enough to add to 
benzyne. However, it also suggested that either zwitterionic 113 or anionic species 114 
created in situ was not able to attack the -carbon next to sulfonyl group and underwent 
rapid proton abstraction in the reaction. The lack of success with these reactions was 















1 1.0 1.0 Rt 16 0 69 
2 1.0 1.0 60 16 0 72 
3 1.0 1.0 80 16 0 79 
4 1.0 1.0 80 8 0 79 
5 1.0 1.0 80 4 0 80 
6 1.2 1.0 80 4 0 77 
7 1.5 1.0 80 4 0 75 
8 2.0 1.0 80 4 0 70 
9 1.0 1.2 80 4 0 68 
10 1.0 1.5 80 4 0 70 












































     deprotonted 
nitrogen by a fluoride
 
Scheme 33 
To rule out the last hypothesis, it was decided to use a better leaving group. As chloride is a 
poor leaving group compared to iodide and bromide, the chlorine was replaced with an 
iodine. 2-Iodosulfonyl amide 117 was generated in two steps from the commercially 












   170-130 °C,
      1 h 116  
92 %








MeNH2 (1.0 M in THF) (2.5equiv)
 
Scheme 34 
We began by testing our conditions to promote phenyl anion intermolecular addition 
(Scheme 35). To our delight, desired sultam 93 was produced in 15% yield along with 

























Successful generation of 93 by this protocol was encouraging. Next was the attempted 
optimisation of the reaction to give the desired sultam as a major product. First a solvent 
screen was performed to investigate the effect of solvents on the reaction (Table 2). As 
expected, the generation of sultam with THF gave the best yield. DMA, DME and toluene all 
failed to give any observable product, but when DMF was adopted as a solvent; trace 
amount of benzene triple bond and significant amount of benzyne precursors was 






















Entry Solvent 93 (%) 118 (%) 
1 THF 18 62 
2 MeCN 15 68  
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3 DMA 0 0 
4 DME 0 0 
5 Toluene 0 0 
6 DMF 0 0 
Table 2, Scheme 36 
Following the discovery of the reaction of benzyne with 2-iodosulfonyl amide in THF to 
generate sultam (Table 2, entry 1), it was important to carry out more optimisation for 
reaction which could then be applied in the generation of the desired product in a better 
yield. A range of conditions were investigated (Table 3). It was found when increasing the 
reaction time, there was no significant increase in isolated yield. The temperature of the 
reaction was decreased to 0 °C, -10 °C and -40 °C in order to slow down the generation of 
benzyne and allow better control of the reaction, but this decreased the yield of desired 
product. However, due to the low yield of cyclised product, the temperature of the reaction 
had to be increased for the intramolecular nucleophilic aromatic substitution to happen 
efficiently. Surprisingly, when the reaction was carried out at high temperatures a new by-
product 119 was isolated. From these results, it should be noted that there was a 
relationship between uncyclised compound and cleaved compound, when amount of 
uncyclised product increased, amount of cleaved product decreased. Also the mechanism of 





































 (93 : 118 : 119) 
1 Rt 16 1 : 3.4 : trace 
2 Rt 48 1: 3.5 : trace 
3 Rt 72 1 : 3.4 : trace 
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4 0 16 1:4:0 
5 -10 16 1:7:0 
6 -40 16 1:10:0 
7 60 16 1:2.9:1 
8 80 16 1:2.4:1.8 
9 100 16 1:1.5:2.5 
Table 3, Scheme 37 
Although we could not explain the mechanism of formation of compound 119, the yields 
obtained for 93 were promising and this encouraged us to further optimise the conditions to 
obtain a higher yield of sultam. The next variable for optimising was the fluoride source. 
Reactions involving CsF (3.0, 4.0 and 5.0 equiv) as the fluoride source failed to provide any 
expected product. When the reaction was carried out at 80 °C, trace amounts of N-arylation 
product could be detected but starting materials were mainly recovered at the end of the 
reaction. Hence, THF was replaced by MeCN which is an ideal solvent for CsF, this also failed 































We then decided to use the tetrabutylammoniumtriphenylsilyldifluoro silicate salt known as 


















TBAT is a non-hygroscopic fluoride source that proved to be efficient in some reactions 
when other fluoride sources such as CsF or TBAF were not.48,49,50 The observed reactivity of 
TBAT was very different compare to TBAF. Reactions performed in both MeCN and THF gave 
complex reaction mixtures with more than six visible spots on TLC whereas reactions using 
TBAF in same solvents gave two to three visible spot. Once again, THF used in the reaction 

























Given these results, we can hypothesise that the nucleophilic attack of the nitrogen occurs 
first and that the failure to cyclise may be due to an intramolecular proton abstraction from 


























From this point our investigation was focused on tetrabutylammonium fluoride (TBAF) as a 
fluoride source. Vaghefi and co-workers63 published the desilylation rates of the ribosyl 
purine and the ribosyl pyrimidine nucleosides by using dry TBAF. They examined the ability 
of TBAF reagents dried with molecular sieves to deprotect an oligo ribonucleotide. Following 
Vaghefi’s work, TBAF was dried over molecular sieves (3 A) for a week at rt.63 The reaction 
was run with the dried TBAF applied. Gratifyingly, when dried TBAF was used, cyclised 
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products could be obtained in a higher yield. Indeed, compound 93 was isolated with 21% 
yield. However, both of uncyclised and by-product compounds were isolated as a majority 



























21 % 62 % 14 %
 
Scheme 41 
In an attempt to reduce further uncyclised product and thus increasing the desired product, 
we examined removal of proton source from the reaction by using a range of common bases 
























Entry Base  Yield (%) NMR 
(93:118) 
1 K2CO3  84 1:2.6 
2 K2CO3  85a 1:2.6a 
3 Triethyl amine 78 1:3.8 
4 Cs2CO3 71 1:5.0 
5 Hünig's base 86 1:2.9 
6 NaHCO3 80 1:5.2 
             a) 2.0 equiv of base used 
Table 4, Scheme 42 
When bases were tested in our reaction, it slightly improved the amount of cyclised product 
(determined by 1H NMR). Employing Hünig's base with tetrabutylammonium fluoride (TBAF) 
improved the yield observed (Entry 5). The use of one equivalent of K2CO3 gave the best 
result (based on 1HNMR spectroscopy, Table 4, entry 1). Increasing by an equivalent of base 
154 
 
did not effect the yield of the reaction (Entry 2). Use of other bases like NaHCO3, caesium 
carbonate and tri-ethylamine lowered the yield of 93 (Entries 3-6). Being encouraged by 
these preliminary results, we protected the secondary amine with a TBDMS group. It was 
proposed that the fluoride source could deprotect both silyl-groups in the reaction. By doing 
this it was believed that the amount of proton in the reaction would be reduced, resulting in 




























The best silyl-protecting group was found to be TBDMS, as the TMS-group was too sensitive 
and upon contact with air underwent hydrolysis. Following a modified procedure, the 
secondary amine 117 was protected with TBDMS-Cl in the presence of DMAP and tri-





H TBDMSCl (1.5 equiv)
   DMAP (0.4 equiv)
Et3N (1.5 equiv),











The reaction also had the advantage of going to completion in a far better yield than the 
TBDPSCl (21% yield obtained for protecting amine). Examining the crude mixture (Scheme 
44) by TLC only the spot of new product was observed. Upon purification of this crude by 
columun chromatography compound 120 a was isolated in good yield. Compound 120 a was 
subsequently applied to our reaction conditions. Interestingly, the yield of desired cyclised 
product was increased dramatically, the ratio between cyclised and uncyclised products was 
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(1.5:1.0 respectively) determined by NMR. Unfortunately, the amount of by-product 119 



























48 % 30 % 11 %
Scheme 45 
Following the success with protected N-methylsulfonyliodide, a variety of amine derivatives 
were therefore synthesized to investigate inthe reaction. Making the TBDMS-amines was 
straight forward, and gave the desired products 120 (b-i) by yields of 64-81% (Scheme 46 






R TBDMSCl (1.5 equiv)
   DMAP (0.4 equiv)
Et3N (1.5 equiv),










Entry R Substrate Yield (%) 
            1 Ethyl 120-b 78 
2 Iso-propyl 120-c 74 
3 Iso-butyl 120-d 68 
4 Amyl 120-e 81 
5 Cyclohexyl 120-f 64 
6 Tert-butyl 120-g 73 
7 Propyl 120-h 80 
Table 5, Scheme 46 
Once products 120 (b-i) had been isolated, reactions were investigated with them. The 
newly developed conditions were used with dried TBAF as fluoride source. The reaction was 
applied to a variety of sulfonamide drivatives, yielding the cyclic products in modest yields 




























14 120 (b-h) 121 (b-h) 122 (b-h) 123 (b-h)
 
Entry R 121 b-h (%) 122 b-h (%) 123 b-h (%) 
            1 Ethyl 51 33 13 
2 Iso-propyl 46 31 22 
3 Iso-butyl 44 35 18 
4 Amyl 48 33 15 
5 Cyclohexyl 38 29 12 
6 Tert-butyl 46 37 13 
7 Propyl 49 33 17 
Table 6, Scheme 47 
All compounds delivered the desired cyclised products as the major compound. We can see 
from this selection of compounds that amides with less hindrance gave better yields than 
those with hindered substituent. The low yields are thought to be due to steric hindrance 
during both the nucleophilic addition and the cyclisation steps. Having a better 
understanding of the substrate range suitable for the reaction, we adopted substituted 
aryne precursors to study the reactivity associated with electronic and steric effects 













































Ratio = 125 a 4:1 125 b Ratio = 126 a 4:1 126 b











































Ratio = 128 a 1.2:1 128 b Ratio = 129 a 1.2:1 129 b







































Ratio = 131 a 2:1 131 b Ratio = 132 a 2:1 132 b
43 % yield 30 % yield
Scheme 48 
For example, the addition of 3-methoxybenzyne 124, occurs with high regioselectivity at C1. 
This can be explained by a combination of the steric repulsion by the methoxy-substituent 
and the inductive electron donating nature of the methoxy- substituent. Bulky 3-substituted 
benzynes, such as naphthalene 130, favour addition at the least hindered position; this is C1 
for the benzyne due to repulsion from the peri-hydrogen. In the case of a meta methyl 
aryne 127, the product was observed as a 1.2:1 mixture of isomers. The slight 
regioselectivity for C2 of 3-methylbenzyne (Fig 3), however, may be due to the electron-
donating nature of the methyl substituent making C1 comparatively electron-rich, thus 


















3.1 Microwave Methodology 
 
Microwave technology has been applied in organic chemistry since the late 1980s when the 
microwave cavity was redesigned thus improving the heating characteristics.52,54 The 
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progress of this technology for organic chemistry has been rather slow compared to 
computational and inorganic chemistry fields.54 This initial slow progress in this field has 
been ascribed to lack of controability, reproducibility, microwave dielectric heating, system 
control for ample temperature and pressure.53 Nevertheless, the number of publications 
associated to this area has dramatically increased since the late-1990s.53,54 The main 
rationales for this remarkable growth is because of development of solvent free reaction, 
shorter reaction times  from days to hours or minutes and the availability of microwave 
equipment.53,54,59  
Furthermore, microwave dielectric heating possesses certain advantages over traditional 
methods due to energy rate that cannot reproduced by refluxing as in a classical heating 
method insufficient energy is transferred to the system. Other advantages are higher yield, 
reduced side reaction and shorter time with microwave reactor method. In addition, in 
pressurized system,52,54,59 it is possible to increase the temperature far above the boiling 
point of the solvent, therefore solvents with lower boiling point could be employed and can 
be easily removed in the reaction mixture during work up or purification.52 
In 2009, Mosses and Zhang56 published the preparation of aromatic azides formed by 
addition of the corresponding anthranilic acid, benzyne precursor and t-BuONO in a 
microwave reactor and irradiating for 15 min at 150 °C. These conditions favoured electron-








       tBuONO, MeCN





R = OMe 134a 86 %
R = NO2   134b 29 %
R = CN    134c 42%
R = OMe 133a 
R = NO2   133b 





In the same year, Ankati and Biehl57applied the microwave click chemistry to prepare 1H-
benzo[d]triazoles in good to excellent yields, with two-component and three-component 





     CsF, MeCN
W, 20 min, 125 °C
            79 %
or KF/18-crown-6, MeCN











     CsF, MeCN
W, 20 min, 125 °C
              81 %
or KF/18-crown-6, MeCN









Greaney’s group developed a single-step method to synthesies acridones in high yield from 









W, 120 °C, 5 min
N
O
139 14 140 92 %  
Scheme 51 
The compatibility of precursor 14 with microwave heating has recently been remarked56,57,58 
upon and is testament to its superb versatility in aryne chemistry, therefore we decided to 
apply this methodology with our reaction conditions using acetonitrile as a solvent as it is 
known to be an ideal microwave solvent, and 2-chloro-sulfonyl amide 108 was chosen to 
























      MeCN














118 (%) 119 (%) 
1 Rt 60  0 24 0 
2 60 60 0 50 0 
3 80 60 14 74 0 
4 100 60 53 5 0 
5 100 20  0 0 0 
6 100 30  0 0 0 
7 100 120 5 64 22 
8 100 180 5 56 31 
9 120 60 5 20 44 
Table 7, Scheme 52 
Successful generation of 93 by this protocol was encouraging. Direct analysis of the results 
shows a clear trend in the isolated yields when increasing the temperature to 100 °C (entry 
4).  Unfortunately, we were unable to reproduce the result when the same conditions were 
applied again. Attempts to further analyse the extent of this trend by increasing the reaction 
temperature to 120 °C produced cleaved product 119 as a major product and trace amount 
of 93. It is important to note that entries 5 and 6 did not reach full conversion after 20 and 
30 minutes, as 14 was still present. Furthermore, the analogous process using non-
microwave methodology would take up to 16 hours to reach completion. With this in mind a 
screening of reaction run-times was performed to achieve a full conversion of 14 at an 
ideally lower reaction temperature. In addition, we increased the run-time of the highest 
yielding reaction temperature (entry 7 and 8) to see if this would increase the isolated yield, 
but only a trace of cyclised product was observed. 
 
4. Conclusion and Future Work 
 
A new optimised route to the synthesis of sultams is described; our method is a simple and 
two step procedure in one pot of reaction. The reaction includes the addition of nitrogen 
nucleophile to phenyl anion following ring closure through intermolecular elimination. In 
fact, the previous publications in aryne methodology concentrated on addition reactions 
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between phenyl halide and sulfonamide. We initially studied this area with the belief that 
phenyl anions endured cyclisation to furnish a variety of annulated rings. In our conditions, 
easily accessible substrates 2-iodomethane sulfonylamide and ortho-silyl aryl triflates 
generate uncyclised product in good yield when TBAF used as the fluoride source. 
Nevertheless, the formation of a mixture of cyclic and acyclic products leads us to consider 
the mechanism entailing second nucleophilic attack to -C next to sulfonyl group. In an 
attempt to increase the amount of the cyclised product in the reaction, we therefore began 
investigating N-protected sulfonyl-2-iodides as alternative substrates. This compound 
produced cyclised product in moderate yield. Based on this result, a series of N-protected 
sulfonyl amine derivatives were shown to form sultams. In addition, it has been shown that 
there is some hope for preparation of sultams by using our conditions in a microwave 
system. 
Future work would include more investigations into the mechanism of the reaction, further 
experimentation is expected to increase yield of cyclised product, for example, by preparing 
anhydous TBAF, using different benzyne precursors or by replacing the iodine group with 
altenative leaving group such as tosyl and mesyl. Stoltz16 previously described ring closure 
via intermolecular conjugate addition; this in turn can be further functionalised to the six or 






































General methods  
Unless otherwise stated, all reactions were carried out under an inert atmosphere of dried nitrogen, 
in glassware which had been oven-dried. Reagents were purchased from Sigma-Aldrich, Acros, Alfa 
Aesar, Fisher Scientific, TCI UK or Lancaster Research Chemicals and were not purified except where 
stated. Solvents were purchased anhydrous and stored over molecular sieves, or distilled under 
nitrogen from an appropriate drying agent in accordance with the procedures of Perrin and 
Armarego. Toluene and THF were distilled from sodium benzophenoneketyl radical while 
dichloromethane and acetonitrile were distilled from calcium hydride. DMSO anhydrous was used as 
obtained fromSigma-Aldrich.Thin layer chromatography (TLC) was carried out using silica gel 60 F254 
aluminium sheets. Spots were visualised by quenching UV irradiation at 254 nm, and by staining with 
2% KMnO4 (w/v) in 20% K2CO3 (w/v) solution, 15% phosphomolybdic acid (w/v) in EtOH. Flash 
column chromatography was carried out using silica gel 60 A, 70-230 mesh, 63-200 µm obtained 
from Sigma–Aldrich. Nuclear magnetic resonance (NMR) spectroscopy was performed on a 
BrukerAvance 400 NMR spectrometer (1H NMR at 400 MHz, 13C NMR at 100 MHz) with the 
appropriate deuterated solvent. Chemical shifts in 1H NMR spectra are expressed as ppm downfield 
from TMS and in 13C NMR, are relative to internal standard, and reported as singlet (s), doublet (d), 
triplet (t), quartet (q) and combinations thereof, or multiplet (m). Coupling constants (J) are quoted 
in Hz and are averaged between coupling partners and rounded to the nearest 0.2 Hz. Mass 
spectrometry was performed using a BrukerMicroTOF-Q instrument with electrospray ionisation in 
the positive mode. FT-IR data was acquired using Thermo Electron Corporation Nicolet 380 FTIR with 
Smart Orbit diamond window instrument with wavenumbers being reported in cm-1.  
General procedure for protecting amine 
To an oven dried round-bottomed flask, flushed with nitrogen, 2-iodomethanesulfonyl 
amide derivatives (1.0 g) was added, and was taken up with MeCN (20 mL). To this 
triethylamine (1.5 equiv) and TBDMSCl (1.5 equiv) was added and stirred for 16 hours at 25 
°C. After this time the mixture was concentrated under reduce pressure and purified by 












Prepared following the general procedure to yield 120a (1.14 g, 77 %) as a colourless solid; 
mp: 128-130 °C; 1H NMR (CDCl3 400 MHz) H 4.38 (s, 2H, I-CH2), 2.58 (s, 3H, 2-CH3), 0.9 (s, 
9H-((CH3)3C-Si(CH2)2), 0.08 (s, 6 H, (CH3)3C-Si(CH3)2); 13C NMR (100MHz, CDCl3): C 30.9 (I-
CH2), 26.4 ((CH3)3C-Si(CH3)2), 25.2 (2-CH3), 14.3 ((CH3)3C-Si(CH3)2), -8 ((CH3)3C-Si(CH3)2); max 
(solid, cm-1); 1335, 1152 (SO2), 1027 (N-C); MSm/z (ESI+) calculated for C8H20INO2SSi 











Prepared following the general procedureto yield 120b (1.13 g, 78 %) obtained as a 
colourless solid; mp : 136-138 °C; 1H NMR (CDCl3 400 MHz) H  4.39 (s, 2H, I-CH2), 2.68 (t, J 
6.4 Hz, 2H, 2-CH2), 1.4 ( s, 3H, 3-CH3), 1.1 (s, 9H ((CH3)3C-Si(CH2)2), 0.08 (s, 6H, (CH3)3C-
Si(CH3)2); 13C NMR (100MHz, CDCl3): C 32.1 (2-CH2), 31.9 (I-CH2), 26.8 ((CH3)3C-Si(CH3)2), 
15.2 (3-CH3), 14.5 ((CH3)3C-Si(CH3)2), -9.5 ((CH3)3C-Si(CH3)2); max (solid, cm-1); 1331, 1150 












Prepared following the general procedureto yield 120c (1.05 g, 74 %) as a colourless solid; 
mp : 156-158 °C; 1H NMR (CDCl3 400 MHz) H 4.39 (s, 2H, I-CH2 ), 3.15-3.10 (m, 1H, 2-CH), 
1.15 ( s, 6H, 3-CH3 and 3’-CH3), 1.05 (s, 9H, (CH3)3C-Si(CH2)2), 0.09 (s, 6H, (CH3)3C-Si(CH3)2); 
13C NMR (100 MHz, CDCl3): C 36.6 (2-CH), 32.2 (I-C), 26.9 ((CH3)3C-Si(CH3)2), 15.2 (3-CH3 and 
165 
 
3’-CH3), 14.6 ((CH3)3C-Si(CH3)2), -9.0 ((CH3)3C-Si(CH3)2); max (solid, cm-1); 1333, 1149 (SO2), 













Prepared following the general procedureto yield 120g (0.96 g, 68 %) as a colourless solid; 
mp : 168-172 °C; 1H NMR (CDCl3 400 MHz) H 4.39 (s, 2H, I-CH2), 1.42 (s, 9H, 3-CH3, 3’-CH3 
and 3’’-CH3), 1.05 (s, 9H, (CH3)3C-Si(CH2)2), 0.08 (s, 6H, (CH3)3C-Si(CH3)2); 13C NMR (100 MHz, 
CDCl3): C 39.4 (2-CH), 33.2 (I-CH2), 30.8 (3-CH3, 3’-CH3 and 3’’-CH3), 25.9 ((CH3)3C-Si(CH3)2), 
15.1 ((CH3)3C-Si(CH3)2), -8.7 ((CH3)3C-Si(CH3)2); max (solid, cm-1); 1337, 1148 (SO2), 1029 (N-














Prepared following the general procedure to yield 120e (1.124 g, 81 %) as a colourless solid; 
mp : 152-156 °C; 1H NMR  (CDCl3 400 MHz) H 4.38 (s, 2H, I-CH2), 2.65 (t, J 6.5 Hz, 2H, 2-CH2), 
1.50-1.55 (m, 2H, 3-CH2), 1.29-1.37 (m, 4H, 4-CH2 and 5-CH2), 1.03 (s, 9H, ((CH3)3C-Si(CH3)2), 
0.96 (t, J 7.0 Hz, 3H, 6-CH3),  0.08 (s, 6H, ((CH3)3C-Si(CH3)2); 13C NMR  (100MHz, CDCl3): C 
40.3 (2-CH2), 33.2 (I-CH2), 30.8 ( 3-CH2), 29.5 (4-CH2), 27.1 ((CH3)3C-Si(CH3)2), 24.6 (5-CH2), 
15.1 (CH3)3C-Si(CH3)2), 14.6 (C-6), -8.7 ((CH3)3C-Si(CH3)2); max (solid, cm-1); 1337, 1148 (SO2), 
















Prepared following the general procedure to yield 120f (0.88 g, 64 %) as a colourless solid; 
mp : 172-176 °C; 1H NMR (CDCl3 400 MHz) H 4.40 (s, 2H, I-CH2), 2.79-2.75 ( m, 1H, 2-CH), 
2.57-1.72 (m, 4H, 3-CH2 and 3’-CH2),1.58-1.43 (m, 6H, 4-CH2,, 4’-CH2 and 5-CH2), 0.98 (s, 9H, 
(CH3)3C-Si(CH3)2), 0.07 (s, 6H, (CH3)3C-Si(CH3)2); 13C NMR(100MHz, CDCl3): C 39.9 (2-CH), 
33.2 (3-CH3 and 3’-CH3),  32.9 (I-CH2), 30.8 (5-CH3), 25.9 ((CH3)3C-Si(CH3)2), 22.3 (4-CH3 and 
4’-CH3),  15.1 ((CH3)3C-Si(CH3)2), -8.7 ((CH3)3C-Si(CH3)2); max (solid, cm-1); 1337, 1148 (SO2), 











Prepared following the general procedureto yield 120d (1.03 g, 73 %) obtained as a 
colourless solid; mp : 168-172 °C; 1H NMR (CDCl3 400 MHz) H 4.38 (s, 2H, I-CH2), 2.62 (t, J 
6.4 Hz, 1H, 2-CH2), 2.09-2.06 (m, 1H, 3-CH),  0.95 (d, J 6.5 Hz, 6H, 4-CH3 and 4’-CH3), 1.03 (s, 
9H, (CH3)3C-Si(CH3)2), 0.09 (s, 6H, CH3)3C-Si(CH3)2); 13C NMR (100 MHz, CDCl3): C 49.9.4 (2-
CH2), 32.2 (I-CH2), 29.8 (3-CH), 26.4 (CH3)3C-Si(CH3)2), 20.5 (4-CH2 and 4’-CH2), 14.3 (CH3)3C-
Si(CH3)2), -9.1 (CH3)3C-Si(CH3)2); max (solid, cm-1); 1337, 1148 (SO2), 1019 (N-C); MSm/z (ESI+) 













Prepared following the general procedureto yield 120h (1.15 g, 80 %) obtained as a 
colourless solid; mp : 136-138 °C; 1H NMR (CDCl3 400 MHz) H 4.39 (s, 2H, I-CH2), 2.69 (t, J 
6.6 Hz, 2H, 2-CH2),1.61-1.59 (m, 2H, 3-CH2),  0.96 ( t, J 7.5 Hz 3H, 4-CH3), 1.0 (s, 9H, (CH3)3C-
Si(CH3)2), 0.08 (s, 6H, (CH3)3C-Si(CH3)2); 13C NMR (100 MHz, CDCl3): C32.1 (2-CH2), 31.9 (I-
CH2), 26.8 ((CH3)3C-Si(CH3)2), 25.2 (3-CH2), 15.2 (CH3)3C-Si(CH3)2), 14.5 (4-CH3), -9.5 (CH3)3C-
Si(CH3)2); max (solid, cm-1); 1331, 1150 (SO2), 1024 (N-C); MSm/z (ESI+) calculated for 
C10H24INO2SSi 377.0342 [M+H]+; found 377.0341. 
 
General method for synthesis of sultams 
To an oven dried microwave vial, flushed with nitrogen, iodomethanesulfonyl-protected 
amine derivatives (100 mg) was added followed by dry THF (2.0 mL). To this, benzyne 
precursor (1.0 equiv) was added and stirred overnight at 25 °C. After this time solvent was 
removed and the mixture was purified by flash column chromatography to yield the title 
compound.  
 







N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-methylamine (100 mg, 0.29 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.97 mg, 0.29 mmol) was reacted following 
the general method to yield 1-methyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide (28 mg, 53 
%) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.34−7.28 (m, 1H, Ar-CH), 7.24−7.19 (m, 
1H, Ar-CH), 7.02 (td, J 7.6, 1.0 Hz, 1H, Ar-CH), 6.78 (d, J 8.0 Hz, 1H, Ar-CH), 4.33 (s, 2H, SO2-
CH2), 3.12 (s, 3H, 1-CH3). 13C NMR (100 MHz, CDCl3) δ 144.3 (Ar-C), 129.8 (Ar-CH), 126.8 (Ar-
CH), 121.9 (Ar-C), 118.5 (Ar-CH), 112.6 (Ar-CH), 54.7 (SO2-CH2), 31.3 (1-C); max (solid, cm-1); 












N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-ethylamine (100 mg, 0.28 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.82 mg, 0.28 mmol) was reacted following 
the general method to yield 1-ethyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide  (28 mg, 51 %) 
as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.37−7.31 (m, 1H, Ar-CH), 7.29−7.25 (m, 1H, 
Ar-CH), 7.03 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.84 (d, J 8.0 Hz, 1H, Ar-CH), 4.32 (s, 2H, SO2-CH2), 
3.14 (t, J 14.4 Hz, 2H, 1-CH2), 1.41 (t, J 7.0  Hz, 3H, 2-CH3). 13C NMR (100 MHz, CDCl3) δ 142.3 
(Ar-C), 132.3 (Ar-CH), 128.5 (Ar-CH), 118.5 (Ar-C), 114.8 (Ar-CH), 112.9 (Ar-CH), 55.2 (SO2-
CH2), 41.3 (1-CH2), 9.9 (2-CH3); max (solid, cm-1); 1343, 1145 (SO2), 1315 (N-C); MSm/z (ESI+) 
calculated for C9H11 NSO2 197.0510 [M+H]+; found 197.0511. 










N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-isopropylamine (100 mg, 0.27 mmol) and 
2-(trimethylsily)phenyltifluoromethanesulfonate (0.79 mg, 0.27 mmol) was reacted 
following the general method to yield 1-isopropyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide  
(26 mg, 46 %) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.36−7.32 (m, 1H, Ar-CH), 
7.27−7.23 (m, 1H, Ar-CH), 6.99 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.68 (d, J 8.0 Hz, 1H, Ar-CH), 
4.32 (s, 2H, SO2-CH2 ), 4.29 (m, 1H, 1-CH), 1.51 (m, 6H, 2-CH3 and 2’-CH3). 13C NMR (100 
MHz, CDCl3) δ 141.1 (Ar-C), 130.2 (Ar-CH), 127.9 (Ar-CH), 117.6 (Ar-C), 113.8 (Ar-CH), 112.5 
(Ar-CH), 55.0 (SO2-CH2), 44.4 (1-CH), 20.1 (2-CH3 and 2’-CH3); max (solid, cm-1); 1335, 1144 
(SO2), 1317 (N-C); MSm/z (ESI+) calculated for C10H13NSO2 211.0667 [M+H]+; found 211.0661. 













N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-isobutylamine (100 mg, 0.26 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.76 mg, 0.26 mmol) was reacted following 
the general method to yield 1-isobutyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide  (26 mg, 44 
%) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.33−7.29 (m, 1H, Ar-CH), 7.24−7.20 (m, 
1H, Ar-CH), 7.0 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.86 (d, J 8.0 Hz, 1H, Ar-CH), 4.33 (s, 2H, SO2-
CH2), 3.41-3.39 (m, 2H, 1-CH2), 2.2-2.1 (m, 1H, 2-CH), 1.01 (s, 6H, 3-CH3 and 3’-CH3). 13C NMR 
(100 MHz, CDCl3) δ 140.8 (Ar-C), 131.1 (Ar-CH), 128.0 (Ar-CH), 118.2 (Ar-C), 113.7 (Ar-CH), 
113.0 (Ar-CH), 55.9 (SO2-CH2), 54.3 (1-CH2), 25.5 (2-CH), 19.9 (3-CH3 and 3’-CH3); max (solid, 
cm-1); 1335, 1144 (SO2), 1329 (N-C); MSm/z (ESI+) calculated for C11H15NSO2 225.0823 
[M+H]+; found 225.0811. 











N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-amylamine(100 mg, 0.25 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.74 mg, 0.25 mmol) was reacted following 
the general method to yield 1-amyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide (29 mg, 48 %) 
as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.41−7.38 (m, 1H, Ar-CH), 7.38−7.29 (m, 1H, 
Ar-CH), 7.01 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.79 (d, J 8.0 Hz, 1H, Ar-CH), 4.34 (s, 2H, SO2-CH2), 
3.58 (t, J 15.0 Hz, 2H, 1-CH2), 1.57-1.52 (m, 2H, -CH2), 1.47-143 (m, 2H, 3-CH2), 1.40-1.33(m, 
2H, 4-CH2), 0.97 (t, J 7.0 Hz, 3H, 5-CH3). 13C NMR (100 MHz, CDCl3) δ 140.8 (Ar-C), 133.1 (Ar-
CH), 128.8 (Ar-CH), 119.4 (Ar-C), 115.1 (Ar-CH), 113.1 (Ar-CH), 54.7 (SO2-CH2), 47.7 (1-CH2), 
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29.6 (2-CH2), 26.6 (3-CH2), 22.5 (4-CH2), 13.9 (5-CH3); max (solid, cm-1); 1343, 1145 (SO2), 
1334 (N-C); MSm/z (ESI+) calculated for C12H17NSO2 239.0930 [M+H]+; found 239.0932 












N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-amylamine(100 mg, 0.24 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.71 mg, 0.24 mmol) was reacted following 
the general method to yield 1-cyclohexyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide (23 mg, 
38 %) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.42−7.38 (m, 1H, Ar-CH), 7.33−7.28 
(m, 1H, Ar-CH), 6.99 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.84 (d, J 8.0 Hz, 1H, Ar-CH), 4.32 (s, 2H, 
SO2-CH2), 3.59-3.56 (m, 1H, 1-CH), 2.19-1.97 (m, 2H, 2-CH and , 2’-CH), 1.77-145 (m, 6H, 3-
CH, 3’-CH and , 4-CH). 13C NMR (100 MHz, CDCl3) δ 141.1 (Ar-C), 134.0 (Ar-CH), 129.6 (Ar-
CH), 119.9 (Ar-C), 115.2 (Ar-CH), 113.6 (Ar-CH), 55.1 (SO2-C), 47.3 (1-CH), 30.6 (2-CH2 and 2’-
CH2), 28.1 (4-CH2), 23.5 (3-CH2 and 3’-CH2); max (solid, cm-1); 1348, 1149 (SO2), 1331 (N-C); 
MSm/z (ESI+) calculated for C13H17NSO2 251.0980 [M+H]+; found 250.0980. 











N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-isobutylamine (100 mg, 0.26 mmol) and 2-
(trimethylsily)phenyltifluoromethanesulfonate (0.76 mg, 0.26 mmol) was reacted following 
the general method to yield 1-tertbutyl-1, dihydrobenzo[c]isothiazole 2,2-dioxide (27 mg, 44 
%) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.39−7.31 (m, 1H), 7.28−7.25 (m, 1H), 
7.02 (td, J 7.5, 1.0 Hz, 1H), 6.84 (d, J 8.0 Hz, 1H), 4.32 (s, 2H, SO2-CH2), 1.78 (s, 9H, 2-CH3, 2’-
CH3 and 2’’-CH3). 13C NMR (100 MHz, CDCl3) δ 141.5 (Ar-C), 131.6 (Ar-CH), 128.2 (Ar-CH), 
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118.7 (Ar-C), 113.8 (Ar-CH), 112.9 (Ar-CH), 55.6 (SO2-CH2), 44.7 (1-CH), 27.3 (2-CH, 2’-CH and 
2’’-CH); max (solid, cm-1); 1332, 1140 (SO2), 1320 (N-C); MSm/z (ESI+) calculated for 
C11H15NSO2 225.0823 [M+H]+; found 225.0813. 









N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-ethylamine(100 mg, 0.27 mmol) and 2-
(trimethylsily) phenyltifluoromethanesulfonate (0.79 mg, 0.27 mmol) was reacted following 
the general method to yield 1-propyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide  (28 mg, 49 
%) as a colourless gum.1H NMR (400 MHz, CDCl3) δ 7.37−7.31 (m, 1H, Ar-CH), 7.29−7.25 (m, 
1H, Ar-CH), 7.03 (td, J 7.5, 1.0 Hz, 1H, Ar-CH), 6.84 (d, J 8.0 Hz, 1H, Ar-CH), 4.32 (s, 2H, SO2-
CH2), 3.14-3.10 (m, 2H, 1-CH2), 1.41 (m, 2H, 2-CH2), 0.96 (t, J 7.0  Hz, 3H, 3-CH3). 13C NMR 
(100 MHz, CDCl3) δ 142.3 (Ar-C), 132.3 (Ar-CH), 128.5 (Ar-CH), 118.5 (Ar-C), 114.8 (Ar-CH), 
112.9 (Ar-CH), 55.2 (SO2-CH2), 41.3(1-CH2), 20.2 (2-CH2), 9.9 (3-CH3); max (solid, cm-1); 1343, 
1145 (SO2), 1327 (N-C); MSm/z (ESI+) calculated for C10H13NSO2 211.0667 [M+H]+; found 
211.0667. 









N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-methylamine (100 mg, 0.29 mmol) and 2-
methYL-6-(trimethylsily)phenyltifluoromethanesulfonate (0.95 mg, 0.29 mmol) was reacted 
following the general method to yield 1-methyl-1,dihydrobenzo[c]isothiazole 2,2-dioxide  
(25 mg, 44 %) as a colourless gum. Major: 1H NMR (400 MHz, CDCl3) δ 7.27−7.24 (m, 1H, Ar-
CH), 7.1-7.03 (m, 1H, Ar-CH), 6.56 (d, J 8.0 Hz, 1H, Ar-CH), 4.26 (s, 2H, SO2-CH2), 3.10 (s, 3H, 
Ar-C-CH3), 2.25 (s, 3H, 1-CH3). 13C NMR (100 MHz, CDCl3) δ 141.3 (Ar-C), 129.7 (Ar-C), 126.6 
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(Ar-CH), 121.9 (Ar-C), 118.5 (Ar-CH), 112.6 (Ar-CH), 52.4 (SO2-CH2), 30.1(1-CH3), 17.9 (Ar-C-
CH3); max (solid, cm-1); 1333, 1144 (SO2), 1314 (N-C); MSm/z (ESI+) calculated for C9H11NSO2 
197.0510 [M+H]+; found 197.0513. 










OMe 11  
N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-methylamine (100 mg, 0.29 mmol) and 2-
methyl-6-(trimethylsily)phenyltifluoromethanesulfonate (0.91 mg, 0.29 mmol) was reacted 
following the general method to yield 1-methoxy-1,dihydrobenzo[c]isothiazole 2,2-dioxide  
(27 mg, 48 %) as a colourless gum: Major; 1H NMR (400 MHz, CDCl3) δ 7.29−7.26 (t, J 16.0 
Hz, 1H, Ar-CH), 7.02-7.00 (t, J 16.0 Hz, 1H, Ar-CH), 6.29 (dd, J 8.0, 2.4 Hz, 1H, Ar-CH), 5.30 (s, 
2H, O-CH3), 4.78 (s, 2H SO2-CH2), 3.89 (s, 3H, O-CH3), 2.83 (s, 3H, 1-CH3). 13C NMR (100 MHz, 
CDCl3) δ 159.6 (Ar-C-OMe), 141.2 (Ar-C), 123.4 (Ar-CH), 122.1 (Ar-C), 118.9 (Ar-CH), 113.7 
(Ar-CH), 55.4 (O-CH3), 52.4 (SO2-CH2), 30.1 (1-CH3); max (solid, cm-1); 1333, 1144 (SO2), 1308 











N-(tert-Butyldimethylsilyl)(iodomethylsulfonyl)-N-methylamine (100 mg, 0.29 mmol) and 2-
naphthaline-6-(trimethylsily)phenyltifluoromethanesulfonate (101 mg, 0.29 mmol) was 
reacted following the general method to yield 1-methoxy-1,dihydrobenzo[c]isothiazole 2,2-
dioxide  (29 mg, 43 %) as a colourless gum: Major; 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J 8.5 
Hz,  2H, Ar-CH), 7.51-7.32 (m, 2H, Ar-CH), 7.16-7.04 (dd, J 8.5, 2.4 Hz, 1H, Ar-CH), 4.63 (s, 2H, 
SO2-CH2), 3.43 (s, 3H, 1-CH3); 13C NMR (100 MHz, CDCl3) δ 144.6 (Ar-C), 136.5 (Ar-C), 128.4 
(Ar-CH), 127.1 (Ar-C), 125.8 (Ar-CH), 123.8 (Ar-CH), 123.7 (Ar-CH), 120.3 (Ar-CH), 120.1 (Ar-
CH), 118.9 (Ar-C), 52.5 (SO2-CH2), 30.3 (1-CH3); max (solid, cm-1); 1333, 1144 (SO2), 1319 (N-
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